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CHAPTER I 
INTRODUCTION 
Septic shock induced by invading gram negative bacteria {GNB) is a 
significant concern of modern day health professionals {68,169,172,286). 
The prevalent use of antibiotics, invasive life support systems, 
catheteriz~tions, immunosuppressive therapy, and organ transplants in 
medical centers have caused the number of GNB-induced cases of septic 
shock to escalate (9,70,80,105,146,270,281,286,288). Indeed, septic 
shock with concomitant hemodynamic, metabolic and neuro-endocrine 
alterations has been called the ultimate disease of meuical progress 
{70). Prior to the 1920's, less than 100 cases of GNB-induced shock were 
reported (72). In the U.S. today, approximately 1% of hospital 
admissions develop GNB-induced sepsis, with more than 100,000 resultant 
deaths yearly (68,170). 
The chain of events responsible for the lethal demise of the septic 
host is complex and as yet unresolved. One long-standing, major 
pathogenetic theory emphasizes that endotoxin (ETX), a lipopolysaccharide 
complex isolated from the cell wall of GNB, is the direct causative agent 
for the morbidity and mortality of GNB induced septic shock{l07,286,288). 
Indeed, ETX treated animals as well as human subjects demonstrate Lhe 
septic symptoms such as fever, cation shifts, increased white blood cell 
counts, mu. ~le wasting, acute phase protein synthesis, decreased 
lipogenesis, hyperinsulinemia, and glucose dyshomeostasis (73,106,107 
1 
2 
243,283) which are associated with septic shock, multiple systems organ 
failure and eventual mortality. 
In recent years an alternate, novel theory of septic shock patho-
genasis proposes that ETX elicits all its pathophysiological effects by 
stimulating cells of the immune system to release septic mediators. In 
particular, macrophages activated either by GNB or their constituent ETX 
release a number of mediators which are now recognized as key components 
in the pathophysiology of septic shock, such as prostaglandins, leuko-
trienes, platelet-activating factor, and the monokines tumor necrosis 
factor (TNF) and interleukin 1 (IL-1) (75,180,220). 
Of all the pathophysiological changes which occur during septic 
shock, altered substrate metabolism may be the eventual critical 
component in the demise of the septic host (17,177). During infection 
and tissue injury cells tend to rely heavily on glucose for the energy 
required to function and survive. Because the liver is the major site 
for systemic glucose production, alterations in hepatic glucoregulation 
may produce the changes in circulating plasma glucose concentrations, 
which in turn impact detrimentally on cell function. In particular, 
monokines released from the liver macrophages, i.e. Kupffer cells, in 
response to invading GNB and ETX (64) may be critical in the glucose 
alterations of septic shock. 
Therefore, the overall purpose of this dissertation is to contribute 
fundamental }W knowledge regarding the role of the mononuclear phagocyte 
system in the pathogenesis of gram negative septic shock. The major 
focus is on the role of TNF in the pathophysiology of lethal endo-
toxicosis in conscious rats. The specific aims include: 1) an in vivo 
3 
evaluation of TNF as a mediator of the endotoxic syndrome including 
mortality, hemodynamic, metabolic, and neuro-endocrine aspects; 2) an in 
vivo examination of the pathophysiological changes induced by co-
.............. 
treatment with TNF and ETX; and 3) an in vitro evaluation of the direct 
glucoregulatory effects of TNF on hepatic carbohydrate metabolism using 
isolated perfused rat livers and jsolated liver parenchymal cells. 
CHAPTER II 
REVIEY OF RELATED LITERATURE 
The relat-ed literature published up to June 1, 1988 was revie•.red in 
this dissertation. Because of the extensive interest in the biological 
activities of TNF, the author realizes that numerous relevant papers have 
been published more recently. Yhen considered to be of tte utmost 
importance to the interpretation of the data, a few of the most recent 
papers have been included in this dissertation. 
A. HISTORY OF TUMOR NECROSIS FACTOR 
For years, physicis~s noted that some cancer patients who be~ame 
infected subsequently demonstrated significant tumor regression. 
Intrigued by these findings, Coley devoted his career to the treatment 
of cancer patients with bacterial products. After one of his cancer 
patients recovered from a neck sarcoma after 2 attacks of erysipelas 
(49), Coley induced erysipelas in his cancer patients as a means of 
treatment (50). However, Coley quickly realized that infecting pat~ents 
already compromised by the cancerous insult frequently led to a fatal 
outcome. Therefore, Coley implemented a filter sterilized preparation of 
the soluble toxins produced by Streptococcus erysipelas and Bacillus 
prodigiosus as a means of cancer treatment rather than live bacteria. In 
1894, Coley reported the successful use of "Coley's Mixed Toxins" in the 
treatment of a patient with inoperable abdomi '.lal walJ. sarc. 'ma (51). An 
extensive report of Coley's works and mixed toxin preparations was later 
published by his daughter in 1953 (184). 
4 
In 1942, Zahl, et al. (287), suggested that the tumor necrotizing 
agent produced by gram negative bacteria might be identical with a 
polypeptide component of the endotoxin antigen (287). Shear, et al. 
(233), had isolated the necrotizing agent from Serratia marcescens 
cultures and determined it to be a polysaccharide-rich fraction; sub-
microgram quantities produced significant tumor necrosis within a few 
hours (232). 
5 
In 1962, O'Malley, et al. (189), demonstrated that serum from normal 
mice injected with Serratia marcescens polysaccharide had dose and time 
dependent tumor necrotizing activity when injected into recipient tumor 
bearing mice. In 1975, Carswell, et al. (40), further examined the 
hypothesis that a serum factor was involved in the bacteria-evoked tumor 
necrotizing activity. Mice were pretreated with the macrophage stimulant 
bacillus Calmette-Guerin (BCG) 14 days prior to challenge with lipo-
polysaccharide (LPS). Within a few hours after LPS challenge, donor mice 
demonstrated significant tumor regressing activity. Carswell,~., 
suggested that lipopolysaccharide acted indirectly to cause tumor 
regression by stimulating the release of a necrotizing substance from the 
macrophages which they called "tumor necrosis factor." 
Concurrently, a group of investigators at Rockefeller University was 
examining the mechanism responsible for the severe cachexia associated 
with chronic infection. In 1980, Rouzer and Cerami (215) reported that 
rabbits infected with the parasite Trypanosoma brucei becan. cachectic in 
spite of elevated circulating levels of triglycerides. In order to 
examine this further, Kawakami and Cerami utilized an ETX model of 
infection rather than a parasitic model (119). They demonstrated a 
6 
dramatic decrease in lipoprotein lipase (LPL) activity and a concomitant 
increase in serum triglyceride levels 16 hours after ETX challenge. A 
similar response was produced in endotoxin-resistant mice administered 
serum from endotoxin-sensitive mice 2 hours after an ETX challenge. 
Thus, a serum factor present in the donor blood was associated with the 
hyperlipemia produced during bacterial or parasitic infection. They 
determined that peritoneal exudate cells produced a LPL-suppressing 
factor after stimulation with ETX. 
Kawakami, et al. (121), continued to study the LPL-suppressing 
factor using th~ well-defined pre-adipocyte cell line, 3T3-Ll (121). 
Media isolated from peritoneal exudate cells stimulated in vitro with ETX 
markedly suppressed LPL activity in 3T3-Ll cells. Beutler, et al. (25), 
purified this cachexia-inducing factor and named it "cachectin". Beutler, 
et al. (23), subsequently determined that the macrophage-released 
mediators, "cachectin" and "tumor necrosis factor," were one in the same. 
B. BIOCHEMISTRY OF TUMOR NECROSIS FACTOR 
1. Isolation and structure 
Studies reported between 1976 and 1981 used serum from mice and 
rabbits treated in the manner described by Carswell, et al. (40), as a 
source for TNF. TNF isolated from mouse and rabbit sera was a protein 
with a molecular weight of 67,000-150,000 daltons, as determined by 
polyacrylamide gel electrophoresis (94,167,216) or 39,000-225,000 daltons 
when determined by gel filtration (132,157,167,168,216). TNF dissociated 
to a smaller molecular weight form under denaturing conditions, thus 
indicating that TNF may exist as an oligomer under natural conditions 
(94,157). Mouse TNF was a glycoprotein (94,132) with a pI-4.8 (157), 
7 
whereas rabbit TNF was a protein with little or no carbohydrate moieties 
and a pI-5.l (167,168,216). Both mouse and rabbit TNF were labile at 
temperatures~ 70°C (94,132,167,168,216) 
Fransen, et al. (85) and Pennica, et al. (197) constructed the 
cDNA for mouse TNF by isolating the mRNA from the monocytic cell line 
PU5.l.8. The amino acid sequence predicted from the cDNA indicated that 
mouse TNF is synthesized as a pre-TNF protein, with a 79 amino acid pre-
sequence attached to the 156 amino acid protein. When produced in vivo, 
TNF is glycosylated at the specific amino acid site predicted by the cDNA 
(197). The amino acid sequence for rabbit TNF also was determined from 
its corresponding cDNA. ·Like mouse TNF, rabbit TNF is synthesized as a 
pre-TNF protein, with an 80 amino acid pre-sequence followed by a 154 
amino acid protein (112). 
Human TNF, isolated from human peripheral blood monocytes and 
monocytic cell lines, was determined initially to be a protein with a 
molecular weight of 40,000-70,000 daltons by gel filtration. Similar to 
mouse and rabbit TNF, human TNF was pH and temperature sensitive 
(7,188,280). Aggarwal, et al. (7) suggested that TNF existed as a dimer 
or trimer under natural conditions which dissociated into a monomer of 
17,000 daltons under denaturing conditions. Pennica, et al. (198) and 
Wang, et al. (273) described the cDNA cloning for human TNF and its 
expression in~. coli to produce recombinant TNF. TNF is synthesized as 
a larger precursor molecule, with a leader sequence of 76 amino acids 
attached to the 157 amino acid protein containing 2 cysteine residues, no 
glycosylation sites, and a pI~5.3 (7,198,273). 
8 
TNF is a highly conserved protein, as illustrated by the homology 
between mouse, rabbit, and human TNF. Mouse and human TNF have 
approximately 80% homology in amino acid sequence (160,197). Similarly, 
Ito, et al. (112) reported an 81.9% homology in amino acid sequence 
between human and rabbit TNF (112). A 33 nucleotide sequence is totally 
conserved in the 3'-untranslated region of mouse and human TNF mRNA (39). 
This 33 nucleotide sequence is composed entirely of A and T residues in a 
repeating octamer of TTATTTAT. The human gene encoding for TNF was 
identified (234) and determined (239) to be encoded within the major 
histocompatibility complex on chromosome 6 and to contain 3 intrans 
(111,160). 
Whether the active form of TNF is a monomer or trimer is still 
under investigation. Smith, ~· (237) reported a 5.5 fold lower 
binding activity of the TNF monomer than that of the TNF trimer. The 
dissociation constants also differed substantially: the Ko=90 pM for the 
trimer and Ko-70 nM for the monomer. The molecular form of TNF in 
solution was dependent on its concentration: as the concentration of TNF 
in solution decreased, TNF dissociated into either a monomer or dimer 
dependent upon the pH in the solution (183). The structure of TNF, as 
determined by Davies, et al. (60), is a non-helical P-sheet rich 
structure which may be a noncovalently associated oligomer. 
2. Source 
Since Carswell's suggestion that macrophages were the cellular 
source of TNF (40), in vivo studies by Green, et al. (95) and Mannel, et 
al. (159) indirectly supported that theory. Green observed that the 
concentration of TNF in the serum of BCG-primed, endotoxin challenged 
9 
mice correlated with a measurable hepatosplenomegaly and suggested that 
the macrophage-rich tissues were the source of serum TNF. Mannel, et al. 
(159) determined that the host's ability to necrotize an invading tumor 
after an endotoxin challenge was dependent on the ETX responsiveness of 
bone marrow cells. 
In vitro studies with isolated macrophages demonstrated directly 
that macrophages were the primary site for synthesis and release of TNF. 
TNF production by mouse, rat, rabbit, and human macrophages was 
stimulated by ETX, BCG, Q. parvum, zymosan, and poke weed mitogen 
(55,81,155,158,165,188). Stimulated macrophages synthesized and released 
more TNF than unstimulated, plastic adhered macrophages (162,164). TNF 
is not stored intracellulaFly; it is produced in response to macrophage 
activation (163). Cycloheximide and actinomycin D treatment inhibited 
TNF production in vitro (81,163,164,165), therefore substantiating that 
TNF is not stored intracellularly but is produced in response to 
macrophage activation. Studies with rabbit antiserum specific for serum 
TNF established that TNF produced in vitro by isolated macrophages was 
the same as TNF produced in vivo (155,158), Macrophage cell lines also 
produce TNF in vitro (25,133) after activation. 
Although macrophages are the primary cellular source of TNF, 
Peters, et al. (201) and Cuturi, ~. (56) demonstrated detectable TNF 
production by natural killer cells. Christmas, et al. (47), however, 
reported 1 ittle or no TNF production by natural killer cells, but 
significant production by T lymphocytes after stimulation with phytohaem-
agglutinin (PHA). T lymphocytes stimulated with phorbol-12,13-di-
butyrate, A23187, PHA, anti-T3 + IL-2, or PMA produced significant 
10 
quantities of TNF (56,241,246). The ca++ -ionophore A23187 potentiated 
TNF production by T cells stimulated with phorbol-12,13-dibutyrate (56) 
and anti-CD3 monoclonal antibody (246). Additionally, epithelial tumor 
cell lines provoked with cycloheximide produced TNF (240). 
3. Production and regulation 
As briefly discussed in section 2, TNF is produced primarily by 
activated macrophages. Agents that enhanced the reticuloendothelial 
system, such as bacillus Calmette-Guerin (40,108,222), Corynebacterium 
granulosum (40), Corynebacterium parvum (40,90,95,108,223), zymosan (40), 
Propionibacterium ~ (100), Listeria monocytogenes (101), and 
thioglycollate (90,91) significantly increased TNF production after an 
endotoxin challenge (83,90,101). Howe7er, endotoxin alone stimulated 
significant TNF production both in vivo (83,90) and in vitro (25,90,131). 
The lipid A moiety of endotoxin and not the polysaccharide-rich fraction 
was responsible for the stimulatory effect (100). 
TNF also is produced in vitro by monocytic cell lines such as HL-
60 and U937 (6,102,198). Stimulation with either PMA, interferon-gamma 
(IFN-7), interferon-alpha (IFN-a), lymphotoxin (TNF p) or TNF produced a 
transient increase in TNF m.RNA which is inhibited with the protein kinase 
C inhibitor, H7 (102). As quickly as 20 minutes after activation, 
measurable levels of TNF m.RNA were produced (221). The stimul~s for TNF 
production must be continuously present during the incubation in order 
for TNF production to co1 ~ ~.nue: for exAmple, removal of ETX at any time 
during the incubation period immediately halted TNF production (91). 
TNF production is enhanced by IFN-7 and inhibited by prostaglandin 
E2 and dexamethasone. IFN-7 'primes' the macrophages so that a greater 
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quantitiy of TNF is produced after ETX stimulation (27,36,91,92). IFN-1 
increased TNF production by acting at both the transcriptional (27,36,52) 
and post-transcriptional (27,36) levels. Incubation with cycloheximide 
increased the transcription of TNF mRNA 12 fold in response to stimu-
lation with phorbol ester (221), whereas transcription of TNF mRNA was 
increased 50 fold in peritoneal macrophages incubated with cycloheximide 
plus IFN-1 (52). 
Prostaglandin E2 and dexamethasone act in a similar manner to 
decrease TNF production. Kunkel, et al. (135,136) reported a dose 
dependent decrease in endotoxin-induced TNF production by prostaglandin 
E2: prostaglandin E2 at concentrations greater than 10 nM decreased TNF 
production by 80%. Prostaglandin E2 acted primarily to decrease the 
transcription of TNF mRNA (135). Pretreatment with dexamethasone 
significantly inhibits TNF production: TNF production is inhibited 50-
90% after pretreatment with dexamethasone (266,267). Just as IFN-7 and 
prostaglandin E2, dexamethasone acted at both the transcriptional and 
post-transcriptional levels to decrease TNF production (24). 
As reported by Beutler, et al. (25), TNF is a major macrophage 
secretory product, comprising 1-5% of total protein synthesized by 
activated macrophages. Within 15 minutes of macrophage activation, 
measurable levels of TNF are produced (22,28,90). Peak serum TNF levels 
are reached approximately 90 minutes after endotoxin injection in humans 
(103,174,175), mice (90,95), rats (266), "abbits (28,Hil), and baboons 
(103). Similar results are observed for TNF production by activated 
macrophages in vitro (102). The half-life for TNF ranges from 0.5 to 27 
minutes (28,31,82,161,266), and the kidneys are important in TNF 
breakdown and elimination (200). 
4. Receptor 
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As documented in table 1, receptors £or TNF are present on a 
number of different cell types. The number of receptor sites per cell 
ranges from 230-11,000, with Ko values of 2.6 x lo-13 - 0.8 x lo-9 M. 
TNF binding is saturable and dependent on experimental conditions, such 
as dose, temperature, and time. After binding to its receptor, TNF is 
internalized and degraded intracellularly (14,110,258). The presence of 
TNF receptors, alone, is insufficient to predict whether the cell will 
respond to TNF (134,244,258). Beutler, et al. (25) determined that TNF 
binding to as few as 5% of the receptors will produce a significant 
cellular response. 
In vivo binding sites for TNF were determined by Beutler, et al. 
(28) after an i.v. bolus injection of 125!-TNF. Thirty-one percent of 
the radiolabeled TNF was recovered in the liver, approximately 30% in the 
skin, 9 and 8% in the G.I. tract and kidneys, respectively. Only 2% was 
found in the lungs and 1% was found in the spleen. When expressed as a 
percentage of the average counts found per gram of tissue wet weight, the 
liver and kidneys possessed the greatest degree of radioactivity, fol-
lowed by the lungs, spleen, and skin. 
The structure of the TNF receptor was examined using radiolabeled 
TNF covalently cross-linked to its receptor prior to is~~ation. 
Tsujimoto, et al. (256) and Scheurich, et al. (226) determined that the 
TNF-receptor complex had a molecular weight of 100 kda and 76 kda, 
CEIJ.. TYPE 
3T3-Ll ADIPOCYTES 
G2 MUSCLE CELLS 
L-M 
L929 
3T3A31 
J774.l 
GPAE 
He, La 
JURKATT 
L929 
FS-4 
(HUMAN PERIPHERAL 
BLOOD MONOCYTES) 
ME-180 
Wl-38 
T24 
PMN 
MCF-7 
TABLE 1 
TUM.OR NECROSIS FACTOR RECEPTORS 
RECEPTOR NUMBER Ko"""CM=).___ 
(sites/cell) 
10,000 
10,000 
1100 
770 
1050 
1100 
1500 
6000 
1100 
2200 
7500 
230 
3800 
2250 
2172 
1512 
6000 
2500 
4000 
o.33 x io-9 
o.33 x io-9 
3 x 10-12 
3 x io-12 
2.5 x io-12 
3 x io- 12 
3 x io- 12 
2 x 10·10 
2.5 x 10·10 
6.1 x io-10 
3.2 x 10-10 
2.6 x lo-13 
i. s x 10-10 
o.31 x lo-9 
0.22 x lo-9 
o.2s x lo-9 
1. 37 x lo-9 
0.13 x io-9 
o.s x lo-9 
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respectively. Kull, et al. (134) observed 2 bands of autoradiographic 
activity; a prominent band at 95 kda and a second band at 75kda. Four 
bands of activity were isolated by Creasey, ~. (54) with molecular 
weights of 138 kda, 90 kda, 75 kda, and 54 kda. Three of the four 
components, 90 kda, 75 kda, and 54 kda, were present on cells whether 
they did or did not respond to the cytotoxic, proliferative, or 
stimulatory effects of 'l'NF. The 138 kda component was determined to 
exist only on cell lines that were sensitive to the cytotoxic effects of 
TNF. The 350 kda globular protein demonstrated by Smith, et al. (238) 
corresponds to the molecular weight of the TNF receptor when all four 
subunits are present. 
TNF receptor binding is significantly influenced by agents such as 
interferon-7, conconavalin A (Con A), and protein kinase G activators. 
Interferon-7 and Con A significantly enhance TNF receptor binding. 
Aggarwal, et al. (5), Tsujimoto, et al. (257,259) and Ruggiero, et al. 
(217) demonstrated a transient 30-300% increase in TNF receptor binding 
with no change in receptor affinity after treatment with IFN-7. Inter-
feron-7 increased TNF receptor binding by increasing receptor synthesis, 
since treatment with actinomycin D blocked the effect (217). The 
stimulatory effect of IFN-7 was dose, temperature, and time dependent, 
and for some cell lines, was influenced by type I interferon (257,259). 
Con A treatment, on the other hand, significantly increased receptor 
binding without increasing TNF receptor synthesis or affinity (8). Con A 
significantly increased receptor binding by decreasing receptor inter-
nalization and degradation. 
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TNF receptor binding is significantly reduced by treatment with 
protein kinase C activators. Agents such as 4~-phorbol 12-myristate 13-
acetate (PMA), l-oleoyl-2-acetyl glycerol (OAG), and ca++ ionophore 
A23187 significantly reduced TNF receptor binding (4,109,115,262). 
Receptor binding decreased from 50-95% (4,262) due to either a decrease 
in receptor affinity (115,262) or a redistribution of TNF receptors 
(4,109). Pretreatment with the protein kinase C inhibitors, H7 or 
staurosporine (115,262), significantly reduced the inhibitory effect of 
PMA on TNF receptor binding. Furthermore, interleukin 1 also decreased 
TNF receptor binding (109). 
C. EFFECTS OF TUMOR NECROSIS FACTOR AT THE CELLULAR LEVEL 
1. Hematocrit and white blood cell counts 
Depending on the model, a single injection of TNF can elicit 
either no change (253) or an increase in hematocrit (16,210,249). 
Tracey, et al. (253) reported no significant change in hematocrit for as 
long as 3 hours after infusion of non-lethal (10 µg/kg) or lethal (100 
µg/ml) doses of TNF, as demonstrated using anesthetized beagle dogs. 
However, a significant hemoconcentration was observed in mice (16,210) 
and rats (249) after a single injection of TNF. Mice injected with 5 and 
10 µg of TNF had a significant hemoconcentration response by 2 hours: 
hematocrit increased significantly from a control value of 38.6 to 46.6 
and 48.8%, respectively (210). After injection of a larger dose of TNF, 
3 mg/kg, an increase in hematocrit of 150% relative to control mice was 
produced by 6 hours (16). Similar observations were reported by Tracey, 
et al. (249) after a lethal injection of TNF in rats (249). 
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After repeated doses of TNF, a significant hemodilution response 
is observed in both humans and rats. Cancer patients administered TNF 
twice weekly for 4 weeks demonstrated a significant drop in hemoglobin 
content from 12 to 9.3 g/dl (31). Tracey, et al. (254) reported a 
similar observation in rats given TNF twice daily for 8 days: hematocrit 
dropped from a control value of 45% to approximately 28% by the eighth 
day. Accounting for the drop in hematocrit was the significant de-
pression in red blood cell mass and hemoglobin content (254). 
The effect of TNF on white blood cell (WBC) counts was time and 
model dependent. Remick, et al. (211) observed in mice a transient 
initial lymphocytosis 15-30 minutes after TNF injection which was 
followed by a rapid drop in lymphocyte number. By 2 hours, a marked 
lymphopenia was observed in mice given TNF, with the relative as well as 
the absolute number of lymphocytes decreasing from 77 to 21% and from 294 
x 104 to 62 x 104 cell/ml, respectively (210). In anesthetized beagle 
dogs, however, Tracey, et al. (253) reported a significant drop in white 
blood cell count within 15 minutes after lethal infusion of TNF; white 
blood cell count dropped from a control value of 6.0 to 1.6 cells/mm3 in 
TNF treated dogs. In human cancer patients, a 50% decrease in lymphocyte 
concentration was observed 4 hours after TNF injection (31). When TNF 
was given repeatedly to rats, a marked leukocytosis was observed. Tracey 
reported that the number of leukocytes increased from a pre-injection 
value - 5.8 x lo-3 cells/mm3 to 14.7 x lo-3 cells/mm3 (254). 
Concomitant with the decrease in lymphocytes was a marked increase 
in neutrophils. Ulich, et al. (261) and Remick, et al. (211) reported a 
transient initial drop in neutrophil number within the first 30 minutes 
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after TNF injection which was followed by a significant increase between 
1 and 2 hours post-injection. Remick, et al. (211) reported both a 
relative and absolute increase in neutrophils: the percentage increased 
from 21 to 79%, while the absolute number of neutrophils increased from 
75 x 104 to 237 x 104 cells/ml (210). Blick reported a significant 
increase in granulocyte number 4 hours after the administration of TNF: 
granulocytes increased from a control value of 4.8 x 103 cells/mm3 to 
7.03 x 103 cells/mm3. However, the neutrophilia was a transient 
response: neutrophil counts returned back to control values by 24 hours 
(31,261). The neutrophilia induced by TNF was caused by the de-
margination of mature PMNs and the influx of immature cells from the bone 
marrow (210,211). 
These studies demonstrated that the hematocrit and white blood 
cell count changes induced by TNF were dependent on the model used and 
the time of measurement. 
2. Polymorphonuclear neutrophils 
PMNs' function in cell-mediated immunity is vital in host defense. 
TNF increases the bactericidal activity of PMNs through: 1) enhancement 
of phagocytic activity; 2) increased superoxide anion production; and 3) 
increased chemotaxis to the site of infection. 
One way by which TNF increased the bactericidal activity of PMNs 
was by augmenting their phagocytic activity. Blanchard, et al. (30) and 
Shalaby, et al. (230) :amined the influence of TNF on the phagocytic 
activity of PMNs. TNF dose dependently (10-1000 U/ml) enhanced the 
bactericidal activity of PMNs for Legionella pneumophilia in vitro (30). 
Similarly, TNF pre-treatment, 10,000-50,000 U/rat for 2-4 hours, 
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increased the removal of 1· pneumophilia bacteria from infected lungs and 
subsequently protected 50% of the animals from the lethal effects of 1. 
Rneumophilia (30). 
A second means by which TNF enhances bactericidal function of PMNs 
is by augmenting superoxide anion production. Larrick, et al. (140) and 
Tsujimoto, et al. (260) demonstrated the direct stimulatory effect of TNF 
on PMN superoxide anion production. Larrick, et al., reported a 2 to 3 
fold increase in superoxide production by PMNs after incubation with 
0.01-1 µg/ml TNF for 15 minutes. Tsujimoto, et al., reported maximal 
stimulation of superoxide production after incubation for 90 minutes with 
10-9 M TNF. Inhibition of intracellular ca++ mobilization significantly 
suppressed superoxide anion production in response to TNF (260). Others 
have reported TNF to be either a weak direct stimulus (129) or to have no 
direct effect (10,20) on superoxide anion production. 
In the presence of PMN activators such as zymosan or f-methionyl-
leucyl-phenylalanine (FMLP), PMN superoxide production is greatly en-
hanced by TNF. Klebanoff, et al. (129) observed a 10 fold increase in 
superoxide production stimulated by unopsonized zymosan plus 50 U of TNF 
over the amount produced after stimulation with TNF alone (129). Pre-
treatment with TNF for only 5-10 minutes increased, 0.5 to 18 fold, 
superoxide anion production stimulated by FMLP (10,20). Atkinson 
reported that TNF enhanced superoxide anion production in response to 
FMLP stimulation by changing all the i.;;:..p binding sites to high affinity 
sites: the total number of receptors remained unchanged but the binding 
affinity increased (10). 
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Thirdly, TNF stimulates PMN migration to the sites of inflam-
mation. Ming, et al. (176) demonstrated in vitro the PMN migratory 
response to a TNF concentration gradient. In the presence of a positive 
TNF concentration gradient of 10-103 U/ml, PMN migration across a poly-
carbonate filter was significant. Cybulsky, et al. (58) demonstrated a 
similar response in vivo: intradermal injections of lo·ll -10·10 moles 
of TNF/injection site induced significant PMN migration to the injection 
site within 1-1.5 hours. TNF also increased the adherence properties of 
PMNs as a means of enhancing their localization to the site of infection. 
Seow, et al. (229) demonstrated a significant increase in PMN adherence 
as early as 5 minutes after treatment with 500 U/ml TNF. Gamble, et al. 
(87) demonstrated enhanced PMN adherence to human umbilical vein endo~ 
thelial cells (HUVE) after treatment with TNF for as little as 5 minutes. 
PMNs' rapid response to TNF stimulation is important for the quick 
mobilization of PMNs to a site of infection. 
3. Fibroblasts 
TNF significantly influences fibroblast function in a number of 
ways. For instance, TNF significantly enhances fibroblast proliferation 
in a dose dependent manner. After screening 39 human and mouse cell 
lines, Sugarman, et al. (244) demonstrated a dose dependent mitogenic 
effect of TNF on the human lung fibroblast cell line, WI-38: TNF at 
doses of 5- 5000 U/ml significantly increased cell number after 48-72 
hours of incubation. Vilcek, et al. (265) reported tl- growth enhancing 
effect of lo-10.10·13 M TNF on the human diploid fibroblast cell line, 
FS-4. TNF stimulated cell proliferation even in contact inhibited FS-4 
cells when 5% fetal calf serum was present in the incubation medium. 
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-. in the presence of additional serum-derived growth factors, TNF's ~,.us, 
mitogenic activity overrides growth inhibitory conditions. 
The mitogenic response resulted from either growth factor or c-
fos and c-myc mRNA production by fibroblasts in response to TNF stimu-
lation. For instance, when protein synthesis was inhibited with 0.1 
mg/ml cycloheximide, TNF at a dose of 10 ng/ml was cytotoxic for human 
diploid fibroblasts (128). However, pretreatment for 4 hours with TNF 
completely protected fibroblasts from the cytotoxicity observed after TNF 
plus cycloheximide co-treatment. This protective effect may be at-
tributed to two proteins of 36,000 and 42,000 molecular weights that are 
synthesized in response to TNF (128), although as many as nine proteins 
were determined after incubation with 1000 U/ml TNF for 24 hours (19). 
The induction of c-fos and c-myc oncogene expression may be more 
important in the mitogenic response to TNF stimulation than protein 
production. Lin and Vilcek (149) reported that incubation with 30 ng/ml 
TNF for 20 minute induced a transient increase in c-fos and c-myc mRNA 
expression, with peak concentrations by 30 minutes followed by a rapid 
decline to control levels by 60 minutes. 
TNF also stimulates the synthesis and release of prostaglandin E2 
and collagenase by cultured fibroblasts. Human synovial cells and dermal 
fibroblasts incubated for 3 days with 3.0 nM TNF maximally produced 
prostaglandin E2 and collagenase, as described by Dayer, et al. (61). 
Normal lung fibroblasts stimulated for 3 days with 20 ng/ml TNF demon-
strated an increased synthesis of glycosaminoglycan (69): Elias et al. 
reported an 159% increase in 3H-glucosamine incorporation into gly-
cosaminoglycan. 
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TNF not only stimulates production of specific growth factors, but 
also stimulates production of specific growth factor binding sites. 
Confluent fibroblasts stimulated with 50-500 ng of TNF for 24 hours 
produced specific growth factors for colony formation by human bone 
marrow granulocytes-macrophages (CFU-GM), erythroid (BFU-E), and 
multipotential progenitor cells (CFU-GEMM) (289). Furthermore, TNF 
stimulated the production of epidermal growth factor (EGF) binding sites. 
Palombella, et al. (193) reported a 67% increase in 125 I-EGF binding by 
human diploid fibroblasts after 24 hour incubation with 1 ng/ml TNF 
(193). TNF treatment increased both the synthesis and maturation of EGF 
receptor, thereby eliciting a 76% increase in the number of specific EGF 
binding sites from 25,000 to 40,000 sites/cell (193). 
Fibroblasts treated with TNF also are protected from the 
pathological effects of encephalomyocarditis virus (EMC). Kohase, 
(130) reported that pretreatment for 24 hours with TNF at doses greater 
than or equal to 3 ng/ml completely protected FS-4 fibroblasts from the 
pathological effects of EMC virus. This protective effect, as determined 
by Kohase, resulted from IFN-P2 production by TNF stimulated fibroblasts. 
However, closer examination by Reis, et al. (209) determined that the 
protective effect resulted from IFN-P rather than IFN-P2 production by 
TNF treated fibroblasts. 
Lastly, TNF has an imrnunomodulatory effect on fibroblasts. 
Collins, et al. (53) demonstrated that human dermal fibroblasts treated 
with TNF had an enhanced expression of class I major histocompatibility 
(MHC) antigens. Class I MHC antigen expression increased approximately 9 
fold after treatment with 20 U/ml of TNF for 4 days as a result of 
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increased mRNA synthesis. An additional immunoregulatory effect includes 
the inability of TNF treated fibroblasts to perform an accessory role in 
the production of IFN-7 by PH.A stimulated T cells. Le and Vilcek (141) 
demonstrated that FS-4 cells pretreated with 1-100 ng/ml TNF for 24 hours 
failed to perform their accessory role in IFN-7 production by PH.A 
stimulated T cells due, perhaps, to the release of a T cell inhibitor by 
the TNF-activated fibroblasts. 
4. Endothelial cells 
One of the functions of TNF is to enhance endothelial cell 
adhesiveness, thereby increasing the propensity for PMN adherence to 
endothelial cell surfaces. Gamble, et al. (87) and Pohlman, et al. (205) 
exam~ned the stimulatory influence of TNF on endothelial cell ad-
hesiveness. Incubation with 100 U/ml TNF for as little as 5 minutes 
increased PMN adherence to the endothelial cell surface (87). A maximal 
25% increase in PMN adherence was achieved after endothelial cells were 
incubated for 4 hours with 100 U/ml of TNF. TNF enhanced adherence of 
PMNs to endothelial cells may be by a protein synthesis dependent process 
(87,205). Pohlman, et al. (205) determined that TNF treatment induced 
the expression of an endothelial cell surface factor which augmented 
neutrophil attraction. The function of the TNF induced endothelial cell 
surface factor was to interact with the neutrophil membrane antigen 
complex CDW18, thereby increasing the endothelial cell surface adherence 
for PMNs. This hypothesis prevailed after the observation that PMN 
adherence to TNF treated endothelial cells decreased 65% after treatment 
with the monoclonal antibody specfic for the membrane antigen complex 
CDW18. A similar mechanism is involved in the TNF enhanced leukocyte 
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adherence to endothelial cell surfaces observed by Pober, et al. 
(203,204). Endothelial cells incubated with 200 U/ml of TNF for 4.5 
hours demonstrated a significant increase in antibody H4/18 binding, 
indicative of the expression of an endothelial cell surface protein which 
is involved in endothelial cell-leukocyte adherence (203,204). 
TNF also increases endothelial cell surface adhesiveness for T and 
B lymphocytes. Cavender, ~. (43) observed a significant increase in 
T and B lymphocyte binding to endothelial cells treated with 10 U/ml TNF 
for 4 hours (43). Experiments with specific monoclonal antibodies 
suggested that TNF induced endothelial cell-lymphocyte binding is 
mediated by an endothelial ceil surface receptor (43). Pober, et al. 
(204) established that TNF treatment induced a rapid elevation of the 
endothelial cell intercellular adhesion molecule, ICAM-1. ICAM-1 
expression increased progressively during 24 hour treatment with 100 U/ml 
TNF and may be the mechanism involved in T lymphocyte binding to 
endothelial cells (204). 
TNF not only influences the adhesiveness of the endothelial cell 
surface for PMNs and lymphocytes, but TNF also modulates the growth of 
endothelial cells both in vivo and in vitro. In vivo, TNF had a 
significant angiogenic effect; doses of 0.5 to 10 µg of TNF induced a 
significant increase in the vascularization of the rabbit cornea (86). 
In vitro, however, TNF had a growth inhibitory effect. Endothelial cells 
inct·'-;.ted with 1 ng/ml TNF for 7 days had a 50% inhibition in cell 
proliferation (86). Normal cell growth resumed after TNFs' removal from 
the incubation medium (86). Stolpen, et al. (242) evaluated the 
morphological changes that accompanied the growth inhibitory effect of 
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TNF observed in vitro. Human umbilical vein endothelial cells treated 
with 20 to 100 U/ml of TNF for 72 to 96 hours became very elongated and 
plump. The cells were arranged in whorls and the uniform cell-cell 
contacta were disrupted, which resulted in areas of overlapping cells. 
Cytoskeletal changes included parallel arrays of actin filaments rather 
than dense parallel bands and proteolytic degradation of fibronectin. 
TNF is a potent inducer of blood procoagulant activity. 
Bevilacqua, et al. (29) and Nawroth and Stern (186) evaluated the 
procoagulant activity induced with TNF treatment of cultured endothelial 
cells. An increase in endothelial cell procoagulant activity was 
demonstrated as early as 15 minutes after incubation with 100 U/ml TNF, 
with a 4 to 15 fold rise evident ufter 4 hours (29). This effect was 
blocked by treatment with cycloheximide or actinomycin D, which suggested 
that it was a protein synthesis dependent process (29). Nawroth and 
Stern attributed the procoagulant activity observed after TNF treatment 
of endothelial cells to: 1) induction of tissue factor expression on the 
endothelial cell surface; and 2) depressed thrombomodulin-dependent 
protein C activated anticoagulant activity. 
Growth factor production by endothelial cells is stimulated with 
TNF. Endothelial cells incubated with 100 U/ml of TNF for 8-24 hours 
produced the hematopoietic growth factor, granulocyte-macrophage colony-
stimulating factor, GM-CSF (32,33). This effect resulted from TNF 
stimulated GM-CSF IIL~"\ production. Endothelial cells cultured with TNF 
were demonstrated by Hajjar, et al. (98) to produce a smooth muscle cell 
mitogenic factor. Conditioned medium from endothelial cells cultured for 
18 hours with 10 ng/ml of TNF induced a 90% increase in smooth muscle 
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cell proliferation, whereas TNF alone stimulated only a 17% increase in 
smooth muscle cell mitogensis. Antibodies to platlet-derived growth 
factor completely abolished the mitogenic activity, suggesting that TNF-
stimulated endothelial cells produced a platlet-derived growth factor-
like molecule that was responsible for the smooth muscle cell pro-
liferation. 
Endothelial cell surface MHC class I antigen expression is 
induced by TNF. Collins, et al. (53) and Wedgewo0d, et al. (278) 
demonstrated that TNF increased endothelial cell surface MHC class I 
antigen but not class II antigen expression. Incubation with TNF for 96 
hours enhanced Hl.A-A,B antigens and P2-microglobulin expression 2 to 9 
fold by increasing 100 fold the steady state level of the 1500 base pair 
transcript for class I MHC heavy chains (53,278). This was a protein 
synthesis dependent process, for incubation with cycloheximide prevented 
the increase in MHC class I antigen expression (53). Leeuwenberg, et al. 
(143) postulated that TNF increased endothelial cell MHC class I antigen 
expression by stimulating IFN-P1 production. They demonstrated, with 
antibodies directed against IFN-P1. that IFN-P1 was important in 
stimulating MHC class I expression by endothelial cells. However, 
Lapierre, et al. (139) determined that TNF induced MHC class I antigen 
expression most likely was not mediated through the production of either 
IFN-p, IFN-a, or IFN-P2-
Prostacyclin synthesis by va .. ~lar endothelial cells is increased 
by treatment with TNF, as reported by Kawakami, et al. (120). Endo-
thelial cells incubated with 3.4 x 10- 9 M TNF for 24 hours produced more 
than twice the amount of prostacyclin than did unstimulated cells. The 
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maximal prostacyclin secretory rate was o~served between 3 and 12 hours 
Stl.·mulation with 3.4 x lo- 8 M TNF. after 
Lastly, TNF stimulates endothelial cells to synthesize and release 
IL-1. Maximal IL-1 activity is produ~sd by confluent endothelial cells 
after incubation with 200 pM TNF for 20 hours (185). TNF acted directly 
on the endothelial cells to stimulate the production and release of IL-1, 
since the addition of cycloheximide to the incubation medium prevented 
the response. 
5. T and B lymphocytes 
TNF has important immunomodulatory effects on both T and B 
lymphocytes. TNF does not effect resting T lymphocytes (225) but does 
influence T cells activated with agents such as PHA or specific T cell 
monoclonal antibodies (97,208,225,285). Scheurich, et al. (225) 
demonstrated that activated T cells incubated with 100 ng/ml of TNF for 
48 hours had an increase Of 136% in HI.A-DR expression. A 50% increase in 
IL-2 receptors on OKT3 activated T cells was observed after 24 hour 
incubation with 10 ng/ml TNF, thereby enhancing the sensitivity to IL-2 
(225). 
TNF also enhances the proliferation of activated T cells (97,208, 
225,285). Yokota, et al. (285) and Hackett, et al. (97) reported a 100-
600% increase in 3H-thymidine incorporation by activated T cells 
stimulated with TNF for 72-96 hours. TNF increased the number of mitogen 
activated T cells entering the cell cycle (97). R' ~es, et al. (208) 
reported that the thymocyte proliferatory response to TNF was species 
specific: recombinant murine TNF, not recombinant human TNF, at 
concentrations of 78 to 2500 U/ml stimulated murine thymocyte 
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proliferation in response to PHA. These TNF induced responses on 
activated T cells are related to the significant increase in TNF receptor 
number, from 300 to 5000 sites/cell, subsequent to T cell activation 
(225). Additio11ally, PHA activation of T cells sti~ulated the production 
of TNF (208). Moreover, the production of TNF by activated T cells is 
enhanced by IL-1, IL-2, and IL-4, suggesting that TNF production by 
activated thymocytes might be involved in the thymocyte proliferation 
stimulated by IL-1, IL-2, and IL-4 (208). 
TNF is also important in cytotoxic T lyni.phocyte development. 
Ranges, et al. (207) reported that 102 U/ml of TNF restored cytotoxic T 
lymphocyte (CTL) generation in mixed lymphocyte cultures suppressed by 
transforming growth factor~ (TGF-~). Part of the suppressive effect of 
TGF-~ on CTL generation was related to the complete inhibition of TNF 
generation by mixed lymphocyte cultures incubated with 1 ng/ml TGF-~ 
(207). From the observations of Ranges, (207) and Jongeneel, et 
al. (118), TNF was important in CTL development but was not essential. 
Not only does TNF significantly influence activated T cells, but TNF 
also significantly influences activated B cells. Similar to activated T 
cells, activated B cells were responsive to TNF stimulation as a 
consequence of the increased number of surface TNF receptors: activated B 
cells have 6000 TNF receptor sites/cell, compared to quiescent cells 
which lacked detectable TNF receptors (122). TNF significantly enhanced 
the B cell immune response to T cell dependent antigens. Jelinek, 
(114) demonstrated that TNF enhanced the generation of immunoglobulin 
secreting B cells stimulated by Staphylococcus aureus in the presence of 
IL-2. Ghiara, et al. (89) reported a similar finding: TNF enhanced the 
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in v1vo B cell response to the T cell dependent antigen, sheep red blood 
cells, but did not enhance the B cell response to the T cell independent 
antigen, type III pneumo- coccal polysaccharide (89). 
TNF also stimulates 3H-thymidine incorporation by activated B 
cells. In the presence of B cell activators, such as the polyclonal B 
cell activator and Staphylococcus aureus, TNF enhanced 3H-thymidine 
incorporation by B cells 4 to 6 fold (114,122). The incorporation of 3H-
thymidine by activated B cells was further augmented by co-treatment with 
IL-2 plus TNF (114,122). Janssen and Kabelitz (113) reported a similar 
stimulatory effect of .L'NF on Epstein-Barr virus (EBV) stimulated B cells. 
TNF induced the rapid proliferation and differentation of a macrophage-
free B cell preparation stimulated with EBV. 
D. EFFECTS OF TUMOR NECROSIS FACTOR AT THE ORGAN AND TISSUE LEVEL 
1. Liver 
The liver performs vital roles in protein, glucose, and lipid 
metabolism. This section will review the literature concerning the 
effects of TNF on hepatic: 1) amino acid uptake and acute phase protein 
synthesis; 2) glucose production; and 3) lipid production. 
In vivo and in vitro effects of TNF on hepatic amino acid uptake 
was assessed by Warren, ~. (275) using male rats. TNF at a dose of 1 
mg/kg significantly increased hepatic a-amino [l-14c]isobutyric acid 
(AIB) uptake in vivo: the AIB distribution ratio was elevated 5 fold 
within 4 hours. However, TNF failed to directly enhance basal AIB uptake 
in vitro by isolated hepatocytes incubated for 20 hours with TNF at doses 
of 0.03 to 30 pM. Under stimulatory conditions with 5 nM glucagon, 0.3 
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pM TNF significantly enhanced glucagon-stimulated AIB uptake from 200% 
above basal to greater than 300% above basal. 
TNF has a direct stimulatory effect on hepatic acute phase protein 
synthesis both in vivo and in vitro. Six hours after an i.p. injection 
of 10-104 ng TNF/mouse, Sipe ~. (236) observed a dose dependent 
increase in serum amyloid A (SAA) concentration. Serum amyloid A 
concentrations increased from a basal value of 2 µg/ml to 80 and 130 
ug/ml by 6 and 20 hours, respectively, after the administration of 104 ng 
of TNF. Mortensen, et al. (181) reported a significant increase in serum 
amyloid P (SAP) concentrations 24 hours after an i.p. injection of TNF: 
SAP concentrations increased 4 fold after an i.p. injection of 5 x 104 U 
of TNF/mouse (approximately 1 µg). When 7.5 µg of TNF was given to each 
mouse, a measurable increase in 2 other acute phase proteins was observed 
24 hours post-injection; serum C3 and fibrinogen (181). Serum C3 con-
centration was elevated ~o 809 µg/ml compared to 747 µg/ml for saline 
treated controls, and fibrinogen concentrations doubled 24 hours after 
TNF injection. A significant increase in a fifth acute phase protein, C-
reactive protein, was demonstrated 24 hours after the subcutaneous 
injection of 100-175 µg/m2 of TNF to cancer patients (276). C-reactive 
protein concentrations more than doubled, increasing from a pre-injection 
concentration of 4.4 to 11.6 mg/dl within 24 hours after TNF admin-
istration. 
Moldawer, et al. (178) examined the effect of chronic TNF 
administration on hepatic acute phase protein synthesis in vivo. Total 
liver protein synthesis was significantly elevated to 167 mg/day in mice 
given daily injections of 0.02 nmoles of TNF for 5 days compared to 136 
30 
mg/day produced by freely fed control mice. Chronic TNF treatment 
significantly increased SAP concentrations approximately 7 fold to 46 
µg/ml compared to the SAP concentrations in the control mice. On the 
contrary, chronic TNF treatment significantly decreased serum albumin 
concentration to 34 mg/ml compared to 44 mg/ml reported for freely fed 
control animals. 
The in vitro effect of TNF on hepatic acute phase protein 
synthesis was examined using isolated hepatocytes and hepatoma cell 
lines. Mortensen, et al. (181) evaluated the direct in vitro effect of 
TNF on hepatic SAP synthesis using isolated hepatocytes. A three fold 
increase in SAP synthesis was produced after 24 hour incubation with 102-
104 U/ml TNF. Perlmutter, et al. (199), Darlington, et al. (59) and 
Mackiewicz, et al. (151) evaluated the effects of TNF on acute phase 
protein synthesis using human hepatoma cell lines. TNF, incubated with 
isolated cells for 18 to 48 hours, significantly enhanced the synthesis 
of the following acute phase proteins; factor B (199), factor C3 
(59,199), and ceruloplasmin (151). Perlmutter (199) and Mackiewicz (151) 
reported a direct inhibition of hepatic albumin synthesis with 100 and 
250 ng/ml TNF, respectively, whereas Darlington (59) reported no change 
in albumin synthesis after treatment with 20-10,000 U/ml TNF. The TNF 
induced changes in hepatic acute phase protein synthesis reflected the 
changes in respective mRNA synthesis induced by TNF (199). 
The effects of TNF on hepatic glucose metabolism has not been 
studied as extensively as the effects of TNF on acute phase protein 
synthesis. Rofe, et al. (212) examined the direct glucoregulatory 
effects of TNF using isolated hepatocytes. The glycogenolytic capacity 
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of hepatocytes isolated from fed rats was unaltered by treatment with 1.2 
nM TNF for 60 minutes. Furthermore, the gluconeogenic ability of 
hepatocytes isolated from 24 hour fasted rats also was not effected by 
TNF treatment: incubation with 1.2 nM TNF treatment for 30 minutes did 
not alter the gluconeogenic response to lactate, alanine, or glycerol. 
Thirdly, the effect of TNF on hepatic lipid metabolism was tested. 
Feingold, et al. (71) observed a stimulatory effect of TNF on hepatic 
lipogenesis in vivo. Within 16-17 hours after the administration of 
0.125 mg/kg TNF, rats demonstrated a significant increase in liver 3H20 
incorporation into fatty acids (67 fold), cholesterol (2.9 fold), and 
total non-saponifiable lipids (2.6 fold). Liver slices obtained from 
rats 16 hours after the administration of 0.125 mg/kg TNF demonstrated 
similar effects in vitro: acetate incorporation into fatty acids, 
cholesterol, and total non-saponifiable lipids was increased 97%, 95%, 
and 74%, respectively (71). Closer examination revealed that TNF 
enhanced lipogenesis by increasing HMG CoA reductase synthesis (71). TNF 
had no effect, however, on hepatic fatty acid utilization, triglyceride 
synthesis, or ketone body production (212). 
2. Muscle 
TNF significantly influenced 3 aspects of muscle physiology: 
muscle fiber membrane potential; glucose metabolism; and protein 
metabolism. TNF triggered muscle membrane depolarization both in vivo 
and in vitro. T: ~ey, et al., demonstrated the muscle membrane 
depolarization activity of TNF both in rats (251) and in dogs (253). 
Intravenous infusion of 0.6 and 1.8 mg/kg TNF produced a measurable 
depolarization of hindlimb adductor muscle fibers 1 hour later; membrane 
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potentials decreased from pre-injection values of -95.0 and -93.4 mV to 
-85.S and -75.6 mV potentials 1 hour after infusions of 0.6 and 1.8 mg/kg 
TNF, respectively (251). Infusion of TNF directly into the hindlimb 
muscle demonstrated significant depolarization within 5-10 minutes, the 
magnitude and duration of which were dose dependent (253). In vitro 
studies conducted by Tracey, et al. (251,252) using rat extensor 
digitorum longus and soleus muscles supported the hypothesis that TNF 
acted directly on the muscle fibers in vivo to elicit an observable 
membrane depolarization. In agreement with the in vivo studies that 
infused TNF directly into the hindlimb muscle, TNF dose dependently 
induced significant muscle fiber membrane depolarization in vitro within 
5 minutes. The largest change in membrane pot~~tial was observed with 10 
nM TNF: membrane potential decreased from a pre-injection value of -71.6 
mV to -58.6 mV after TNF treatment. 
A second area influenced by TNF treatment is muscle glucose 
metabolism. A significant increase in glucose transport by L6 myotubes 
was observed after 19 hours of incubation with 0.1-10 µg/ml TNF (142). A 
100% increase in 3H-2-deoxy-D-glucose uptake over control value~ was 
demonstrated by myotubes incubated with 10 µg/ml TNF. Concomitant with 
the rise in glucose uptake was a significant increase in lactate pro-
duction by the TNF treated muscles. On the contrary, Rafe, et al. (212) 
observed no significant increase in lactate production by rat hemi-
diaphragms treated with 1.2 nM Tc·~ for 2 hours. However, Rafe did 
demonstrate a 31% increase in glucose oxidation by the TNF treated rat 
hemidiaphragms. 
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A less defined, third effect of TNF on muscle physiology concerns 
muscle protein metabolism. Kettelhut, ~. (126) reported no signi-
ficant effects on in vitro muscle protein degradation or synthesis using 
soleus and extensor digitoru.~ longus muscles isolated from TNF pre-
treated rats. Regardless of the route of administration, intravenous or 
subcutaneous, pretreatment with 4 mg/kg TNF in vivo did not influence 
muscle metabolism in vitro 24 hours later. Daily administration of TNF 
for 5 days also failed to cause any measurable difference in muscle 
protein metabolism in vitro by muscles isolated 6 hours after the fifth 
injection (126). Furthermore, TNF at doses of 104 to 105 U/ml incubated 
directly with soleus and extensor digitorum longus muscles for 2 hours in 
vitro also failed to significantly influence muscle protein metabolism 
(126). A comparable study performed by Rofe, et al. (212) measuring 
alanine release as an index of rat hemidiaphragm protein degradation, 
further supports the findings that TNF does not directly influence muscle 
protein metabolism. 
Contrary findings concerning muscle protein metabolism were 
reported by Warren, et al. (276). Cancer patients given an i.v. 
injection of 10-100 µg/m2 TNF demonstrated a significant net efflux of 
amino acids from the forearm by 6 hours: total amino acid efflux nearly 
doubled. More specifically, net alanine and glutamine efflux increased 
from control values of 105 and 144 nmoles/min/lOOml to 278 and 214 
nmoles/min/lOOml, respectively, 6 hours after TN~ injection. 
3. Adipose tissue and adipocytes 
As discussed earlier in this dissertation, TNF mediates the 
hypertriglyceridemia observed during chronic infection. Chronic 
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administration of exogenous TNF in vivo induced the same response. 
Cancer patients administered TNF twice weekly for 4 weeks developed 
significant hypertriglyceridemia (31). Plasma triglyceride con-
centrations increased significantly from a pretreat~ent value of 119 to 
125 mg/dl after 4 weeks of treatment. However, the hyperlipemic effects 
of TNF were also demonstrated much earlier (195). As early as 3.5 hours 
after an i.v. injection of 250 µg/kg TNF, rats developed a significant 
hypertriglyceridemia, with triglyceride concentrations elevated to 210 
mg/dl from a pre-injection value of 67 mg/dl (195). This was not a 
transient response since triglyceride concentrations remained elevated 
for 7 hours (195). 
There are several mechanisms responsible for the hyperlipemic 
effect of TNF. One mechanism is the lipoprotein lipase inhibiting effect 
of TNF. Semb, et al. (228) evaluated the effects of TNF on lipoprotein 
lipase (LPL) activity using mice, rats, and guinea pigs. TNF at doses of 
10, 20, and 30 µg significantly depressed adipose tissue LPL activity in 
mice, rats, and guinea pigs at 4, 6, and 15 hours post-injection, 
respectively. However, TNF significantly increased liver and plasma LPL 
activity in all 3 animal models (228). The hypothesis that TNF directly 
suppressed adipose tissue LPL activity in vivo is supported by the in 
vitro studies of Patton, et al. (196). Using the murine adipocyte cell 
line, 3T3-Ll, a dose dependent inhibition of heparin-releasable LPL 
activity was exhibited after incubation with 0.01-100 nM TNF fo_ 16 
hours. Approximately 90% inhibition was demonstrated with 1 nM TNF. 
Secondly, TNF induces hyperlipemia through the inhibition of lipid 
synthesis. Using 3T3-Ll cells, the influence of 0.0001-lOnM TNF on 3H-
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acetate uptake was investigated (196). TNF inhibited 3H-acetate uptake 
in a dose dependent manner: 80% inhibition of 3H-acetate uptake was 
induced by treatment with 1 nM TNF for 24 hours. TNF inhibited 3H-
acetate incorporation into ali classes of lipids, but especially ~h~ 
triglycerides. 
Direct inhibition of key lipogenic enzymes is the mechanism 
responsible f0c TNF-induced inhibition of lipid synthesis. Pape, et al. 
(194) determined that TNF directly inhibited the synthesis of an 
important lipogenic enzyme using the pre-adipocyte cell line, 30A-5. 
Incubation with 200 U/ml TNF for 8 days directly inhibited acetyl-CoA 
carboxylase mRNA accumulation by 80% (194). Treatment with TNF also 
prevented pre-adipocyte differentiation and cellular lipid accumulation 
as a result of inhibiting lipogenic enzyme synthesis (194,248). Failure 
to maintain lipid synthesis was observed after incubating mature adi-
pocytes with TNF (248). After 6 days of culture with macrophage con-
ditioned medium containing TNF, only 10% of the mature adipocytes had 
identifiable lipid droplets; the rest of the cells had lost their stored 
triglycerides. The resultant loss in lipid droplets was caused by a 
rapid decrease in the synthesis of key lipogenic enzymes: within 12 to 
24 hours after TNF addition, there was a 90% drop in lipogenic enzyme 
mRNA levels (248). 
Thirdly, TNF directly stimulates lipolysis, thereby increasing 
serum triglyceride levels. Using 3T3-Ll adipocytes, Patton, et al. (196) 
demonstrated the lipolytic effect of TNF in vitro. TNF at a dose of 1.5 
nM directly increased free fatty acid efflux from 3T3-Ll adipocytes 
Within 8 to 24 hours. TNF, however, failed to influence fatty acid 
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efflux from epidydimal fat pads removed from rats pre-treated with 4 
mg/kg TNF for 4 hours (126). Furthermore, both epidydimal fat pads (126) 
and adipocytes {212) isolated from control rats failed to demonstrate a 
direct effect of TNF on in vitro lipolysis. Neither epidydimal fat pads 
nor isolated adipocytes demonstrated an increase in glycerol release as a 
result of incubation with 4 µg/ml or 1.2 nM TNF, respectively (126,212). 
4. Organ pathology 
Close examination of major organs after in vivo treatment with TNF 
revealed significant pathophysiological changes. The gastro-intestinal 
tract was very sensitive to TNF treatment. For instance, Patton (195) 
observed a 2.5 to 4.5 fold increase in the stomach weights of mice and 
rats 3.5 hours after the i.v. injection of 0.25 mg/kg TNF. Incomplete 
gastric emptying, accompanied by swelling and gas retention, was 
responsible for the increase in stomach weights. Areas of infarction on 
the cecum were rapidly observed even after sub-lethal doses of TNF 
(195,249). The small intestines exhibited areas of segmental ischemia, 
inflammation, and edema after TNF treatment (195,210,249). Microscopic 
examination demonstrated mononuclear cell and neutrophil accummulation in 
the lamina propria of villi and intestinal glands {195). Electron 
microscopic examination demonstrated necrosis of intestinal epithelial 
cells with significant vacuolization of the cytoplasm (210). The blood 
vessels were lined by damaged endothelial cells, thus accounting for the 
increased adherence of mononuclear cells and neutrophils to the endo-
thelial cell surface (195), edema formation, and the accumulation of PMNs 
and RBCs in the interstitium (210). In some animals, TNF administration 
resulted in intussusception of the ileocecal valve into the cecum (210). 
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Assessment of TNF-induced liver damage revealed a significant 
increase in liver weight compared to controls (88). Histological 
examination of TNF treated livers demonstrated hepatocyte swelling, 
narrowing of liver canaliculi, and increased Kupffer cell number (88). 
After chronic administration of TNF for up to _10 days, Tracey, et al. 
(254) reported areas of focal parenchymal cell necrosis, extramedullary 
hematopoiesis, and proliferation of small bile ducts in the portal 
tracts. 
Discrete areas of hemorrhage and scattered hyperemia were observed 
in the lungs after TNF treatment (249,253). Histological examination of 
these areas revealed large arteries occluded by thrombi composed pri-
marily of PMNs (249). In rats, significant pulmonary edema occurred, as 
reflected in the significant increase in lung wet weights from 696 to 941 
mg after TNF treatment (88). Tracey (253) reported significant 
thickening of the alveolar membranes with peribronchiolar pneumonitis and 
PMN infiltration. 
Chronic exposure to TNF resulted in inflammatory cell infiltration 
into the subendocardium of the heart (254). This was associated with 
significant hypertrophy and hyperplasia of intimal endothelial cells and 
subintimal fibroblasts. Focal areas of myocardial cell hypereosinophilia 
and necrosis were also reported (254). 
Changes also were observed in the kidneys, pancreas, and adrenal 
glands as a result of TNF administration. Kidneys became enlarged and 
hyperemic, with discrete areas of tubular necrosis and damage to the 
nephrons (249,253). Focal areas of hemorrhage and inflammation were 
present in the pancreas (249). Medullary hemorrhagic necrosis as well as 
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prominent inflammatory changes were observed in the adrenal glands after 
TNF treatment (249,253). 
5. Alterations in body weight 
Since TNF is responsible for mediating the severe cachexia 
associated with chronic infection, then repeated administration of TNF 
should result in severe weight loss. Oliff, et al. (191) used an 
interesting technique to replicate the chronic release of TNF in vivo 
without administering repeated injections of TNF. Oliff constructed a 
rodent tumor cell line, CHO/TNF-20, which continuously secreted TNF and 
inoculated nude mice with the TNF-secreting tumor cells. During the 
first 14 days, they reported an initial weight gain, after which the mice 
began to lose weight. By 32 days post-inoculation with the TNF secreting 
tumor cells, animals had lost an average of 3.4g, or 17.6% of total body 
weight. Moreover, the TNF treated animals lost all body fat: autopsy 
revealed no prominent iutrascapular, perirenal, or subcutaneous fat. The 
severe wasting associated with the TNF secreting tumor was associated 
with a significant drop in food intake. 
The suppressed food consumption associated with TNF secretion from 
the TNF-secreting tumors was substantiated in young and adult rats given 
repeated injections of TNF (126,254). Within 24 hours after the first 
TNF injection, a 33% and 60% drop in food consumption were reported for 
young and adult rats, respectively (126,254). Even though repeated TNF 
administratior {,nduced a 20-30% decrease in food intake, the rate of 
growth relative to food consumption was similar for both the control and 
TNF treated rats (126). The weight loss observed in the TNF treated rats 
was similar to the weight loss observed in the pair-fed controls (254). 
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There was a signifi~ant difference, however, in protein and fat content 
between the pair-fed controls and the TNF treated rats. Pair-fed control 
animals demonstrated a drop i.n percent body fat from 11.9% to 6.0% and no 
change in protein content. TNF treatment, however, resulted in little 
fat mobilization, observed as a slight drop in percent body fat from 
11.9% to 8.3%, and a significant .mobilization of protein, reflected by a 
decrease in percent protein from 22.7 to 19.8%. Therefore, TNF induced 
cachexia resulted from suppressed food intake and altered fuel mobil-
ization. 
E. FEVER INDUCING PROPERTIES OF TUMOR NECROSIS FACTOR 
TNF has thermoregulatory effects in rabbits, rats, mice, and humans. 
Dinarello, et al. (66) were first to demonstrate the dose-dependent 
fever-inducing properties of TNF. Using rabbits, a monophasic fever 
response was elicited after an i.v. injection of 1 µg/kg TNF: peak 
temperature elevation occurred within 48-54 minutes post-injection and 
returned back to basal levels by 180 minutes. When the dose of TNF 
administered was increased 10 fold to 10 µg/kg, a biphasic fever profile 
was demonstrated (66): The initial peak in temperature, which cor-
responded to the monophasic peak observed after the 1 µg/kg dose of TNF, 
was followed by a second peak at 3.5 hours post-injection. Pre-
treatment with ibuprofen (10 mg/kg) blocked the initial rise in 
temperature, indicating that it resulted from TNF-induced prostaglandin 
release. The second fever pe .. · , however, was due to TNF- induced IL-1 
release (66). 
Thermoregulatory changes induced by TNF administration were 
dependent not only on the dose but also on the route of administration. 
r 
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young rats (60g) given an i.v. injection of 4 mg/kg TNF had a measurable 
drop in rectal temperature fro~ 36.8 to 34.3°C by 1 hour (125). Just 
prior to death, i.e. 3-4 hours after injection, rectal temperature had 
dropped further to 29.5-32°C. However, i.p. or subcutaneous injections 
of 4 mg/kg TNF resulted in the opposite response (126). A significant 
hyperthermia was measured in these rats 3 and 4 hours after i.p. and 
subcutaneous injections, respectively. Three hours after the peak 
hyperthermic response, temperatures began to fall and returned to control 
levels within 24 hours. 
Contaminating endotoxin in the recombinant TNF preparation was not 
responsible for the thermoregulatory activity of TNF. Mannel evaluated 
the thermoregulatory activity of TNF using both ETX-sensitive (C3H/HeN) 
and ETX-resistant mice (C3H/HeJ) (154,156). Within 5 hours after i.v. 
injections of 3-4 mg/kg TNF to C3H/HeN and C3H/HeJ there was a signi-
ficant decrease in body temperatures from 38 to 30°C in both groups of 
mice. If the hypothermic effect of TNF had resulted from contaminating 
ETX in the TNF preparation, then the ETX-resistant mice would have failed 
to demonstrate a significant thermoregulatory effect. 
Finally, there is substantial evidence which demonstrated signi-
ficant febrile responses shortly after TNF administration to humans. 
Blick, et al. (31) and Warren, et al. (276) examined the in vivo effects 
of TNF administered to cancer patients as an anti-neoplastic drug twice 
weekly for 4 weeks. Regardless of the route r administration, intra-
venous, intramuscular, or subcutaneous, a significant febrile response 
was determined. The time to peak temperature elevation, however, varied 
according to the route of administration: patients that received 10-100 
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µg/m2 TNF i.v. demonstrated peak elevation in body temperature within 1-2 
hours whereas 4-8 hours were required after the subcutaneous injection of 
l00-175 µg/m2 TNF (276). Associated with the febrile response were 
numerous clinical flu-like symptoms such as headache, fatigue, chills, 
and rigor (31,276). 
F. HEMODYNAMIC CHANGES INDUCED BY TUMOR NECROSIS FACTOR 
The hemodynamic effects of TNF were examined using beagle dogs 
(253), rats (13), and cancer patients (31,276). Anesthetized beagle 
dogs, infused intra-arterially with a non-lethal dose of 10 µg/kg TNF, 
hdd a measurable drop in mean arterial blood pressure (MBP) from a pre-
injection control value of 145 mmHg to 113 mmHg 1 hour post-infusion 
(253). In spite of the fall in MBP, there was no measurable change in 
heart rate. When a non-lethal dose of TNF was infused into conscious 
rats, a slightly different hemodynamic profile was observed. Bagby, et 
~- (13) reported no measurable ch~nges in MBP and heart rate either 
during the infusion of 0.15 mg/kg TNF over a period of 3 hours or for 2 
hours after completion of the infusion. Similar findings were reported 
in the clinical trials conducted by Blick, et al. (31) and Warren, et al. 
(276): conscious cancer patients administered non-lethal doses of TNF 
demonstrated no measurable change in mean arterial pressure. 
More dramatic hemodynamic changes were observed after highly lethal 
doses of TNF were administered to beagle dogs (253) and rats (249). 
Anesthetized beagle dogs infused over 40 minutes with 100 µg/' . ..., TNF 
demonstrated a rapid drop in mean arterial pressure from 141 to 45 mmHg 
by 3 hours after completion of the infusion (253). Heart rate, however, 
was unaltered and remained at an average rate of 166 beats per minute 
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•te of the significant hypotensive response. Similarly, anesthetized inspi 
Sprague-Dawley rats infused with a highly lethal dose of 1.8 mg/kg TNF 
demonstrated a significant 40 mmHg drop in systolic pressure approxi-
mately 75 minutes after onset of the infusion (249). This was a 
transient hypotensive response, for systolic pressure returned to near 
control values by 120 minutes. Unlike the anesthetized beagle dogs, 
anesthetiz~<l rats demonstrated a significant elevation in heart rate from 
450 to 550 beats per minute within the first 60 minutes after onset of 
TNF infusion. 
G. METABOLIC GRANGES INDUCED BY TUMOR NECROSIS FACTOR 
1. Plasma glucose 
Non-lethal doses of TNF have no effect on plasma glucose con-
centrations in both human cancer patients and experimental rats. Plasma 
glucose concentrations remained at control values for as long as 6 hours 
after the subcutaneous injection of 100-175 µg/m2 TNF to human cancer 
patients (276). Although there was no net change in plasma glucose 
concentrations for conscious rats infused with a sub-lethal dose of TNF 
(13), there were measurable changes in the rates of glucose appearance 
and utilization. Bagby, et al. (13) demonstrated a 25% increase in the 
rate of plasma glucose appearance during the 3 hour infusion of 0.15 
mg/kg TNF. Concomitant with the increased rate of glucose appearance was 
a 28% increase in glucose utilization (173). Meszaros, et al. (173) 
determined that the macrophage-rich tissues, such as spleen, liver, and 
kidneys, were largely responsible for the increased glucose utilization 
measured after TNF administration (173). Hence, even though there were 
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no measurable changes in plasma glucose concentrations, TNF did increase 
both glucose production and glucose utilization. 
Significant changes in plasma glucose concentrations were de-
monstrated after lethal doses of TNF. A significant hyperglycemic effect 
of TNF was determined in 60 g rats as well as adult rats. Kettelhut, 
al. (125), using 60 g rats, evaluated the glucoregulatory effects of TNF 
by changes in venous plasma glucose concentrations from samples taken by 
jugular vein puncture. TNF significantly increased venous glucose 
concentrations from 130 mg/dl to 200 mg/dl within 1 hour after the i.v. 
administration of 4 mg/kg TNF. Tracey, et al. (249), using anesthetized 
adult rats infused with 0.2-1.8 mg/kg TNF, reported elevated plasma 
glucose concentrations betweem 15 and 90 minutes after TNF adminis-
tration. At the later time points after lethal injections of TNF, 
significant hypoglycemia was observed. Two hours after TNF injection, 
Kettelhut (125), using 60 g rats, reported a significant drop in venous 
plasma glucose concentrations to approximately 30 mg/dl. Bauss, et al. 
(16) reported a similar hypoglycemic response in C3H/HeN mice 6 hours 
after injection with 3.0 mg/kg TNF. Plasma glucose concentrations, 
determined for samples taken under ether anesthesia, dropped to 
approximately 60 % of control values. 
2. Plasma lactate 
Dose dependent changes in plasma lactate were observed after TNF 
administration. Non-lethal doses of TNF induced no significant changes 
in plasma lactate concentrations for as long as 3-5 hours after ad-
ministration to adult rats (13) or anesthetized beagle dogs (253). In 
contrast, significant hyperlactacidemia was observed after the ad-
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winistration of lethal doses of TNF. Tracey, et al. (253) reported a 4 
fold increase in plasma lactate 3 hours after the infusion of a lethal 
dose of TNF, 100 µgjkg, to anesthetized beagle dogs: plasma lactate 
concentrations increased from 0.66 to 2.55 mM by 3 hours. When Tracey, 
sa.t al. (249) examined the hyperlactacidemia-inducing property of TNF in 
anesthetized rats, a similar response was observed. Anesthetized rats 
given a lethal infusion of 1.8 mg/kg TNF demonstrated a 3 to 5 fold 
increase in plasma lactate concentrations compared to pre-infusion 
values. A smaller increase was reported for mice injected with a lethal 
dose of TNF: only a 160% increase in plasma lactate concentrations was 
determined for samples taken under ether anesthesia within 6 hours after 
the injection of 3.0 mg/kg TNF (16). 
H. NEURO-ENDOCRINE CHANGES INDUCED BY TUMOR NECROSIS FACTOR 
1. Insulin and glucagon 
The effects induced by TNF on the pancreatic hormones, insulin and 
glucagon, were examined in vivo as well as in vitro. The in vivo changes 
in plasma insulin and glucagon concentrations induced by TNF were dose 
dependent and model dependent. When tested in cancer patients, non-
lethal doses of TNF (100-175 µg/m2) injected subcutaneously elicited no 
significant changes in either plasma insulin or glucagon concentrations 
(276). Plasma insulin and glucagon concentrations were 65 µU/ml and 354 
pg/ml, respectively, prior to injection and were not significantly 
different 6 hours after TNF injection at 43 µU/ml and 429 pg/ml, re-
spectively. Significant changes in plasma insulin as well as glucagon 
concentrations, however, were reported for studies performed in animal 
models. Bagby, et al. (13) demonstrated a transient 3 fold in~rease in 
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plasma insulin concentrations within 1 hour after the onset of a non-
lethal infusion of TNF in conscious rats. Plasma insulin concentrations 
were 30 and 9 µU/ml in TNF and saline treated rats, respectively. 
Although the plasma insulin concentrations were 3 fold higher in the TNF 
treated rats compared to the saline controls, the pre-injection insulin 
concentrations were not determined for either group of rats. Since the 
real control value for the TNF treated rats is the pre-injection insulin 
concentration, it is difficult to definitely conclude that TNF induced a 
hyperinsulinemic response. 
Significant dose dependent changes in plasma glucagon concentra-
tions also were induced after TNF administration. Tracey, et al. (253) 
reported no significant ch~nge in plasma glucagon concentrations 3 hours 
after the infusion of a non-lethal dose of TNF (10 µg/kg) in anesthetized 
beagle dogs. Although there was a slight elevation in plasma glucagon 
concentration 3 hours after TNF infusion, the difference was not sta-
tistically significant, ie. 179 and 98 pg/ml, respectively. However, a 
significant rise in plasma glucagon concentration was induced after the 
administration of a lethal dose of TNF (109 µg/kg) to anesthetized beagle 
dogs (253). Plasma glucagon concentrations increased from a control 
value of 64 to 558 pg/ml within 3 hours after a lethal dose of TNF. 
Similarly, a significant elevation in plasma glucagon concentration was 
observed in conscious rats infused with a non-lethal dose of TNF. Bagby, 
et al. (13) ~eported significantly elevated plasma glucagon concen-
trations for the TNF infused rats compared to the saline treated rats at 
1 and 3 hours after start of the TNF infusion: plasma glucagon con-
centrations were 530 and 607 pg/ml, respectively, for the TNF treated 
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rats compared to 276 and 287 pg/ml, respectively, for the saline treated 
rats. The limitation of this study is that Bagby failed to report the 
pre-infusion glucagon concentrations for both groups of rats, thereby 
making it difficult to definitely conclude that TNF induced significant 
hyperglucagonemia. 
Direct in vitro effects of TNF on pancreatic hormone secretion 
were examined using isolated pancreatic Islets of Langerhans. TNF 
reduced insulin release from isolated rat islets by 40% (18). As 
reported by Bendtzen, et al. (18), islets incubated with TNF at doses 
greater than 1 µg/ml for 6 days exhibited a 40% reduction in insulin 
release. TNF suppressed insulin release without damaging islet integrity 
(153) or changing insulin content (18). 
Profound modulation of pancreatic hormone release was observed 
after treatment with TNF in combination with IL-1 (152) and IFN-7 (206). 
TNF, at doses as low as 25 ng/ml, potentiated 5 to 10 fold the inhibitory 
effect of IL-1 on glucose-stimulated insulin release by cultured islets 
(152). Moreover, cultured islets pretreated with 2 ng/ml IL-1 prior to 
incubation with 2.5 ng/ml TNF released 36% less insulin than islets pre-
treated with TNF prior to incubation with IL-1 (152). TNF also enhanced 
the cytotoxic effects of IFN-7. Pukel, et al. (206) determined that rat 
islet cell monolayers incubated for 4 days with 25 ng/ml TNF plus 1000 
U/ml IFN-7 released more intracellular 5lcr than did cells incubated with 
IFN-7 alone; 36.8% versus 7 ~%, respectively. Even greater islet cell 
cytotoxicity was demonstrated after treatment with all three mediators; 
TNF, IL-1 and IFN-7. Co-treatment with 1000 U/ml IFN-7 plus 25 ng/ml TNF 
plus 0.39 ng/ml IL-1 resulted in the release of 47% of intracellular 
Slcr. 
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TNF mediates p cell destruction in vivo not only by enhancing the 
cytotoxic activity of IFN-1 and IL-1, but also by increasing the ex-
pression of MHC class I antigens on P cells (37). Campbell, et al. (37) 
reported that incubation for 6 days with 20 ng/ml TNF increased the 
expression of MHC class I proteins on human and mouse P cells. An 
increase in class II MHC antigen expression was observed after co-
treatment with IFN-1 (500 U/ml) plus TNF (10 ng/ml). 
2. Plasma catecholamines 
Changes in plasma epinephrine and norepinephrine concentrations 
induced by TNF administration were dose dependent. Non-lethal doses of 
TNF induced either no change (253) or an increase (13) in plasma 
catecholamines. Tracey, et al. (253) reported no significant changes in 
plasma epinephrine or norepinephrine concentrations measured in anes-
thetized beagle dogs after infusion of a non-lethal dose of TNF (10 
µg/kg). Bagby,~. (13), however, demonstrated a significant increase 
in plasma epinephrine and norepinephrine concentrations after the in-
fusion of a non-lethal dose of TNF (150 µg/kg) in conscious rats. Plasma 
epinephrine concentration was significantly elevated 1 hour after onset 
of the TNF infusion relative to the concentration reported for the saline 
treated rats; 447 vs. 170 pg/ml, respectively. By 3 hours, both plasma 
epinephrine and norepinephrine concentrati ·3 were significantly elevated 
relative to the saline treated rats: plasma epinephrine and nor-
epinephrine concentrations for the TNF treated rats, 583 and 460 pg/ml, 
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respectively, were significantly greater than the corresponding values 
determined for the saline treated rats, 167 and 182 pg/ml. 
The influence of a highly lethal dose of TNF on plasma 
catecholamine concentrations was examined by Tracey, et al. (253). 
Anesthetized beagle dogs infused with 100 µg/kg TNF demonstrated sig-
nificant elevations in plasma epinephrine and norepinephrine concen-
trations. Plasma epinephrine increased from a pre-injection value of 58 
pg/ml to 1148 pg/ml within 15 minutes after the infusion of TNF. By 3 
hours, plasma epinephrine was significantly elevated at 1623 pg/ml 
relative to the baseline control. Plasma norepinephrine concentrations 
increased significantly from a baseline value of 282 pg/ml to 1400 and 
1982 pg/ml by 15 and 180 minutes, respectively, after TNF infusion. 
3. Plasma cortisol 
The influence of TNF on a stress and glucoregulatory hormone, 
cortisol, also was evaluated. Plasma cortisol concentrations are 
elevated even by non-lethal doses of TNF. As reported by Warren, et al. 
(276), cancer patients injected subcutaneously with a non-lethal dose of 
TNF, 100-175 µg/m2, had significantly elevated serum cortisol concen-
trations 6 hours after TNF administration: plasma cortisol increased 
from 18 to 30 µg/ml. Tracey, et al. (253), however, reported a 
significant increase in plasma cortisol only after a lethal infusion of 
TNF in anesthetized beagle dogs. Plasma cortisol increased greater than 
3 fold, from 42 to 146 ng/ml, as early as 15 minutes after . lethal 
infusion of TNF and remained elevated for as long as 3 hours after the 
infusion. 
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I. MORTALITY AND MORBIDITY INDUCED WITH TUMOR NECROSIS FACTOR. 
Lethal, shock-like effects were induced by TNF in mice, rats and 
dogs. Mice were the most resistant, compared to rats and dogs, to the 
lethal effects of TNF. The LD50 dose for TNF administered as an i.p. 
bolus injection to adult mice was 300 µg/mouse (approximately 12 mg/kg) 
for a 48 hour observation period (15). Approximately 10% and 80% 
mortality rates were observed after subcutaneous and i.p. injections of 8 
and 20 mg/kg TNF, respectively, in adult mice (145,214). However, when 
injected intravenously, mice were more sensitive to the lethal effects of 
TNF: 67% of ti1e mice died by 24 hours after an i.v. bolus injection of 
4.3-4.5 mg/kg TNF (16). Rats, on the other hand, were more sensitive 
than mice to the lethal effects of TNF. The LD50 dose, determined for a 
12 hour observation period, was calculated to be 0.7 mg/kg for adult rats 
given an i.v. bolus injection of TNF (249). Although similar mortality 
rates of 64% were observed after the i.v. injec~ions of 0.6 and 1.8 mg/kg 
TNF, the mean survival time was less for the 1.8 mg/kg treated rats 
(249). One hundred percent of both young and adult rats died after the 
i.v. injections of 4.0 and 3.6 mg/kg TNF, respectively (125,249).' When 
TNF was administered as an i.v. continuous infusion, no deaths were 
observed after the 3 hour infusion of 0.15 mg/kg TNF (13). More chronic 
administration of TNF, as reflected in the 5 day infusion of 0.1 mg/kg 
TNF/day, produced a mortality rate of 20% during the 5 day study (88). 
When a comparable dose of TNF was infused into anesthetized beagle dogs, 
ie. 0.1 mg/kg, all of the dogs died within 3 hours (253), indicating that 
dogs were more sensitive than rats and mice to the lethal effects of TNF. 
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Additionally, lethal as well as non-lethal doses of TNF induce 
clinical signs commonly associated with infections in both animal models 
and human cancer patients. Clinical signs of morbidity, such as diar-
rhea, ruffled fur, piloerection, tachypnea, and ocular exudates were 
observed after TNF administration to mice and rats (16,88,125,145,214, 
249). Similarly, clinical flu-like symptoms, such as headache, fatigue, 
chills, nausea, and rigur, were reported by human cancer patients in-
jected with non-lethal doses of TNF (31,175,276). 
J. RATIONALE 
Information concerning tl.e role of TNF as a mediator of the patho-
physiological changes associated with septic shock has escalated since 
the demonstration by Beutler, ~. (26) that passive immunization 
against TNF protected mice from the lethal effects of ETX. Although 
numerous studies have evaluated and compared the alterations induced by 
TNF to those asaociated with endotoxicosis and sepsis (13,16,24,103,125, 
126,142,145,156,161,173,174,175,249,250,251,253) a clear dose- and time-
related study evaluating the hemodynamic, metabolic, and neuro-endocrine 
alterations induced by comparably lethal doses of TNF and ETX has not 
been examined in conscious, unrestrained, cannulated, adult rats. Ad-
ditionally, the interactions of these two agents to elicit a highly 
lethal response has not been evaluated with relation to the hemodynamic, 
metabolic, and endocrine alterations induced after co-treatment with low 
doses of TNF and ETX. Furthermore, the direct in vitro ability of TNF to 
act as a glucoregulatory agent has not been examined using the isolated 
perfused rat liver preparation. Although Rofe, et al. (212) briefly 
evaluated the direct effect of TNF on isolated hepatocytes, a dose-
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dependent study has not been performed. Therefore, this study was 
performed to address specific in vivo as well as in vitro effects of TNF. 
CHAPTER III 
MATERIALS AND METHODS 
A. ANIMALS 
Male Holtzman rats weighing approximately 350-400 grams were used 
for all experiments. Rats were obtained from either the Holtzman Co. 
(Madison, Wt) or Sasco-King (St. Louis, MO). The rats were housed in 
stainless steel wire mesh cages while maintained in a temperature of 24°C 
for at least 5 days prior to experimentation on a 12 hour light (0700-
1900)/dark cycle. Purina rat chow and tap water were allowed ad libitum 
throughout the acclimat5on period. All experiments were initiated 
between 1000 and 1400 hours. 
B. AGENTS 
1. Tumor necrosis factor 
Recombinant human tumor necrosis factor-a (TNF) used for this 
study was either donated by Genentech Inc. (courtesy of H. Michael 
Shepard; South San Francisco, CA) or purchased from Amgen Biologicals 
(Thousand Oaks, CA). The Genentech TNF was lot #3056-55 with a specific 
activity of 5.02 x 107 units/mg protein, as assessed by lysis of 
actinomycin D treated L-M cells. This supply of TNF was received as a 
solution of 0.5 mg TNF/ml of buffer, containing monobasic and dibasic 
sodium phosphate and sodium chloride, pH-7.0. Endotoxin contamination 
was determjned by Genen~ech to be less than or equal to 0.125 endotoxin 
units/ml, which is equivalent to 0.25 endotoxin units/mg of TNF (Limulus 
Amoebocyte Lysate Assay; 1 endotoxin unit~ 0.1 ng of ETX). TNF 
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purchased from Amgen Biologicals was lot #902 with a specific activity of 
8 x 106 ~nits/mg protein, as assessed by lysis of mitomycin treated mouse 
L929 cells. Amgen Biologicals' TNF was received as a solution of 0.3 mg 
TNF/rnl of 40 mM Tris/0.1 M NaCl, pH-8.5. Contaminating endotoxin content 
was assayed by Amgen and was found to be less than 2.5 endotoxin units/mg 
protein (Limulus Amoebocyte Lysate Assay). 
2. Heat-inactivated tumor necrosis factor 
For one set of in vivo experiments, heat-inactivated TNF (H.I.-
TN~) was used as a control for the contaminating endotoxin inherent in a 
recombinant TNF preparation. Heating the TNF solution to 80°C for 60 
minutes inactivates the monokine but not the small quantity of con-. 
taminating endotoxin. For this reason, changes induced in the H.I.-TNF 
treated animals were probably the result of the contaminating endotoxin. 
3. Endotoxin 
Lyophilized Salmonella enteritidis lipopolysaccharide Boivin, lot 
#733346, was purchased from Difeo Laboratories (Detroit, MI). For use in 
these experiments, the lipopolysaccharide (endotoxin; ETX) was suspended 
in 0.9% sodium chloride. 
C. IN VIVO EXPERIMENTS 
1. Cannulation procedure and feeding regimen 
For one set of experiments, rats underwent surgery at 1400 hours 
on the day prior to experimentation. Rats were anesthetized with either 
5% Halothane (Halocarbon Tqboratory Inc .. Hackensack, N.J.) in 100% 
oxygen until the animal became unconscious, or an i.v. injection of 
sodium pentobarbital (46 mg/kg). A midline incision was made on the neck 
and the area was blunt dissected to expose the left carotid artery and 
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the right jugular vein. Heparinized polyethylene tubing (PE-50) was 
inserted into each vessel and advanced approximately 3 cm to either the 
ascending aorta aorta for the arterial line or to the junction of the 
right atrium and superior vena cava for the venous line. Each cannula 
was tied in place, was tunneled under the skin, and was exteriorized on 
the back of the neck. Animals were placed in individual cages with water 
and observed for post-surgical complications. These animals were not 
provided with food after surgery and so are considered to be in a fasted 
state for the experiment conducted at 1000 hours the next morning. 
For the second set of experiments, cannulae were implanted on the 
morning of experimentation. Ad libitum fed animals were anesthetized 
with Halothane and surgery was performed in the same manner as described 
above. The rats were given 4 hours to recover from surgery before the 
experiment was begun. Because the surgery was performed on rats that had 
free access t~ food, they are considered to be fed animals at the time of 
experimentation. 
2. Experimental procedure for cannulated rats 
Prior to the onset of experimentation, each cannula was extended 
with an additional piece of PE-50 tubing. The arterial line was con-
nected to a saline filled Statham pressure transducer (model number P23) 
which was used to record pulsatile as well as mean blood pressure, to 
determine pulse rate, and to obtain arterial blood samples. Extension of 
the venous line provided a convenient mt "1S for i. v. inj ec ti on of saline, 
H.I.-TNF, TNF at 0.1, 0.5, or 1.0 mg/kg, ETX at 1.55 or 30 mg/kg, or co-
treatment with TNF plus ETX at 0.1 and 1.55 mg/kg, respectively. Before 
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beginning each experiment, rats were acclimated to their environment as 
determined by normal, steady blood pressures and quiet behavior. 
Arterial blood samples were taken prior to and at 30, 60, 90, 
l20, 180, or 360 minutes after i.v. injection, depending upon which plas-
ma constituents were to be measured in each blood sample. For experi-
ments in which plasma glucose, lactate, insulin, corticosterone, nor-
epinephrine, and epinephrine concentrations were determined, arterial 
blood samples (l.S ml) were taken prior to and at 30, 90, 180, and 360 
minutes post-injection. Experiments for which only plasma glucose, 
lactate, and insulin concentrations were measured, samples (0.8 ml) were 
taken prior to and at 30, 60, 90, and 120 minutes post-injection. Re-
gardless of which sampling schedule was followed, plasma was removed trom 
each blood sample and the red blood cells (RBCs) were resuspended in an 
equal volume of saline and returned intravenously to each animal. Blood 
volume depletion and the complications associated with that condition 
were minimized by handling the animals in this manner. 
Upon completion of each experiment, the carotid artery and jugular 
vein cannulae were resealed and rats were allowed free access to water. 
For the next 24 hours, these animals were periodically checked to 
determine survival. Additionally, each animal was surgically checked 
either at death or after 24 hours to insure that their cannulae were 
placed in the appropriate location and for any gross organ pathology. 
3. Glucan treated animals 
Under light ether anesthesia, rats were injected i.v. with saline 
or 10 mg/kg particulate glucan (lot #lFSSOO; Fleischmann Laboratories; 
Stamford, CT) suspended in saline. Animals were returned to our animal 
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research facility and allowed food and water ad libitum. Seventy-two 
hours later, these rats were anesthetized with ether and injected i.v. 
with either saline, TNF (0.1 mg/kg), or ETX (1.25 mg/kg) and were 
monitored to determin~ 24 hour survival. 
D. ISOIATED.PERFUSED RAT LIVER EXPERIMENTS 
1. Liver perfusion apparatus 
Livers were perfused in a liver Perfusion-Aeration Apparatus 
(Medical Research Apparatus; Clearwater, FL). Krebs bicarbonate buffer 
(KRB; 118 mM NaCl, 4.7mM KC!, 2.5mM CaClz-2HzO, l.2mM KH2P04, l.2mM 
MgS04-7HzO, and 25mM NaHC03) containing 2 mg/ml bovine albumin (RIA 
gr~de; Sigma ) was continuously recirculated through the system using a 
Masterflex peristaltic pump (Cole-Parmer Instrument Co.; Chicago, IL). 
Total volume of perfusion fluid continuously recirculated through the 
system was 150 ml. Temperature was maintained at 36-37°C with a heat 
lamp and heating wires. The perfusate was oxygenated continuously with 
95% Oz / 5% COz by passing over a gas exchange lung. Two lucite filters 
lined with silk mesh were used to filter the perfusate free of any 
particulate or fibrous material which the liver may have produced during 
the perfusion. 
Oxygen tension in the perfusion fluid going to and coming from the 
liver was measured with a YSI model 53 biological oxygen monitor (Yellow 
Springs Instrument Co., Inc.; Y~llow Springs, OH). Glucose and lactate 
concentrations in the perfusate as a result of net liver production were 
measured continuously with YSI model 26 continuous glucose and lactate 
monitors, respectively. Both glucose concentration and oxygen saturation 
in the perfusate were recorded continuously on a Linear 1202 chart 
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recorder (Linear Instrument Corporation; Reno, NV). A Gilmont spherical 
float flowmeter (size number 3; Thomas Scientific; Swedesboro, NJ) was 
used to determine flow rate to the liver. Livers were perfused with an 
average flow rate of 50 ml/min. 
2. Liver removal 
Fed rats were injected i.v. with sodium pentobarbital until there 
was only a slight res~onse to a tail pinch. This insured that the 
animals were anesthetized adequately without significantly depressing 
liver blood flow. A midline abdominal incision was made and followed by 
2 lateral incisions, one to the right and left side. This provided easy 
access to the portal area. The intestines were reflected gently to the 
animal's left side, thus exposing the portal vein and abdominal vena 
ca~a. Heparin (500 units/rat) was injected into the abdominal vena cava 
and was allowed to circulate in the animal for 5 minutes before pro-
ceeding with the rest of the surgery. The portal vein was cannulated 
with PE-260 tubing and flow to the liver established immediately with 
KRB. Quickly the chest was opened with a midline incision and outflow 
from the liver was established by cannulating the thoracic vena cava 
through the right atrium with PE-260 tubing. Yith KRB rapidly flushing 
the liver of all RBCs, the liver was excised gently from the animal and 
was placed in the perfusion chamber within 4 minutes from the time the 
portal vein was cannulated. 
3. Liver perfusion 
The excised liver was placed on a glass platform, inflow 
established, and outflow adjusted such that the liver was not distended 
but was perfused well. Temperature, Oz tension, glucose (mg/dl) and 
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lactate (mg/dl) were measured in the perfusate coming from the liver 
before it returned to the reservoir. The perfusion fluid was mixed in 
the reservoir prior to being pumped through a lucite filter to the gas 
exchange lung. After passing over the lung, the perfusate was filtered 
through a second filter, and was pumped to the liver, constantly 
measuring flow rate and oxygen tension. The difference between the 
standing level of perfusate in the gla~s lung and the level of inflow to 
the liver was used to determine the pressure head, which averaged 20 cm 
of H20 for these experiments. 
Oxygen consumption rate by the liver was calculated from the 
difference in 02 tension in the perfusate going to and coming from the 
live~ using the formula: µl 02/min/gm liver - Oxygen amount in 
solution(µl/ml) x flow rate(ml/min) x difference in 02 saturation(%)/100 
x l/gm liver wet weight. Net glucose production rate by the liver was 
calculated in the following manner: µmoles glucose/gm liver wet 
weight/hour - [8mg glucose produced in 5 minutes/100 ml] x 150ml x 1000 
µmoles/180 mg x 12/hour x l/gm liver wet weight. Net liver lactate 
production rate was ~alculated as follows: µmoles lactate/gm liver wet 
weight/hour - [8mg lactate produced in 5 minutes/100 ml] x 150 ml x 1000 
µmoles/90 mg x 12/hour x l/gm liver wet weight. 
The initial 30 minutes of perfusion were used as a control period. 
During this time, net glucose production and oxygen consumption reached a 
steady state. Perfused livers had to meet the following criteria in 
~rder to be included in this study: 1) average basal net glucose 
production rate = 94 µmoles glucose/gm liver wet weight/hour; 2) average 
basal oxygen consumption rate = 57 µl of oxygen/gm liver wet weight/ 
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minute; 3) average flow to the liver ~ 50 ml/minute; 4) good liver color; 
and 5) well perfused liver lacking areas of inadequate perfusion or 
swelling. If any of these criteria were compromised, the liver perfusion 
was terminated and data not included in the study. 
After the control period, either 1 ml of phosphate buffered saline 
(PBS) or 150 or 300 µg of TNF was added directly to the perfusion 
reservoir to achieve an initial TNF concentration of l and 2 µg/ml. 
Measurements of net glucose and lactate production, oxygen tension, and 
flow rate were taken every minute for the subsequent 15 minutes. This 
was followed by maximal stimulation of liver glucose production with the 
addition of glucagon (1 µM final concentration; Sigma). As described 
above, measurements were taken every minute for the next 15 minutes, 
resulting in a total liver perfusion time of 64 minutes. Upon completion 
of the perfusion, liver wet weight was determined for use in the cal-
culation of glucose and lactate production rates and oxygen consumption 
rates. 
E. ISOIATED LIVER PARENCHYMAL CELL EXPERIMENTS 
1. Isolation procedure 
Parenchymal cells were isolated by a modification of the Berry and 
Friend technique (21). Livers were excised from fed rats and were 
perfused in a liver Perfusion-Aeration Apparatus as previously described. 
For these studies, however, the perfusate was a calcium-glucose-free-
Hanks ~·iffer (CGFH; pH=7.4; 137mM NaCl, 5.37mM KCl, 0.34mM NazHP04, 
0.44mM KHzP04, 4.17rnM NaHC03, 0.4lmM MgS04-7HzO, 0.49mM MgClz-6HzO) 
containing 0.05% collagenase (Type l, Sigma) and 0.10% hyaluronidase 
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(Type l, Sigma). Perfusate was oxygenated continuously with 100% 02 and 
was recirculated with a minimum flow rate of 40 ml/min. 
After approximately 20 minutes, before any obvious breaks in the 
liver capsule were evident, the liver was removed from the system and 
placed in an ice cold Nalgene beaker with 50 ml of perfusion fluid. 
After chilling for 7 minutes, the liver was cut into extremely small 
pieces, was mashed gently, and was filtered through gauze and silk into 2 
ice cold 50 ml Nalgene centrifuge tubes. The resulting cell suspension 
was centrifuged (50g x 3 minutes) and was washed 3 times with ice cold 
CGFH. After the final wash, the liver parenchymal cells were resuspended 
to 40ml final volume in ice cold KRB containing 2 mg/ml bovine albumin. 
Cells were counted with a hemocytomcter and dye exclusion of trypan blue 
was used as a measure of cell viability, which ranged from 80-95%. 
2. Incubation conditions 
After determining cell number with the hemocytometer, KRB con-
taining 2 mg/ml albumin was added to the cell suspension to adjust the 
final cell concentration to 2 x 106 cells/ml. Cells were placed in 25ml 
siliconized (Sigmacote; Sigma) Erlenmeyer flasks, were gassed with 95% 
02/ 5% C02 for 1 minute, and then were incubated at 37°C for 60 minutes 
in a gently shaking water bath. Effect of TNF on basal glucose pro-
duction rate was determined by incubating the cells (2.8 ml x 2xl06 
cells/ml) with added saline or added TNF (0.01 to 5 µg/ml final con-
centration); final in~··~ation volume was 3 ml. In order to ascertain the 
effect of TNF on hormone stimulated glucose production, cells were 
incubated with added saline plus glucagon or saline plus vasopressin (1 
µM final concentration), or with added TNF plus glucagon or TNF plus 
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vasopressin. At the end of the indicated incubation time, 200 µl of 
sample was removed from each flask and was used for glucose and lactate 
measurements. 
3. Glucose utilizat~on by isolated hepatocytes 
Isolated liver parenchymal cells from fed rats were isolated in 
the manner previously described and were resuspended in KRB containing 2 
mg/ml albumin, 1 mg/ml D-glucose and 0.1 µCi/ml 14c-glucose (Amersham). 
Cells (S ml) were incubated for 2 hours at 37°C in si.liconized metabolic 
flasks in the absence or presence of added TNF (0.01 to S µg/ml final 
concentration). After the 2 hour incubation and then the addition of 1 
ml of 62.5% citric acid to the incubation media, expired 14co2 was 
collected on methylbenzethonium hydroxide (Sigma) saturated filter paper 
in scintillation vials for 60 minutes. After the 60 minute collection 
period, liquid scintillation fluor (15 ml; 1 liter toluene, 4 gm PPO, 0.1 
gm POPOP) was added to each vial. Vials were counted in a liquid 
scintillation counter for 10 minutes, after a dark adaptation period of 
30 minutes. 
F. GLUCOSE AND IACTATE MEASUREMENTS 
1. Glucose determination 
A YSI model 23A glucose monitor (Yellow Springs Instrument Co.; 
Yellow Springs, OH) was used to determine plasma glucose concentrations 
and isolated hepatocyte glucose production. For isolated perfused liver 
experiments, glucose production was dl. Jrmined using a YSI model 26 
continuous glucose monitor. 
The same operating principles pertain for both machines. The tip 
of the glucose probe is covered with a 3-layer membrane. The outer layer 
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Polycarbonate material which is freely permeable to glucose, oxygen, is a . 
hydrogen peroxide, water and salt. The middle layer contains a thin 
layer of glutaraldehyde resin in which glucose oxidase is immobilized. 
The inner layer consists of a cellulose acetate material which is freely 
permeable only to hydrogen peroxide, oxygen, water, and salt. Hence, 
glucose in the sample chamber readily passes through the outer membrane 
layer and reacts with the glucose oxidase to produce gluconic acid and 
hydrogen peroxide by the following reaction: D-glucose + 02 ---> 
gluconic acid+ H202. A portion of the hydrogen peroxide produced 
diffuses through the inner layer and then is oxidized at the platinum 
anode: H202 ---> 2H+ + 02 + 2e·. Thus, the current produced at the 
platinum anode is directly proportional to the amount of hydrogen 
peroxide that was generated and had diffused through the inner membrane. 
2. Lactate determination 
Lactate concentration (mM) for in vivo and isolated cell experi-
ments were determined with YSI model 23A lactate analyzer. Online 
measurements of lactate produced during isolated perfused liver 
experiments were made with a YSI model 26 continuous lactate monitor. 
The principles of operation for lactate measurements are similiar 
to those for glucose determinations, except that a different membrane 
system was used. In this case, the 3-layer membrane contained an 
immobilized L-lactate oxidase and flavin dinucleotide (FAD) between the 
outer and inner membranes. Lactate in the sample char.· "r readily 
diffuses through the outer layer and reacts with L-lactate oxidase in the 
presence of FAD to produce pyruvate and hydrogen peroxide in the fol-
lowing manner: lactate + 02 ---> pyruvate + H202. Hydrogen peroxide 
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generated in this reaction diffuses through the inner membrane and is 
oxidized at the platinum anode. Thus, the current generated is directly 
proportional to the amount of hydrogen peroxide that is generated and 
diffuses through tile inner membrane. 
G. INSULIN MEASUREMENTS 
Plasma insulin for in vivo experiments was measured using a double 
antibody radioimmunoassay (Cambridge Medical Technology Corp.; Billerica, 
MA). This assay had a sensitivity level of 2.0 µU/ml and an interassay 
coefficient of variability less than 10%. 
H. NOREPINEPHRINE AND EPINEPHRINE MEASUREMENTS 
Plasma norepinephrine and epinephrine levels were determined using a 
radioenzymatic assay (Upjohn Diagnostics; Kalamazoo, MI). A dose of 20 
µl of a solution containing EGTA (90 mg/ml) and glutathione (60 mg/ml) 
was added to each milliliter of whole blood collected. The arterial 
blood sample was centrifuged, the plasma was removed and then was stored 
at -40°C until analyzed. This assay had a sensitivity of 2 pg/ 50 µl 
and an interassay variation of approximately 10%. 
I. CORTICOSTERONE MEASUREMENTS 
Plasma corticosterone levels were determined using a double antibody 
radioimmunoassay (Radioassay Systems Lab; Carson City, CA). The 
sensitivity of this assay was 2.5 ng/tube and an interassay variation of 
6.5%. 
J. PROTEIN DETERMINATION 
For each isolated liver parenchymal cell experiment, samples were 
taken for protein determination by the Bio-Rad protein assay technique 
(Bio-Rad; Richmond, CA). Protein samples were diluted 1 to 3 in water 
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and 100 µl quantities were used to measure protein concentration. The 
color change of Coomassie Brillant Blue G-250 in response to various 
concentrations of protein was reflected in 00595 value changes. Bovine 
albumin (20-140 µg/tube) was used ~o generate the standard curve. By 
linear regression analysis of the bovine albumin standard curve, the 
protein content of each experimental sample was determined from its 
corresponding 00595 value. 
K. STATISTICAL ANALYSIS 
Results are reported as mean ± standard error of the mean 
(mean±SEM). A 2-way ANOVA (treatment, time) with repeated measures 
followed by post-hoc analysis (Student Newman-Keuls, Tukey's, or Least 
Significant Difference tests) were performed on the in vivo data. Exact 
probability tests were performed on the survival data. For the isolated 
perfused liver experiments, statistical significance was determined by 
Student's unpaired t-test. A 1-way ANOVA was performed on the isolated 
liver parenchymal cell data. In each case, significance was accepted at 
p$ 0.05. 
CHAPTER IV 
RESULTS 
A. IN VIVQ EFFECTS OF TUMOR NECROSIS FACTOR 
1. Experimental groups 
Initial experiments were conducted to evaluate the effects of TNF 
and ETX in conscious, unrestrained, fas~ed cannulated rats. The fasted 
rats were healthy, without any sign of discomfort, before they were 
arbitrarily assigned to one of the following eight treatment groups: 1) 
saline; 2) H.I.-TNF; 3) 0.1 mg/kg TNF; 4) 0.5 mg/kg TNF; 5) 1.0 mg/kg 
TNF; 6) 1.55 mg/kg ETX; 7) 30 mg/kg ETX; or 8) co-treatment with 0.1 
mg/kg TNF plus 1.55 mg/kg ETX. In addition, two groups of fed, can-
nulated, unrestrained conscious rats were treated with either saline or 
high dose TNF (1.0 mg/kg). 
2. Mortality and morbidity induced with TNF, ETX, and TNF plus ETX 
co-treatment 
The mortality rates observed at 4, 6, and 24 hours after an i.v. 
bolus injection of saline, H.I.-TNF, TNF (0.1, 0.5, or 1.0 mg/kg), ETX 
(1.55 or 30 mg/kg), or TNF plus ETX co-treatment (0.1 + 1.55 mg/kg, 
respectively) in fasted rats are presented in table 2. The fractions 
represent the number of animals that died out of the total number of rats 
injected for each group. As anticipated, none of the animals in the two 
co~trol groups died as a consequence of saline or H.I.-TNF injection. 
They appeared healthy at the onset of the protocol and remained that way 
for the subsequent 24 hours. 
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The mortality and morbidity observed after TNF administration were 
dose dependent (table 2). A low dose of TNF, 0.1 or 0.5 mg/kg, resulted 
in the death of 1 animal in each group during a 24 hour period. There 
were no deaths in either group early on, even though some of the animals 
began to look ill. When fasted rats were given a higher dose of TNF, 1.0 
mg/kg, 4 out of 6 rats died within 4 hours. An additional rat died by 6 
hours, but no additional rats died in the subsequenc 18 hours. When a 1 
mg/kg dose of TNF was injected into fed cannulated rats (table 3) a lower 
mortality rate was observed within the first 6 hours as compared to that 
observed with fasted cannulated rats given this same dose (table 2): 1 
death was observed at 4 hours, 2 deaths were observed by 6 hours. The 
death rate by 24 hours was 3 out of 5. Rats given TNF manifested ruffled 
fur, cyanotic extremities, and labored breathing. 
Two groups of animals were treated with different doses of ETX in 
order to compare the mortality and morbidity induced with TNF to that 
induced with ETX. Animals given a low dose of ETX, 1.55 mg/kg, 
demonstrated a mortality rate at 24 hours that was identical to the 
mortality rate observed in rats given a low dose of TNF, 0.1 mg/kg; 1 out 
of 5 rats died. This death occurred within 3 hours after ETX injection, 
suggesting that this rat was somewhat more sensitive to ETX than the 
others, even though there were no observable signs which indicated such a 
difference. When a much higher dose of ETX was given, 30 mg/kg, 2 deaths 
occ·-red within the first 4 hours. By 6 hours, 2 more rats had died, and 
by 24 hours all the rats had died. These animals demonstrated clinical 
signs of illness similar to those observed after a 1 mg/kg dose of TNF: 
their fur was ruffled, extremities were cyanotic, and their breathing was 
TABLE 2 
TIME AND DOSE DEPENDENT EFFECTS OF TNF- AND ETX.-INDUCED LETHALITY IN 
FASTED CANNlJLATED RATS 
TREATMENT DOSE(mg/kg) 4 hours 6 hours 24 hour.; 
SALINE 0/11 0/11 0/11 
H. I. -TNF O/S O/S O/S 
TNF 0.1 0/6 0/6 l/S 
o.s 0/6 0/6 l/S 
1.0 4/6 S/6 S/6 
ETX 1. SS l/S l/S l/S 
30 2/6 4/6 6/6 
(TNF+ETX) (0.1+1.SS) 6/6*+ 
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Left carotid artery and right jugular vein cannulae were surgically 
implanted 16 hours prior to experimentation. Fasted rats were injected 
i.v. with saline (0.l-0.6S ml), heat-inactivated TNF (H.I.-TNF; 0.6S 
ml), TNF (0.1, O.S, or 1 mg/kg), ETX (l.SS or 30 mg/kg), or co-treatment 
with TNF plus ETX (0.1 + l.SS mg/kg, respectively). *P~ O.OS, low dose 
TNF or ETX alone vs. co-treatment with TNF plus ETX; +p~ O.OS, high dose 
ETX vs. low dose TNF plus ETX co-treatment. 
TABLE 3 
LETHAL EFFECTS OF HIGH DOSE TNF IN FED CANNUIATED RATS 
TREATMENT OOSE(mg/kg) 
SALINE 
TNF 1.0 
4 hours 
0/5 
1/5 
6 hours 
0/5 
2/5 
24 hours 
0/5 
3/5 
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Left carotid artery and right jugular vein cannulae were implanted in fed 
rats under 5% Halothane. Animals were allowed 4 hours to recover from 
surgery before they were given an i.v. bolus injection of saline (0.65ml) 
or TNF (l.O mg/kg). 
labored. These rats, however, also manifested 2 other clinical signs 
that were not observed with the TNF treated animals, i.e. porphyrin-
tinged ocular discharge and diarrhea. 
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Additionally, rats were co-treated with low dose TNF plus low dose 
ETX to evaluate the lethal response. Fasted cannulated rats were given 
an i.v. bolus injection of 0.1 mg/kg TNF followed immediately with an 
i.v. bolus injection of 1.55 mg/kg ETX. As reported in table 2, co-
treatment with TNF plus ETX resulted in a mortality rate of 100% within 4 
hours. Co-treatment with TNF plus ETX was significantly more lethal by 4 
hours than a bolus injection of a high dose of ETX (30 mg/kg). Compared 
to the mortality rate observed by 4 hours after a high dose of TNF (1 
mg/kg), co-treatment with TNF plus ETX was just as lethal if not more so. 
This data suggests that the combined effects of a low dose of TNF (0.1 
mg/kg) with a low dose of ETX (1.55 mg/kg) may be more detrimental early 
on than a highly lethal dose of either agent given alone. 
3. TNF- and ETX- induced mortality after glucan pretreatment 
It was hypothesized that an agent which increased an animal's 
sensitivity to the lethal effects of ETX, such as glucan, also may 
sensitize an animal to the lethal effects of TNF. This hypothesis was 
tested in the following manner. Fed rats were pretreated with saline or 
glucan 72 hours prior to the injection of saline, 0.1 mg/kg TNF, or 1.25 
mg/kg ETX (table 4). Doses of 0.1 mg/kg TNF and 1.25 mg/kg ETX injected 
into these rats were sublethal, as indicated by 0% mortality observed for 
the saline pretreated groups. Glucan pretreatment greatly enhanced the 
animals' sensitivity to ETX as demonstrated by 7 out of 7 deaths after 
the injection of 1.25 mg/kg ETX. However, animals pretreated with glucan 
70 
TABLE 4 
EFFECTS OF GLUCAN PRETREATMENT ON TNF- OR ETX- INDUCED LETHALITY 
TREATMENT 1 TREATMENT 2 DOSE (mg{kg) LETHALITY 
SALINE SALINE 0/6 
TNF 0.1 0/6 
ETX 1.25 0/6 
GLUCAN SALINE 0/5 
TNF 0.1 0/5 
ETX 1. 25 7/7* 
Rats were injected i.v. either with saline or 10 mg/kg particulate glucan 
and returned to their cages with ample food and water. After 72 hours, 
they were challenged with saline, TNF (0.1 mg/kg), or ETX (1.25 mg/kg) 
and were observed for 24 hours to determine survival. *p~ 0.05 
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were not more sensitive to the lethal effects of TNF: 1.25 mg/kg of TNF 
was a sublethal dose for the glucan pretreated animals as well as the 
saline pretreated animals. Glucan pretreatment enhanced ETX sensitivity 
such that a 24x smaller dose given to rats was just as lethal as a 30 
mg/kg dose given to non-sensitized rats. However, this was not the case 
for TNF: a lOx smaller dose of TNF did not have the same lethal effects 
in glucan pretreated rats (table 4) as a 1.0 mg/kg dose had in normal 
rats (table 3). 
4. Hemodynamic effects of ETX, TNF, and ETX plus TNF co-treatment: 
mean blood pressure 
As a simplified index of overall hemodynamic status, mean blood 
pressure (MBP) was recorded from the carotid artery cannula of conscious, 
unrestrained rats. MBP was recorded and compared for the following 
groups of animals: 1) high dose ETX and high dose TNF treated fasted 
rats; 2) low dose ETX and low dose TNF treated fasted rats; and 3) low 
dose ETX plus low dose TNF co-treated fasted rats. High dose TNF was 
tested also in fed cannulated rats. 
ETX administration resulted in significant modifications of MBP in 
fasted animals. Sixty minutes after a low dose of ETX (l.55 mg/kg), MBP 
had dropped to 83 mmHg from a pre-injection level of 128 mmHg (figure 3). 
MBP rebounded by 90 minutes to 98 mmHg, even though it was still sig-
nificantly lower than the saline control MBP. The MBP for ETX treated 
rats also was significantly lower ~han those for the low dose TNF treated 
animals at 60, 90, and 120 minutes, respectively. 
Administration of a high dose of ETX (30 mg/kg) to fasted rats 
(figure 1) resulted in a significant hypotensive response at 30, 60, and 
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90 minutes post-injection. MBP dropped to levels of 82, 76, and 88 mmHg 
by 30, 60, and 90 minutes, respectively, from a pre-injection level of 
127 mmHg. These pressures at 30, 60, and 90 minutes also were sig-
nificantly lower than those observed in the saline and high dose TNF 
treated groups. By 120 minutes, the ETX-induced hypotension had subsided 
and the MBP was up to 106 mmHg, same as the saline control values. 
Contrary to the effects observed after ETX, treatment with either 
low (0.1 mg/kg; figure 3) or high (1 mg/kg; figure 1) doses of TNF 
produced no significant alterations in MBP in fasted rats as compared to 
the saline controls. MBP for the low dose TNF group averaged 117 mmHg 
(figure 3) which was consistant with that recorded for the saline control 
animals. A high dose of TNF given to fasted cannulated rats elicited no 
observable change in MBP, which averaged 108 mmHg (figure 1). In fed 
rats, however, a 1 mg/kg dose of TNF resulted in a statistically 
significant elevation in mean blood pressure to 137 and 131 mmHg at 90 
and 120 minutes post-injection, respectively (figure 2). These values 
were significantly higher than 124 and 115 mmHg observed in the saline 
control animals at 90 and 120 minutes, respectively. This was a 
transient increase in MBP; by 210 minutes the TNF treated animals had a 
MBP identical to the saline controls. 
Co-treatment with low dose ETX plus low dose TNF in fasted rats 
resulted in a significant depression in MBP within 30 minutes (figure 3). 
The MBP remained significantly depressed relative to the saline control 
MBP throughout the study. By 30 minutes, co-treatment with ETX plus TNF 
resulted in a significant drop in MBP to 98 mmHg, which was significantly 
lower than the saline control value of 118 mmHg. More importantly, 
FIGURE 1 
EFFECTS OF HIGH DOSE TNF AND ETX ON MEAN BIDOD PRESSURE 
IN FASTED CANNUIATED RATS 
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Rats were injected i.v. with either saline (n-3), heat-inactivated TNF 
(H.I.-TNF; n-5), 1.0 mg/kg TNF (n-6), or 30 mg/kg ETX (n=6). Values 
reported are mean blood pressures ± SEM (mmHg) in surviving rats. Mean 
pressures reported at 240-330 minutes for the TNF treated group are the 
average of 2 values. The 360 minute value reported for the TNF treated 
group is the mean blood pressure in the single surviving rat. Pressures 
reported at 330 and 360 minutes for the ETX treated group represent the 
means of 2 values. ...:ps 0.05 treatment vs saline. 1f:ps 0.05 TNF vs. 
ETX. 
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FIGURE 2 
EFFECTS OF HIGH ~OSE TNF ON MEAN BLOOD PRESSURE IN FED CANNULA.TED RATS 
Rats were given an i.v. bolus iujection of saline (n-5) or 1 mg/kg TNF 
(n=5). Values reported are mean blood pressures± SEM (mmHg) in 
surviving rats. ....:p~ 0.05 TNF vs. saline. 
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FIGURE 3 
EFFECTS OF I.DY DOSE TNF, I.DY DOSE ETX, AND I.DY DOSE TNF PLUS ETX CO-
TREATMENT ON MEAN Bl.DOD PRESSURE IN FASTED CANNUI.ATED RATS 
Rats were injected i.v. with either saline (n-7), 0.1 mg/kg TNF (n=6), 
1.55 mg/kg ETX (n=4), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg 
ETX (n=6). Values reported are mean blood pressures± SEM (mm.Hg) in 
surviving rats .... :ps 0.05 treatment vs saline. ():ps 0.05 ETX vs. TNF. 
+:ps 0.05 TNF plus ETX co-treatment vs. TNF. ():ps 0.05 TNF plus ETX 
co-treatment vs. ETX. 
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co-treatment with ETX plus TNF elicited a drop in MBP at 30 minutes which 
was significantly lower than the 116 mmHg pressure observed for the low 
dose ETX (1.55 mg/kg) treated rats. Co-treatment with ETX plus TNF 
resulted in significantly lower MBP than observed in the low dose TNF 
treated rats at 60, 90, and 120 minutes. Co-treatment with ETX plus TNF 
appeared to augment the hypotensive effect of ETX alone at 60, 90 and 120 
minutes, even though the pressures were not significantly different 
statistically. Co-treatment with ETX plus TNF also appeared to result in 
a slower recovery of MBP than observed after low dose ETX treatment 
alone. 
5. Hemodynamic effects of ETX, TNF, and ETX plus TNF co-treatment: 
pulse rate 
Pulse rates were counted as an indicator of heart rates from the 
carotid artery pulsatile blood pressure tracings recorded with a Grass 
polygraph. Pulse rates were counted and compared for the following 
groups of conscious, unrestrained rats: 1) high dose ETX and high dose 
TNF treated fasted rats; 2) low dose ETX and low dose TNF treated fasted 
rats; and 3) low dose ETX and low dose TNF co-treated fasted rats. Ad-
ditionally, the influence of high dose TNF on pulse rates in fed, con-
scious rats was evaluated. Saline treated animals for each treatment 
group maintained fairly steady pulse rates throughout the course of these 
studies. H.I.-TNF treated rats had a slight but physiologically insig-
~ificant elevation in pulse rate (figure 4). 
Dose dependent changes in pulse rate were observed with ETX 
treated rats. A low dose of ETX (l.55 mg/kg) injected into rats resulted 
in a transient decrease in pulse rate relative to saline control rats by 
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60 minutes (figure 6). At 90 minutes, the pulse rate in ETX treated 
animals was 360 ppm compared to 423 ppm in saline control rats. This 
pulse rate observed in the ETX treated rats at 90 minutes was also 
significantiy lower than the pulse rates of 426 p~m and 415 ppm deter-
mined for low dose TNF and ETX plus TNF co-treated rats, resp~ctively. 
Quite opposite results were observed with rats given a high dose of ETX, 
ie. 30 mg/kg (figure 4). Pulse rates increased from a pre-injection 
value of 392 ppm to a peak value of 480 ppm 180 minutes later. Within 30 
minutes after the injection of a high dose of ETX, pulse rates in these 
r~ts increased to 443 ppm, which was significantly higher than the 
corresponding pulse rate for saline controls and high dose TNF treated 
rats, 361 and 404 ppm, respectively. By 90 minutes, the tachycardia 
induced with ETX was no longer significantly different from that 
demonstrated after 1 mg/kg TNF. 
A low dose of TNF (0.1 mg/kg) produced no distinguishable changes 
in pulse rate (figure 6). Mean pulse rates remained relatively steady at 
an average rate of 420 ppm. However, a ten fold greater dose of TNF 
resulted in significant elevations in pulse rates (figures 4 and 5). The 
tachycardia induced with high dose TNF in fasted, cannulated rats was 
evident by 30 minutes and was statistically significant, relative to 
saline control rates, by 90 minutes after TNF injection. Ninety minutes 
after TNF (1 mg/kg) injection, the pulse rate was 466 ppm, approximately 
100 ppm greater than the saline control rate. The tachycardi~ ~ncreased 
to 518 ppm by 180 minutes and remained elevated. A similar profile was 
observed with fed rats given 1 mg/kg TNF (figure 5): TNF-induced 
elevation in pulse rate was evident at 30 minutes and continued to 
81 
FIGURE 4 
EFFECTS OF HIGH DOSE TNF AND ETX ON PULSE RATE IN FASTED CANNUI.ATED RATS 
Rats were injected i.v. with either saline (n=3), heat-inactivat~d TNF 
(H.I.-TNF; n-5), 1.0 mg/kg TNF (n=5), or 30 mg/kg ETX (n=6). Values 
reported are mean pulses per· minute± SEM (ppm) in surviving rats. 
Values reported at 360 minutes for the TNF and ETX treated groups 
represent the average of 2 determinations. 1f:ps 0.05 treatment vs. 
saline. ():ps 0.05 TNF vs. H.I.-TNF. j::{:ps 0.05 ETX vs. TNF. 
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FIGURE 5 
EFFECTS OF HICH DOSE TNF ON PU'....SE RATE IN FED CANNULATED RATS 
Rats were given an i.v. bolus injection of saline (n=S) or 1 mg/kg TNF 
(n=S). Values reported are mean pulses per minute± SEM (ppm) measured 
in surviving rats. l\":p~ 0.05 TNF vs saline. 
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FIGURE 6 
EFFECTS OF L(J~l DOSE TNF, ID\l DOSE ETX, AND IDW DOSE TNF PLUS ETX CO-
TREATMENT ON PUI.SE RATE IN FASTED CANNUIATED RATS 
Rats were injected i.v. with either saline (n-7), 0.1 mg/kg TNF (n=6), 
1.55 mg/kg ETX (n-4), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg 
ETX (n~6). Values reported are mean pulses per minute± SEM (ppm) 
measured in surviving rats. ....:ps 0.05 treatment vs. saline. ():ps 0.05 
ETX vs. TNF. ():ps 0.05 ETX vs. TNF plus ETX co-treatment. 
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increase further during the subsequent 6 hours. Pulse rates in the fed 
rats given TNF increased from a pre-injection rate of 420 ppm to 542 ppm 
by 6 hours. Resultant TNF-induced tachycardia was not the consequence of 
contaminating ETX, as demonstrated by the pulse rates reported for H.I.-
TNF rats in figure 4. Mean pulse rates determined at 90, 180, and 360 
minutes for the high dose TNF treated animals were significantly greater 
than the puise rates in H.I.-TNF treated controls. 
Co-treatment with low dose ETX plus low dose TNF resulted in 
neither an increase in pulse rate as observed after a high dose of ETX or 
TNF alone, nor a decrease in pulse rate as observed after a low dose of 
ETX alone. There were no significant changes in pulse rates measured in 
low dose ETX plus low dose TNF co-treated.rats relative to both the 
respective pre-injection rate of 382 ppm and the saline controls (figure 
6). It appeared that the bradycardia inducing effect of low dose ETX was 
obliterated by co-treatment with low dose TNF. 
6. Metabolic effects of TNF, ETX, and TNF plus ETX co-treatment: 
plasma glucose 
Arterial blood samples were taken from the indwelling carotid 
artery cannula of conscious, unrestrained rats in order to assess changes 
in plasma glucose concentration as a result of the following treatments: 
1) high dose TNF and high dose ETX in fasted rats; 2) low dose TNF and 
low dose ETX in fasted rats; and 3) co-treatment with low dose TNF plus 
low dose ETX in fasted rats. The glucoregulatory changes induced by high 
dose TNF were assessed also in fed, conscious, unrestrained rats. 
The in vivo glucoregulatory effect of TNF was dose dependent. A 
low dose of TNF (0.1 mg/kg) elicited no measurable changes in plasma 
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glucose concentrations in fasted rats (figure 9). However, a significant 
glucoregulatory effect was demonstrated with 1 mg/kg TNF in both fasted 
and fed rats. As illustrated in figure 7, a high dose of TNF induced a 
slight hyperglycemia, reflected in the increase in fasted plasma glucose 
concentrations by 90 minutes. Plasma glucose concentration increased to 
153 mg/dl by 90 minutes, which was significantly greater than the plasma 
glucose concentration of 115 mg/dl in the H.I.-TNF group. It was 
postulated that the hyperglycemia-inducing effect of TNF might be better 
illustrated in fed rats as opposed to fasted rats. Therefore, fed 
cannulated rats were challenged with a 1 mg/kg dose of TNF, as illus-
trated in figure 8. A significant hyperglycemia was measured 60 minutes 
after a high dose of TNF: plasma glucose concentration increased to 195 
mg/dl, a significant elevation above the saline control value of 161 
mg/dl. 
The decrease in plasma glucose concentrations observed 360 minutes 
after high dose TNF administration was of a larger magnitude than the 
initial increase in plasma glucose observed at 90 minutes (figure 7). 
When fasted rats were injected with 1 mg/kg TNF, plasma glucose levels 
dropped to 76.3 mg/dl, significantly lower than the 136 mg/dl con-
centration observed in the saline controls. The glucose concentration 
reported at 360 minutes for high dose TNF treated fasted rats was the 
average value obtained from two rats; 133 and 19 mg/dl. The second 
value, 19 mg/dl, was obtain,~ from a rat in the agonal stages after TNF 
treatment. Similar degrees of hypoglycemia were observed in the fed rats 
that died after treatment with 1 mg/kg TNF (data not shown). 
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As a comparison to the changes induced by TNF, dose and time 
dependent alterations in plasma glucose concentrations induced by ETX 
administration are shown in figures 7 and 9. Rats injected with a low 
dose of ETX (1.55 mg/kg) deffionstrated a significant hyperglycemia as 
early as 30 minutes after injection, which increased further by 60 and 90 
minutes (figure 9). Plasma glucose concentrations increased to 201, 273, 
and 290 mg/dl by 30, 60, and 90 minutes, respectively, after ETX in-
jection. By 120 minutes, plasma glucose concentration dropped to 245 
mg/dl. These concentrations were significantly higher than the average 
glucose concentrations observed for the saline and low dose TNF treated 
rats, 126 and 141 mg/dl, respectively. 
High dose ETX induced a biphasic change in plasma glucose 
concentrations (figure 7). Plasma glucose concentration almost doubled 
by 30 minutes after ETX (30 mg/kg) injection, increasing from a pre-
injection value of 134 mg/dl to 257 mg/dl. Peak hyperglycemia induced 
with high dose ETX occurred earlier than with low dose ETX: peak 
elevation occurred by 30 and 90 minutes after injection of 30 mg/kg and 
1.55 mg/kg of ETX, respectively. The hyperglycemia elicited by high dose 
ETX was followed by significant hypoglycemia at 360 minutes. Plasma 
glucose concentrations at 360 minutes for the two surviving rats were 69 
and 64.5 mg/dl. Analogous to the severe hypoglycemia observed during the 
agonal phase after high dose TNF administration, high dose ETX induced a 
severe hypoglycemia in the rats that suct · ,1bed to the lethal effects of 
ETX (data not shown). 
Co-treatment with TNF plus ETX induced changes in plasma glucose 
concentration which closely parallel the changes in plasma glucose 
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FIGURE 7 
EFFECTS OF HIGH DOSE TNF AND ETX ON PIASMA GLUCOSE IN FASTED CANNUI.ATED 
RATS 
Rats were injected i.v. with either saline (n-4), heat-inactivated TNF 
(H.I.-TNF; n-5), 1.0 mg/kg TNF (n-6), or 30 mg/kg ETX (n-6). Values 
reported are mean plasma glucose concentrations ± SEM (mg/dl) in 
surviving rats. Values reported at 360 minutes for the TNF and ETX 
treated group represent the average of 2 determinations . 
.... :p~ 0.05 treatment vs saline. ():p~ 0.05 TNF vs. H.I.-TNF. 
--tf:p~ 0.05 ETX vs. TNF. 
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FIGURE 8 
EFFECTS OF HIGH DOSE TNF ON PIASMA GLUCOSE IN FED CANNUIATED RATS 
Rats were injected i.v. with saline (n~S) or 1 mg/kg TNF (n=S). Values 
reported are mean plasma glucose concentrations ± SEM (mg/dl) in 
surviving rats. *:p::5 0.05 TNF vs. saline. 
200 
D SALINE 
* 
.TNF 
...... 
~ 
! S!50 
f;j 
0 
0 
3 
"' ~ !00 
0.. 
so 
0 
~ .., 
_L ~ .. ~ 
I :S> I x I . 
)I[.) ~ ~ ~ .,}A ) ~ t ~ )I >< ) ) ) & ) >~ "'.)!. ~.,, ) ~ ~ ) ~ x )I ~ ~) ) ) 
~ )I ~ ~ ) ) y ) ~ ~) ) ) ~ ~) 
I 
) 
) 
)) ) )~) 
) 
~~ ) ~ ) ) I ~ ) )" ~ 
"> )I 
)~ 
y )~ ) ~) ) ;) ,,;.,. 
..,. ) )' ~~ ~ ) ~ ~ ""'~ )I) "> ""} § ~ )I ""} .,.,,. ~ ,,, 
CONTROL 30 60 90 180 360 
TIME (minutes) 
94 
FIGURE 9 
EFFECTS OF LOW DOSE TNF, LOW DOSE ETX, AND LOW DOSE TNF PLUS ETX CO-
TR.EATMENT ON PIASMA GLUCOSE IN FASTED CANNUIATED RATS 
Rats were injected i.v. with either saline (n-7), 0.1 mg/kg TNF (n=6), 
1.55 mg/kg ETX (n=5), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg 
ETX (n-7). Values reported are mean plasma glucose concentrations± SEM 
(mg/dl) in surviving rats. "*'=P~ 0.05 treatment vs saline. ():p~ 0.05 ETX 
vs. TNF. +:p~ 0.05 TNF plus ETX co-treatment vs. TNF. 
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observed after a low dose of ETX alone (figure 9). A significant 
hyperglycemia was observed as early as 30 minutes after TNF plus ETX co-
treatment. The plasma glucose concentration reported at 30 minutes for 
the TNF plus ETX co-treated group, ie. 234 mg/dl, was higher than the 201 
mg/dl concentration determined for the low dose ETX treated group, even 
though the difference was not statistically significant. Peak plasma 
glucose concentrations occurred 60 minutes after co-treatment; plasma 
glucose increased from a pre-injection concentration of 141 mg/dl to 304 
mg/dl by 60 minutes. Plasma glucose concentrations at 90 and 120 
minutes, 277 and 209 mg/dl respectively, indicated that the hyperglycemia 
induced with TNF plus ETX co-treatment was transient. Just as observed 
during the agonal phases after high dose ETX or high dose TNF treatment, 
rats that died after co-treatment with TNF plus ETX had plasma glucose 
concentrations as low as 19 mg/dl. 
7. Metabolic effects of TNF, ETX, and TNF plus ETX co-treatment: 
plasma lactate 
Changes in arterial plasma lactate concentrations of conscious, 
unrestrained, cannulated rats were determined for the following treatment 
groups: 1) high dose TNF and high dose ETX in fasted rats; 2) low dose 
TNF and low dose ETX in fasted rats; 3) co-treatment with low dose TNF 
plus low dose ETX in fasted rats. Additionally, the effect of high dose 
TNF on plasma lactate concentration was examined in fed, conscious, 
unrestrained, cannulated rats. 
Alterations in plasma lactate concentration induced by TNF were 
dose dependent. A low dose of TNF, 0.1 mg/kg, resulted in an insig-
nificant increase in plasma lactate concentration from 0.65 to 1.07 mM by 
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120 minutes post-injection (figure 12). However, a high dose of TNF (1 
mgfkg) induced a significant increase in plasma lactate concentration in 
fasted cannulated rats. By 90 minutes post-injection, plasma lactate had 
increased from a pre-injection value of 0.63 to 1.7 mM (figure 10). 
Plasma lactate concentrations continued to increase, so that by 180 
minutes, plasma lactate concentrations were elevated to 3.79 mM, which 
was significantly higher than the corresponding lactate concentrations in 
saline and H.I.-TNF treated rats. At 360 minutes, the plasma lactate 
concentration reported for the high dose TNF treated rats was an average 
obtained from two rats; 7.85 mM for the dying animal and 0.9 mM for the 
24 hour survivor. 
Significant hyperlactacidemia was elicited also in fed rats 
administered a high dose of TNF. As shown in figure 11, a significant 
hyperlactacidemia was demonstrated as early as 30 minutes after a 1 mg/kg 
dose of TNF. Plasma lactate increased from a pre-injection value of 0.87 
to 1.49 mM by 30 minutes. Plasma lactate concentration continued to 
increase and reached 2.30 mM by 360 minutes post-injection. The 
significant hyperlactacidemia produced after a high dose of TNF in fed 
rats was not as severe as the hyperlactacidemia produced in fasted rats. 
Rats injected with ETX demonstrated similar changes in plasma 
lactate concentrations as described for TNF treated animals. Low dose 
ETX induced a statistically significant increase in plasma lactate 
relative to saline treated rats by 60 minutes (figure 12). Lactate 
concentrations increased from a pre-injection value of 0.58 mM to 2.6 mM 
by 60 minutes. Plasma lactate concentrations continued to increase to 
3
.64 mM by 90 minutes and then remained elevated. High dose ETX 
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administration elicited an even greater hyperlactacidemia than that 
observed after low dose ETX (figure 10). Plasma lactate concentrations 
increased significantly from a pre-injection value of 0.58 to 4.35 rnM by 
30 minutes post-injection and continued to increase to 5.43 ;n..'1 by 350 
minutes. The plasma lactate concentration reported at 360 minutes was 
the average of 2 determinations; 5.65 and 5.20 mM. Peak hyper-
lactacidemia elicited after a high dose of ETX was similar to that 
produced after a high dose of TNF at 180 and 360 minutes. However, the 
initial increase in plasma lactate occurred earlier and to a greater 
degree a=ter a high dose of ETX than after a high dose of TNF. 
Co-treatment with low dose TNF plus low dose ETX resulted in a 
greater hyperlactacidemia than that reported after high dose ETX or high 
dose TNF alone. Plasma lactate increased from a pre-injection con-
centration of 0.73 mM to 1.87 mM by 30 minutes after co-treatment with 
low dose TNF plus ETX. The elevation in plasma lactate produced by TNF 
plus ETX co-treatment was significantly greater than the plasma lactate 
concentrations observed in saline control and low dose TNF treated rats 
at 30 minutes post-injection. Although the initial increase in plasma 
lactate reported after co-treatment with low dose TNF plus ETX was not 
significantly different from that observed after a low dose of ETX alone, 
by 90 minutes the increase in lactate observed after TNF plus ETX co-
treatment was significantly greater than that observed after low dose 
ETX. Plasma lactate concentration increased to 8.72 mM by 120 minute~ 
after TNF plus ETX co-treatment, which was higher than the values 
reported for saline controls, low dose TNF, low dose ETX, and the peak 
values reported after treatment with high dose TNF or ETX. 
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FIGURE 10 
EFFECTS OF HIGH DOSE TNF AND ETX ON PIASMA IAGTATE IN FASTED GANNULATED 
RATS 
Rats were injected i.v. with either saline (n-4), heat-inactivated TNF 
(H.I.-TNF; n-5), 1.0 mg/kg TNF (n-6), or 30 mg/kg ETX (n=6). Values 
reported are mean plasma lactate concentrations ± SEM (mM) in surviving 
rats. Plasma lactate concentrations reported at 360 minutes for the TNF 
and ETX treated groups represent the average of 2 values. 
1t:ps 0.05 treatment vs saline. ():ps 0.05 TNF vs. H.I.-TNF. 
tf:ps 0.05 ETX vs. TNF. 
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FIGURE 11 
EFFECTS OF HIGH DOSE TNF ON PIASMA IACTATE IN FED CANNUIATED RATS 
Rats were given an i.v. bolus injection of saline (n=5) or 1 mg/kg TNF 
(n=5). Values are mean plasma lactate concentrations± SEM (mM) in 
surviving rats. "*'=P~ 0.05 TNF vs. saline. 
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FIGURE 12 
EFFECTS OF ID\J DOSE TNF, ID\J DOSE ETX, AND ID\J DOSE TNF PUJS ETX CO-
TREATMENT ON Pl.ASMA LACTATE IN FASTED CANNUIATED RATS 
Rats were injected i.v. with either saline (n=7), 0.1 mg/kg TNF (n-6), 
1.55 mg/kg ETX (n-5), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg 
ETX (n-7). Values reported are mean plasma lactate concentrations± SEM 
(mM) in surviving rats. ....:ps 0.05 treatment vs saline. ():ps 0.05 ETX 
vs. TNF. +:ps 0.05 TNF plus ETX co-treatment vs. TNF. O:ps 0.05 TNF 
plus ETX co-treatment vs. ETX. 
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8. Endocrine effects of TNF, ETX, and TNF plus ETX co-treatment: 
plasma insulin 
Arterial blood samples from conscious, unrestrained, cannulated 
rats were analyzed to determine the endocrine modulatory effects, as 
assessed by changes in plasma insulin concentration, of the following 
treatments: 1) high dose TNF and high dose ETX in fasted rats; 2) low 
dose TNF and low duse ETX in fasted rats; and 3) co-treatment with low 
dose TNF plus low dose ETX in fasted rats. Moreover, the influence of 
high dose TNF on plasma insulin was evaluated also in fed, conscious, 
unrestrained, cannulated rats. 
The ability of TNF to influence plasma insulin concentrations was 
investigated in fasted and fed rats. Frqm the data in figure 15, it was 
difficult to determine if low dose TNF (0.1 mg/kg) had a direct effect on 
plasma insulin in fasted rats. Because the pre-injection plasma insulin 
concentration for the TNF treated rats was significantly elevated 
relative to the saline control value, the concentration reported 30 
minutes after TNF injection was not statistically different from the pre-
injection control value. However, the 30 minute value for the TNF 
treated rats was significantly greater than the corresponding value 
reported for the saline injected rats; 25.3 µU/ml versus 18.8 µU/rnl, 
respectively. Plasma insulin concentrations for the TNF treated animals 
were not different from those determined in the saline control rats at 
60, 90, and 120 minutes. When compared to the respective pre-injection 
value of 27.5 µU/ml, however, plasma insulin concentrations appeared to 
decrease at 90 and 120 minutes as a result of TNF treatment; 18.0 and 
14.3 µU/ml, respectively. 
106 
Significant changes in plasma insulin concentration were observed 
in fasted and fed rats after treatment with high dose TNF (1 mg/kg). 
Plasma insulin concentrations were significantly depressed relative to 
the saline controls at 90 and 360 minutes after high dose TNF ad-
ministration to fasted rats (figure 13). By 90 minutes, the plasma 
insulin concentration determined for the TNF treated animals was ap-
proximately half the value determined for the saline treated rats, 12.9 
versus 24.5 µU/ml, respectively. The hypoinsulinemic effect of TNF also 
was evident at 360 minutes post-injection: 22.3 versus 10.0 µU/ml for 
the saline control and high dose TNF treated rats, respectively. The 
value reported at 360 minutes for the TNF treated group was the average 
from two rats; 9.51 and 10.56 µU/ml. When tested in fed rats, a high 
dose of TNF elicited a biphasic change in plasma insulin concentrations 
(figure 14). A significant hyperinsulinemia was reported at 60 minutes, 
with plasma insulin concentration elevated to 62.0 µU/ml for the TNF 
treated rats. By 360 minutes, a significant hypoinsulinemia was 
demonstrated in the TNF treated group: plasma insulin concentration 
dropped to 20.5 µU/ml. Hence, a significant TNF-induced hyperinsulinemia 
was demonstrated only in fed rats, whereas significant hypoinsulinemia 
was observed by 360 minutes post-injection in both fed and fasted rats. 
Dose .dependent changes were observed in plasma insulin con-
centration after ETX administration. No significant changes in plasma 
insulin concentration were elicitec .fter low dose ETX administration, as 
shown in figure 15. Although the pre-injection plasma insulin con-
centration for the low dose ETX treated rats appeared to be greater than 
the values reported for the other groups, the difference was not 
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FIGURE 13 
EFFECTS OF HIGH DOSE TNF AND ETX ON PIASMA INSULIN IN FASTED CANNUIATED 
RATS 
Rats were injected i.v. with either saline (n=4), heat-inactivated TNF 
(H.I.-TNF; n-5), 1.0 mg/kg TNF (n-6), or 30 mg/kg ETX (n-6). Values 
reported are mean plasma insulin concentrations ± SEM (µU/ml) in 
surviving rats. Plasma insulin concentrations reported at 360 minutes 
for the TNF and ETX treated groups represent the average of 2 
determinations .... :p~ 0.05 treatment vs saline. ~:p~ 0.05 TNF vs. ETX. 
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FIGURE 14 
EFFECTS OF HIGH DOSE TNF ON Pl.ASMA INSULIN IN FED CANNUI.ATED RATS 
Rats were given an i.v. bolus injection of saline (n-5) or 1 mg/kg TNF 
(n=5). Values reported are mean plasma insulin concentrations± SEM 
(µU/ml) in surviving rats. 1c:p~ 0.05 TNF vs. saline. 
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FIGURE 15 
EFFECTS OF LOW' DOSE TNF, LOW' DOSE ETX, AND LOW' DOSE TNF PLUS ETX CO-
TREATMENT ON Pl.ASMA INSULIN IN FASTED CANNUl.ATED RATS 
Rats were injected i.v. with either saline (n=7), 0.1 mg/kg TNF (n=6), 
1.55 mg/kg ETX (n-5), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg 
ETX (n-7). Values reported are mean plasma insulin concentrations± SEM 
(µU/ml) in surviving rats. ...:ps 0.05 treatment vs saline. 
TNF vs. ETX. +:p~ 0.05 TNF vs. TNF plus ETX co-treatment. 
TNF plus ETX co-treatment vs. ETX. 
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statistically significant. High dose ETX administration, however, 
induced an observable but not statistically significant increase in 
plasma insulin concentrations by 30 and 90 minutes relative to the 
respective pre-injection control value (figure 13). A significant 
hypoinsulinemia was elicited 360 minutes after a high dose of ETX. The 
plasma insulin concentration reported at 360 minutes for the high dose 
ETX treated rats, 3.60 µU/ml, was the average for 2 rats; 3.96 and 3.23 
µU/ml. 
Co-treatment with low dose TNF plus ETX resulted in a significant 
change in plasma insulin which was unlike that reported for rats treated 
with either TNF or ETX alone. No significant alterations in plasma 
insulin concentration occurred within the first 90 minutes after co-
treatment with TNF plus ETX (figure 15). By 120 minutes, however, there 
was a significant increase in plasma insulin concentration to 34.3 µU/ml, 
which was significantly greater than the values reported for the saline 
control, low dose TNF, and low dose ETX treated groups; 15.7, 14.3, and 
20.1 µU/ml, respectively. 
9. Neuro-endocrine effects of TNF: plasma catecholamines 
The effects of high dose TNF on plasma epinephrine and nor-
epinephrine concentrations were evaluated in fasted, conscious, un-
restrained, cannulated rats. Saline treated rats had no measurable 
changes in plasma epinephrine or norepinephrine concentrations; plasma 
epinephrine and norepinephrine remained steady thrc,<,hout the experiment 
at average mean values of 72.l and 82.l pg/ml, respectively. Because 
changes in plasma epinephrine and norepinephrine concentrations are 
sensitive indicators of stress, the failure to demonstrate a significant 
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FIGURE 16 
EFFECTS OF HIGH DOSE TNF ON PIASMA EPINEPHRINE IN FASTED CANNULATED RATS 
Rats were injected i.v. with either saline (n=3), heat-inactivated TNF 
(H.I.-TNF; n=4), or 1.0 mg/kg TNF (n=6). Values reported are mean plasma 
epinephrine concentrations± SEM (pg/ml) in surviving rats. The value 
reported at 360 minutes for the TNF treated group represents the average 
of 2 determinations. .,fr:p~ 0.05 treatment vs saline. ():p~ 0.05 TNF vs. 
H.I.-TNF. 
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FIGURE 17 
EFFECTS OF HIGH DOSE TNF ON PIASMA NOREPINEPHRINE IN FASTED CANNULATED 
RATS 
Rats were injected i.v. with either saline (n-3), heat-inactivated TNF 
(H.I.-TNF; n=4), or 1.0 mg/kg TNF (n-6). Values reported are mean plasma 
norepinephrine concentrations ± SEM (pg/ml) in surviving rats. The value 
reported at 360 minutes for the TNF group represents the average of 2 
values. 1f:p~ 0.05 treatment vs saline. (l:p~ 0.05 TNF vs. H.I.-TNF. 
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elevation in their concentrations after saline injection supported the 
belief that the experimental procedure per se was not stressing the 
animals. 
Significant elevations in plasma epinephrine and norepinephrine 
concentrations occurred by 90 minutes after high dose TNF administration. 
Plasma epinephrine increased to 3509 pg/ml from a pre-injection value of 
116 pg/ml (figure 16). Peak elevation in plasma epinephrine was de-
monstrated at 180 minutes with a value of 8004 ± 3674 pg/ml. By 360 
minutes, only 2 animals remained: the 24 hour survivor had a plasma 
epinephrine concentration of 459 pg/ml, whereas the dying animal had a 
value of 11587 pg/ml. Plasma norepinephrine concentrations increased 
significantly from a pre-injection value of 120 pg/ml to 1374 pg/ml by 90 
minutes after high dose TNF administration (figure 17). Norepinephrine 
concentrations continued to increase to 3042 ± 1528 and 4039 pg/ml by 180 
and 360 minut~s, respectively. The value reported at 360 minutes was the 
average of 2 determinations; 544 pg/ml determined for the 24 hour 
survivor and 7534 pg/ml determined for the agonal stage rat. 
10. Endocrine effects of TNF: plasma corticosterone 
Plasma corticosterone concentrations were measured after high dose 
TNF treatment in fed, conscious, unrestrained, cannulated rats (figure 
18). Saline. injected rats had no measurable change in plasma corti-
costerone concentration; mean plasma corticosterone concentration 
averaged 196 ng/ml. However, high dose -.-p induced a significant in-
crease in plasma corticosterone: by 30 minutes, plasma corticosterone 
increased to 400 ng/ml versus 230 ng/ml for the saline control rats. TNF 
treated animals maintained significantly elevated plasma corticosterone 
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FIGURE 18 
EFFECTS OF HIGH DOSE TNF ON PLASMA CORTICOSTERONE IN FED C~lJIATED RATS 
Rats were injected i.v. with saline (n=S) or 1 mg/kg TNF (n=S). Values 
reported are mean plasma corticosterone concentrations ± SEM (ng/ml) in 
surviving rats. '*':p~ 0.05 TNF vs. saline. 
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concentrations relative to saline treated animals for 360 minutes. Final 
plasma corticosterone concentrations were 563 ng/ml in the TNF treated 
group and 168 ng/ml in saline treated controls. 
B. IN VITRO EFFECTS OF TNF: ISOI.ATED PERFUSED RAT LIVERS 
TNF induced significant alterations in plasma glucose concentration 
comparable to those induced after ETX administration in conscious, can-
nulated rats (figure 8). These observations suggested that the changes 
in hepatic glucoregulation observed after ETX administration might be 
mediated by endogenous TNF, released from ETX-activated Kupffer cells, 
directly influencing neighboring hepatocyte function. To evaluate this 
hypothesis initially, TNF was tested for direct hepatic glucoregulatory 
effects using the isolated perfused rat liver model. Livers were excised 
from fed male rats under sodium pentobarbital anesthesia and perfused in 
a recirculating liver perfusion apparatus with glucose-free K.RB con-
taining 2 mg/ml albumin, as described in chapter III. Because the 
perfusion buffer was glucose-free, the glucose concentration measured in 
the buffer during the perfusion was the net result of hepatic glucose 
mobilization from endogenous stores of glycogen. 
The liver was allowed to stabilize in the perfusion system for 30 
minutes. During that time, net hepatic glucose production stimulated by 
the absence of glucose in the perfusion buffer and oxygen consumption 
reached steady state levels of 92.6 µmoles glucose/gm liver wet weight/ 
hour and 56.4 µl of oxygen/gm liver wet weight/minute, respectively. 
As reported in table 5, the direct effect of TNF on net liver 
glucose production rates was examined using the isolated perfused rat 
liver model. Control glucose production rates determined at 30 minutes 
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were similar for each group of livers; 94.2, 93.0, and 90.7 µmoles of 
glucose/gm liver wet weight/ hour. At 31 minutes, either 1 ml of PBS 
(n-6), 150 µg of TNF (n=5), or 300 µg TNF (n=4) was added directly to the 
perfusion reservoir. During the subseqeunt 15 minutes of perfusiou, 
there was a slight reduction in glucose production rate observed in the 
PBS treated livers: net glucose production rate decreased from a value 
of 94.2 to 72.S µmoles glucose/gm liver wet weight/hour by 46 minutes. 
Livers administered 150 µg of TNF (1 µg/ml final concentration) demon-
strated a greater reduction in net glucose output by 46 minutes than was 
observed for the PBS treated livers. After 15 minutes of perfusion with 
1 µg/ml TNF, net glucose production rate dropped to 56.6 µmoles glucose/ 
gram liver wet weight/hour, which appeared to be lower than the rate 
reported for the PBS treated controls (p~0.10). 
In order to pursue further the possibility that TNF might directly 
modulate hepatic glucose production, livers were challenged at 46 minutes 
with a maximal stimulatory dose of glucagon (1 µM final concentration). 
As reported in table 5, net glucose production rate increased approxi-
mately 4 fold for the PBS treated control group to 294 µmoles glucose/gm 
liver wet weight/hour. Glucagon challenge of the TNF (1 µg/ml) treated 
livers resulted in an increase in net glucose production rate to 202 
µmoles glucose/gm liver wet weight/hour, which was less than that ob-
served with the PBS treated livers (p~ 0.10). 
The basal and glucagon stimulated net glucose production rates for 
livers perfused with 1 µg/ml TNF suggested that a higher dose of TNF 
might significantly (p~0.05) modulate net hepatic glucose production. 
Therefore, a group of livers was tested in the same manner as j~st 
CONTROL 
94.2±10 
93.0±6.7 
90.7±18 
TABLE 5 
EFFECTS OF TNF ON GLUCOSE PRODUCTION RATES 
BY ISOLATED PERFUSED RAT LIVERS 
_N_ TREATMENT BASAL 
6 PBS 72. 8±5 .1 
5 TNF( lµg/ml)· 56.6±6.3* 
4 TNF(2µg/ml) 65.5±9.3 
123 
GLUCAGON 
(1 uM) 
294±23 
202±39* 
222±46 
Values reported are mean net glucose production rates ± SEM by isolated 
perfused rat livers (µmoles glucose/gm liver wet weight/hour). Livers 
were excised from pentobarbital anesthetized rats and were perfused with 
KRB + 2 mg/ml albumin. The control values represent the net glucose 
production rates after 30 minutes of perfusion. Either PBS (1 or 2 ml) 
or TNF (150 or 300 µg) was added directly to the perfusion reservoir 
after 31 minutes of perfusion. After 46 minutes of perfusion, maximum 
glucose production was achieved with the administration of glucagon (1 µM 
final concentration). Total perfusion time was 64 minutes. *p~ 0.10 TNF 
VS PBS. 
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described except that a 2 fold greater dose of TNF was added directly to 
the perfusion reservoir after 31 minutes of perfusion, ie. 300 µg. 
However, there was no significant difference between the net glucose 
production rate of TNF treated livers (2 µg/ml) and PBS treated livers; 
65.5 vs. 72.8 µmoles glucose/gm liver wet weight/hour, respectively. 
Furthermore, TNF treatment (2 µg/ml) failed to alter the glucagon 
stimulated increase in net hepatic glucose production. After challenge 
with 1 µM glucagon for 15 minutes, net glucose production rates increased 
to 222 µmoles glucose/gm liver wet weight/hour in the TNF treated livers, 
which was not significantly different from the rate reported for the PBS 
treated livers, 294 µmoles glucose/gm liver wet weight/hour. 
Net hepatic lactate production was continuously monitored during the 
perfusion and the calculated rates are reported in table 6. Net lactate 
production rates determined during the 30 minute control period were 
similar for all 3 groups of livers; 26.3, 20.9, and 11.5 µmoles lactate/ 
gram liver wet weight/hour, respectively. Perfusion with 1 or 2 µg/ml of 
TNF for 15 minutes did not influence net lactate production rates. The 
rates determined after 15 minutes of treatment with 1 and 2 µg/ml TNF, 
24.0 and 21.l µmoles lactate/gm liver wet weight/hour, were not sig-
nificantly different from the rate reported for the PBS treated group, 
17.7 µmoles .lactate/gm liver wet weight/hour. After challenge with 1 µM 
glucagon, livers removed lactate from the perfusate rather than release 
lactate into the perfusion buffer. Thereft ~. net lactate uptake rates, 
presented as negative values for net lactate production rates, are 
reported in table 6. TNF treatment did not influence hepatic lactate 
uptake in response to 1 µM glucagon. Fifteen minutes after challenge 
CONTROL 
26.3±5.6 
20.9±10 
11. 5±17 
TABLE 6 
EFFECTS OF TNF ON IACTATE PRODUCTION RATES 
BY ISOIATED PERFUSED RAT LIVERS 
_N_ TREATMENT BASAL 
6 PBS 17.7±7.5 
5 TNF(lµg/ml) 24.0±12 
4 TNF(2µg/ml) 21.1±3.9 
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GLUCAGON 
___ll-1!!1.L 
-12.7±6.7 
-13.1±5.9 
-14.9±8.3 
Values reported are mean net lactate production rates ± SEM by isolated 
perfused rat livers (µmoles lactate/gm liver wet weight/hour). The 
addition of glucagon resulted in a net uptake of lactate by the livers 
as indicated by the negative values. 
CONTROL 
58.3±3.0 
57.4±2.6 
53.6±2.5 
TABLE 7 
EFFECTS OF TNF ON OXYGEN CONSUMPTION RATES 
BY ISOLATED PERFUSED RAT LIVERS 
_N_ TREATMENT BASAL 
6 PBS 59.8±2.8 
5 TNF(lµg/ml) 58. 1±1. 2 
4 TNF(2µg/ml) 57.6±2.7 
126 
GLUCAGON 
(1 uM) 
62.9±4.2 
60. 8±1. 9 
60. 2±1. 7 
Values reported are mean net oxygen consumption rates ± SEM by isolated 
perfused rat livers (µl of oxygen/gm liver wet weight/min). Liver oxygen 
consumption rates were calculated from the difference in oxygen 
saturation of the perfusion fluid going into and coming out of the 
perfused liver. 
127 
with 1 µM glucagon, net lactate uptake rates were 12.7, 13.1, and 14.9 
µmoles lactate/gm liver wet weight/hour for PBS, 1 and 2 µg/ml TNF 
treated livers, respectively. 
I~ addition to net hepatic glucose and lactate production, liver 
oxygen consumption was measured during the perfusion, as discussed in 
chapter III. During the control period, liver oxygen consumption rates 
were similar for each group of livers: 58.3, 57.4, and 53.6 µl oxygen/gm 
liver wet weight/minute, table 7. After 15 minutes of continuous per-
fusion with 1 or 2 µg/ml TNF, there was no measurable change in oxygen 
consumption rate relative to the control rate determined for PBS treated 
livers. The slight increase in oxygen consumption rate observed after 
challenge with 1 µM glucagon was not altered by treatment with TNF. 
Fifteen minutes after challenge with 1 µM glucagon, oxygen consumption 
rates reported for PBS, 1 µg/ml TNF, and 2 µg/ml TNF treated livers were 
62.9, 60.8, and 60.2 µl oxygen/gm liver wet weight/minute, respectively. 
There were no other observable changes in livers perfused with 1 or 
2 µg/ml TNF. Flow rate to the livers remained steady at 50 ml/minute for 
both PBS and TNF treated livers. The outward appearance of the livers 
during perfusion with 1 or 2 µg/ml TNF was unaltered: there was no 
hepatic swelling or discoloration after TNF administration. 
C. IN VITRO EFFECTS OF TNF: ISOLATED LIVER PARENCHYMAL CELLS 
As a final step in determining the direct, short-term, hepatic 
glucoregulatory ef:! ;ts of TNF, isolated hepatocytes from fed rats were 
incubated with various doses of TNF. Unlike the isolated perfused liver 
model, hepatocytes were in direct contact with TNF without significant 
interference from other non-parenchymal liver cells, such as Kupffer 
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cells and endothelial cells. Furthermore, the dose dependent influence 
of TNF on hepatic glucoregulation was easily evaluated with the cells 
isolated from each individual liver, rather than different cell 
preparations for each dose of T,fF tested. 
TNF at doses of 0.01-5.0 µg/ml had no effect on net glucose 
production rates, as reported in table 8. Basal rates of glucose 
production in ttc presence of 0.01-5.0 µg/ml TNF averaged 0.970 µmoles 
glucose/mg protein/hour, which was not significantly different from the 
basal rate of 0.939 µmoles glucose/mg protein/hour reported for the PBS 
treated control cells. Just as done with the isolated perfused livers, 
isolated hepatocytes were maximally stimulated with 1 µM glucagon to 
determine if TNF treatment modulated the hormonal response. Glucose 
production stimulated by the cAMP-dependent hormone glucagon was tested 
in cells incubated with PBS or 0.01-5.0 µg/ml TNF (table 8). PBS treated 
control cells stimulated with 1 µM glucagon demonstrated an increase in 
net glucose production rate to 1.45 µmoles glucose/mg protein/hour from a 
basal rate of 0.939. TNF treatment failed to modify the cellular 
response to 1 µM glucagon, as reflected by the net glucose production 
rates. The average glucose production rate observed with hepatocytes 
stimulated with 1 µM glucagon in the presence of 0.01-5.0 µg/ml TNF was 
1.39 µmoles glucose/mg protein/hour, a rate not significantly different 
from the control rate of 1.45 reported for the PBS treated cells. 
Since hepatic glucose production also is stimulated by a ca++_ 
dependent pathway as well as a cAMP-dependent pathway, the ca++_dependent 
glucoregulatory hormone, vasopressin, was tested in PBS and 0.01-5.0 
µg/ml TNF treated cells. Under the same conditions as just described, 
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TABLE 8 
EFFECTS OF TNF ON BASAL AND GLUCAGON-STIMUIATED GLUCOSE PRODUCTION RATES 
BY ISOLATED HEPATOCYTES 
TREATMENT DOSE (ug/ml) BASAL GLUCAGON (1 uM) 
PBS 0.939±0.040 1.45±0. 28 
TNF 5 0.975±0.082 1. 42±0. 27 
TNF 1 0.963±0.071 1. 44±0. 28 
TNF 0.5 0.958±0.064 1.41±0.28 
TNF 0.1 0.951±0.074 1. 38±0. 29 
TNF 0.05 0.986±0.11 1. 38±0. 27 
TNF 0.01 0.986±0.10 1. 33±0. 28 
Values reported are mean net glucose production rates ± SEM determined 
from four different cell preparations (µmoles glucose/mg protein/hr.). 
For each preparation, cells were isolated and incubated in triplicate for 
60 minutes at 37°C in KRB + 2 mg/ml albumin in the absence or presence of 
the indicated doses of TNF ± glucagon. 
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TABLE 9 
EFFECTS OF TNF ON BASAL AND VASOPRESSIN - STIMUIATED GLUCOSE PRODUCTION 
RATES BY ISOLATED HEPATOCYTES 
TREATMENT DOSE (ug;Lml} BASAL VASOPRESSIN 
(1 uM} 
PBS 0.681±0.021 0.780±0.078 
TNF 5 0.650±0.046 0.767±0.072 
TNF 1 0.592±0.011 0.794±0.079 
TNF 0.5 0.647±0.054 0.774±0.065 
TNF 0.1 0.644±0.059 0.743±0.072 
TNF 0.05 0.607±0.048 0.759±0.073 
TNF 0.01 0.644±0.053 0.780±0.072 
Values reported are mean net glucose production rates ± SEM for three 
separate cell preparations (µmoles glucose/mg protein/hr). For each 
preparation, cells were isolated and were incubated in triplicate for 60 
minutes at 37°C in KRB + 2 mg/ml albumin in the absence or presence of 
the indicate"d doses of TNF ± vasopressin. 
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TNF had no effect on the basal rate of glucose production by isolated 
hepatocytes (table 9). The average glucose production rate in response 
to TNF was 0.631 µmoles glucose/mg protein/hour, which was not signi-
ficanLly different from the PBS control rate cf 0.681 µmoles glucose/mg 
protein/hour. In response to maximal stimulation with l µM vasopressin, 
PBS treated control cells and TNF treated cells responded similarly, as 
assessed by net hepatic glucose production rates. Glucose production 
rates increased to 0.780 and an average value of 0.770 µmoles glucose/mg 
protein/hour for PBS treated and TNF treated cells, respectively. Hence, 
under short-term conditions, TNF failed to directly influence hepatic 
glucoregulation under both basal and hormone stimulated conditions. 
In conjunction with evaluating the direct effects of TNF on net 
hepatic glucose production, TNF also was evaluated for a direct effect on 
net lactate production by isolated hepatocytes. As reported in table 10, 
TNF did not influence the basal rate of lactate production by isolated 
hepatocytes. The average rate of lactate production under the influence 
of TNF was 0.354 µmoles lactate/mg protein/hour, which was insignifi-
cantly different from the PBS control rate of 0.343 µmoles lactate/mg 
protein/hour. Similar to the results obtained with the isolated perfused 
liver model, stimulation with l µM glucagon blunted the net lactate 
production by isolated hepatocytes. In the presence of l µM glucagon, 
net lactate production rate dropped to 0.073 µmoles lactate/mg protein/ 
hour from a basal value of 0. 343 µmoles lactate/mg protein1:1our for the 
PBS treated control cells. And just as observed with the isolated 
perfused livers, TNF treatment did not interfere with the hepatocytes' 
ability to use lactate as a gluconeogenic substrate after stimulation 
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TABLE 10 
EFFECTS OF TNF ON I.ACTATE PRODUC/rION RATES BY ISOI.ATED HEPATOCYTES 
TREATMENT DOSE (ug/ml) BASAL GLUCAGON (luM) 
PBS 0.343±0.050 0.073±0.005 
TNF 5 0.333±0.050 0.085±0.006 
TNF 1 0.333±0.040 0.093±0.016 
TNF 0.5 0.350±0.051 0.098±0.018 
TNF 0.1 0.365±0.046 0.133±0.050 
TNF 0.05 0.373±0.037 0.073±0.012 
TNF 0.01 0.370±0.071 0.113±0.040 
Values reported are mean net lactate production rates ± SEM for four 
separate cell preparations (µmoles lactate/mg protein/hr). For each 
preparation, cells were isolated and were incubated in triplicate for 60 
minutes at 37°C in KRB + 2 mg/ml albumin in the absence or presence of 
the indicated doses of TNF ± glucagon. 
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TABLE 11 
EFFECTS OF TNF ON I.ACTATE PRODUCTION RATES BY ISOI.ATED HEPATOCYTES 
IN THE ABSENCE OR PRESENCE OF VASOPRESSIN 
TREATMENT DOSE {ugLml) BASAL VASOPRESSIN 
{luM) 
PBS 0.244±0.053 0.358±0.092 
TNF 5 0.276±0.022 0. 321±0. 066 
TNF 1 0.215±0.063 0.287±0.048 
TNF 0.5 0.301±0.038 0.323±0.007 
TNF 0.1 0.232±0.053 0.307±0.072 
TNF 0.05 0.217±0.044 0.319±0.065 
TNF 0.01 0.270±0.070 0.323±0.052 
Values reported are mean net lactate production rates ± SEM for three 
separate cell preparations (µmoles lactate/mg protein/hr). For each 
preparation, cells were isolated and were incubated in triplicate in KRB 
plus 2 mg/ml albumin for 60 minutes at 37°C in the absence or presence of 
the indicated doses of TNF ± vasopressin. 
134 
TABLE 12 · 
EFFECTS OF TNF ON GLUCOSE UTILIZATION BY ISOLATED HEPATOCYTES 
TREATMENT DOSE (ug/ml) GLUCOSE OXIDATION 
CONTROL 333±54 
TNF 5 344±15 
TNF 1 341±55 
TNF 0.5 354±52 
TNF 0.1 338±27 
TNF 0.05 356±27 
TNF 0.01 298±18 
Values reported are mean 14c counts ± SEM from four separate cell 
preparations (DPM/mg protein). For each preparation, cells were isolated 
and were incubated in triplicate for 120 minutes at 37°C in KRB con-
taining 2 mg/ml albumin, 1 mg/ml D-glucose, and 0.1 µCi/ml 14c-D-glucose 
in the absence or presence of TNF. Expired 14co2 was collected for 60 
minutes on methlybenzethonium hydroxide saturated filter paper after the 
addition of 62.5% citric acid. 
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with glucagon (table 10). Hepatocytes treated with 0.01-5.0 µg/ml TNF 
responded to the glucagon challenge in a manner similar to the PBS 
treated control cells. Net lactate production rates dropped as a result 
of glucagon-stimulated hepatic uptake to an average value of 0.099 µmoles 
lactate/mg protein/hour for the TNF treated hepatocytes, which was not 
significantly different from the rate of 0.073 µmoles lactate/mg protein/ 
hour repor~ed for the control cells. Moreover, TNF also failed to 
influence the net lactate production rate of hepatocytes stimulated with 
1 µM vasopressin (table 11). Just as reported in table 10, TNF did not 
modulate the basal lactate production rate reported in table 11. The 
average net lactate production rate in the presence of 0.01-5.0 µg/ml TNF 
was 0.252 µmoles la9tate/mg protein/hour, which was not different from 
the control value of 0.244 µmoles lactate/mg protein/hour. TNF also 
failed to alter the net lactate production rate determined after treat-
ment with 1 µM vasopressin. Net lactate production rates determined in 
the presence of 1 µM vasopressin were 0.358 for PBS treated cells and an 
average rate of 0.313 µmoles lactate/mg protein/hour for the TNF treated 
cells. 
Finally, TNF was tested to determine if its direct hepatic gluco-
regulatory influence was on hepatocyte glucose utilization rather than 
net glucose or lactate production. Since net hepatic glucose and lactate 
production are crude indices of more subtle cellular changes, TNF was 
evaluated for a dose dependent influence on glucose oxidation by isolated 
hepatocytes. Hepatocytes were incubated for 2 hours x 37°C in KRB 
containing 2 mg/ml albumin, 1 mg/ml D-glucose, 0.1 µCi/ml 14c-glucose and 
either PBS or 0.01-5.0 µg/ml TNF. Released 14co2 was collected for 1 
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hour as a measure of 14c-glucose oxidation. As reported. in table 12, TNF 
did not significantly influence glucose utilization by isolated hepato-
cytes. The DPM/mg protein released by PBS treated control cells was 333, 
which was not significantly different from the average value of 338 
DPM/mg protein reported for the TNF treated groups. 
CHAPTER V 
DISCUSSION 
A. IN VIVO EVALUATION OF TNF AS A MEDIATOR OF ENDOTOXIC SHOCK 
This study compared select pathophysiological changes observed after 
comparably lethal, i.v. bolus injections of ETX vis-a-vis TNF in un-
anesthetized, unrestrained, cannulated rats. This modai was implemented 
for a number of reasons. First, conscious, unrestrained, cannulated 
adult rats were used so that hemodynamic monitoring and blood samplings 
were easily obtained and analyzed without the use of anesthesia during 
the experimental protocol. Secondly, since exogenous ETX results in a 
"spike-like" increase in endogenous plasma TNF concentrations (103,174), 
exogenous TNF was administered as an i.v. bolus injection such that peak 
blood levels of exogenous TNF were reached quickly (31,82) and were 
followed by a rapid decline (31,82). Although a continuous infusion of 
exogenous TNF achieves the level in plasma TNF elicited after exogenous 
ETX administration (175), the rise and subsequent decline in plasma TNF 
concentration are slower. Since both the magnitude of TNF release 
(103,224) as well as the duration (127) of the spike may be important in 
the severity of the TNF insult, an i.v. bolus injection of exogenous TNF 
was used for this study rather than a continuous infusion. Additionally, 
the doses of exogenous TNF administered resulted in levels of plasma TNF 
comparable to those measured after an ETX challen~e. Lssuming that 
exogenous TNF is confined to the extracellular space (82), high dose TNF 
(1.0 mg/kg) administered to 350 gram rats resulted in a calculated 
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initial plasma TNF concentration equivalent to 5 µg/ml, which was similar 
to the 5.5 µg/ml TNF produced in vivo in BCG-primed rabbits stimulated 
with ETX (1). Low dose TNF (0.1 mg/kg) administration resulted in a 
calculated initial plasma concentration of 0.5 µg/ml, which was greater 
than the sub-nanogram per milliliter peak concentrations reported for 
humans either infused with non-lethal doses of TNF (175) or given a non-
lethal bolus injection of ETX (103,174). Sub-microgram per milliliter 
peak concentrations were observed in baboons (103) and rabbits (161) 
following a lethal injection of Escherichia coli and ETX, respectively. 
1. Mortality and morbidity comparisons 
Comparison between the pathophysiological changes induced by ETX 
and TNF in vivo demonstrated important similarities as well as salient 
differences. Both TNF and ETX had dose dependent lethal effects in 
conscious, unrestrained, cannulated rats; however, on a milligram per 
kilogram basis, rats were more sensitive to the lethal effects of TNF 
than the lethal effects of ETX. TNF at doses of 1 and 1.8 mg/kg resulted 
in mortality rates of 83% in 24 hours (table 2) and 64% in 12 hours 
(249), respectively. Comparable doses of ETX, ie. 1.55 mg/kg, produced 
only a 20% mortality in 24 hours; a 30 mg/kg dose of ETX was required for 
100% mortality rate during 24 hours. When rats were pretreated with 
glucan, which enhanced the reticuloendothelial system (78), sensitivity 
to the lethal effects of ETX increased whereas sensitivity to the lethal 
effects of TNF remained unaltered. The differential sensitivity to TNF 
and ETX under normal and RES stimulated conditions provide useful in-
sights in the pathogenesis of endotoxic shock. Since greater quantities 
of TNF are presumably released in response to ETX challenge under RES 
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stimulated conditions than under normal conditions, the enhanced sen-
sitivity to ETX observed after glucan pretreatment is correlated with the 
enhanced TNF activity. Failure to demonstrate an augmentation in the 
sensitivity to TNF under RES stimulated conditions suggests that the 
pathological changes elicited by TNF were not mediated through TNF 
stimulated macrophage cytotoxicity (202) or mediator secretion (12,38, 
67). Other agents, such as actinomycin D (34,46) and D-galactosamine 
(145) which interfere with cellular function rather than stimulate the 
RES, increase the sensitivity to both ETX and TNF, therefore supporting 
the hypothesis that the lethal effects induced by ETX and TNF are 
related. 
The dose dependent morbidity incblced by TNF and ETX was 
indistinguishable: rats exhibited piloerection, labored breathing, 
hunched-over posture, and progressive cyanosis subsequent to either ETX 
or TNF injection. Diarrhea was consistently observed in the ETX treated 
rats but not in the TNF treated rats, even though TNF-induced diarrhea 
had been reported by other investigators (13,125,214,249). These 
symptoms in rats are analogous to the flu-like symptoms, such as chills, 
headache, myalgia, nausea, and fever, reported by humans given either a 
bolus injection of ETX (174,175) or an infusion of TNF (175). 
Neutralization of endogenous TNF by either rabbit antiserum (26) 
or specific monoclonal antibodies (250) reduced the lethal effects of ETX 
anc 1 ive gram negative bacteria. Furthermore, the inability to produce 
TNF in response to an ETX challenge likewise reduces the mortality and 
morbidity associated with lethal endotoxicosis. For instance, endotoxin-
resistant mice fail to produce TNF in response to an ETX challenge as a 
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result of pre- and post-translational defects (24). Moreover, the 
therapeutic effect of steroid treatment prior to an ETX challenge is 
related to the steroid-induced block in macrophage TNF production (24). 
These findings indeed implicate a role for endogenoils TNF in the 
mortality and morbidity observed durin~ endotoxicosis and septic shock. 
2. Hemodynamic comparisons: mean blood pressure and pulse rate 
Even though comparably lethal doses of ETX and TNF were used in 
this study, the pattern of blood pressure changes induced by each agent 
differed. ETX repeatedly produced a significant hypotensive response, 
both in this study and in other studies (107,116). TNF, on the other 
hand, did not produce any significant change in MBP as demonstrated in 
this study using conscious rats and in other studies using phase I cancer 
patients (31,276) or conscious rats administered a non-lethal dose of TNF 
(13). In contrast, studies performed by other investigators using 
anesthetized dogs (253) and rats (249) demonstrated significant TNF-
induced hypotension. Since anesthesia is known to interfere with 
cardiovascular function, the hypotension observed after TNF admin-
istration in anesthetized animals suggests that the response to TNF was 
altered by the state of the animals. 
Even though TNF did not significantly alter MBP under conscious 
conditions, TNF did induce a significant tachycardia in conscious rats. 
Similarly, previous studies have demonstrated a significant elevation in 
heart rate after peak blood TNF levels were reached subsequent to __ 1 ETX 
injection (174,175) or during a continuous infusion of TNF (175) in 
conscious humans. The tachycardia-inducing property of TNF implicates 
TNF as a mediator of the persistant tachycardia observed in ETX treated 
rats long after the MBP returned to control levels after the initial 
hypotensive response. 
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Thus, a comparison between the hemodynamic changes induced by ETX 
and those induced by TNF suggest the following: 1) the transient hypo-
tension elicited by ETX is not mediated by endogenously produced TNF 
since exogenous TNF did not elicit a hypotensive response; and 2) the 
persistant ta~hycardia observed in ETX treated rats long after the MBP 
has returned to control values is possibly mediated by endogenously 
produced TNF. 
3. Metabolic ..:omparisons: plasma glucose and lactate 
Both ETX and TNF elicited an initial hyperglycemia. However, the 
initial hyperglycem~a observed during endotoxicosis (73,106,137,282) most 
likely is not mediated by the hyperglycemia-inducing ability of TNF 
(125,249). This conclusion is based on the following observations. 
First, the hyperglycemia induced by ETX occurred more rapidly than the 
rise in plasma glucose induced by exogenous TNF. Second, the hyper-
glycemia induced with high dose TNF was only a fraction of the hyper-
glycemia elicited by both low and high dose ETX. Since the TNF induced 
effects are delayed and reduced compared to those induced by ETX, it is 
unlikely that endogenous TNF mediated the ETX induced hyperglycemia. 
Third, the increase in plasma glucose observed after ETX administration 
occurred coincident with rather than subsequent to the production of 
endogenous TNF (28,90,95,103,161,174,175,266). Although the hyper-
glycemia inducing property of TNF probably was not involved in the 
initial hyperglycemia of endotoxicosis, it might be involved in delaying, 
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but not preventing, the hypoglycemia which is observed late in the course 
of endotoxlcosis. 
More dramatic was the profound hypoglycemia demonstrated during 
both ETX- and TNV-induced shock (figure 7). Rats that succumbed to the 
lethal effects of ETX (73,77,106,137,187,282) and TNF (16,125,249) did so 
with accompanying hypoglycemia and convulsive episodes. It may be that 
endogenous TNF is responsible for the hypoglycemic effect of ETX either 
by interfering with hepatic glucose production through modulation of 
glycogenolysis and/or gluconeogenesis or by enhancing glucose util-
ization. The direct effect of TNF on hepatic glucoregulation will be 
discussed in section C. However, TNF may participate in enhanced 
peripheral glucose utilization by increasing glucose uptake (142) and 
utilization by muscle (142) and macrophage-rich tissues (173). Moreover, 
since chronic exposure to TNF modulates the utilization of two important 
energy sources, fat and protein (254), it may be reasonable to suspect 
that TNF also interferes with the regulation of the third energy 
substrate, glucose. 
The hyperlactacidemia which accompanies endotoxicosis (137,187, 
282) may be mediated, in part, by endogenous TNF (16,249,253). Since the 
hyperlactacidemia induced by low and high dose ETX was significantly 
earlier than that elicited by high dose TNF, it suggests that the initial 
increase in plasma lactate probably is not mediated by endogenous TNF 
activity. The initial rise i~ plasma lactate observed after ETX 
administration probably results from the increased availability of 
glucose under conditions of hypoperfusion or hypoxia due to the ETX-
induced hypotension. However, the progressive elevation in plasma 
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lactate observed subsequent to high dose TNF administration suggests that 
TNF is more likely involved in the persistant elevation in plasma lactate 
observed after ETX administration. The progressive hyperlactacidemia 
which develops after TNF admir.istration probably is the result of TNF-
induced tissue hypoxia. TNF-induced endothelial cell procoagulant 
activity (29,186) and endothelial cell disruption (242) compromise organ 
blood flow and oxygen delivery, which leads to an elevation in plasma 
lactate concentrations and organ damage. 
Thus, the comparison between the metabolic changes observed during 
endotoxicosis to those induced by TNF showed the following: 1) endo-
genous TNF most likely is not involved in the initial hyperglycemia 
observed after ETX administration, although it may participate in 
maintaining plasma glucose concentrations at elevated levels; 2) endo-
genous TNF activity is more likely to participate in eliciting the 
profound hypoglycemia observed late in the course of endotoxicosis; and 
3) endogenous TNF activity contributes to the hyperlactacidemia observed 
during the latter stages of endotoxicosis as a result of TNF-induced 
tissue hypoxia. 
4. Neuro-endocrine comparisons: alterations in plasma insulin, 
catecholamines, and corticosterone 
The hormonal changes observed after TNF and ETX administration 
strongly support the role of TNF as a mediator of these endocrine 
alterations. The hypoinsulinemia observed ~ ite after ETX administration, 
as reported here and by Kelleher, et al. (123), may result from the 
accompanying hypoglycemia. However, as observed in this study, the 
magnitude of the hypoinsulinemic responses induced by ETX and TNF were 
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larger than warranted based on the accompanying plasma glucose con-
centrations, thus suggesting that TNF may contribute to the severity of 
the hypoinsulinemia of sepsis. This conclusion is supported not only by 
the in vivo comparison, but also by the in vitro studies which demon-
strated that TNF reduced insulin secretion by 40% (18) without damaging 
islet integrity (153) or insulin content (18). 
Additionally, although not dramacically demonstrated in this 
study, a significant basal hyperinsulinemia usually occurs within the 
first 90 minutes after ETX administration (35,117,123) as a result of 
pancreatic hypersecretion (283). TNF also may contribute to the hyper-
insulinemia of endotoxicosis, as demonstrated by the slight increase in 
plasma insulin concentrations reported after high dose TNF (figures 13 
and 14) and by the 3 fold increase in plasma insulin reported by Bagby, 
et al. (13). Their conclusions, however, are limited since the pre-
injection control insulin concentrations were not reported. While the 
data supporting the role of TNF in the hypoinsulinemia of endotoxic shock 
is credible, further studies need to be done in order to ascertain the 
ability of TNF to modulate the hyperinsulinemic response observed early 
during endotoxicosis. 
The elevations in plasma epinephrine and norepinephrine con-
centrations induced by exogenous TNF suggest that TNF partially mediates 
the increase in plasma catecholamine concentrations reported during 
endotoxicosis. Although the effects of ETX on plasma catecholamines were 
not evaluated in this study, Jones and Romano (116) documented the 
changes in conscious, cannulated rats: plasma epinephrine and nor-
epinephrine concentrations increased dramatically within the first 30 
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minutes after the bolus injection of ETX and remained significantly 
elevated for 360 minutes. The initial elevation in plasma catecholamine 
levels coincided with the hypotensive effect of ETX, thereby suggesting 
that the initial elevations in plasma epinephrine and norepinephrine were 
a reflex response to the ETX-induced hypotension. However, plasma 
catecholamine concentrations remained elevated for 360 minutes, which was 
long after the mean blood pressure had returned to control levels at 120 
minutes. In light of the increase in plasma catecholamine concentrations 
induced by exogenous TNF administration both in this study and in studies 
performed by other investigators (13,253), the persistant elevation in 
plasma epinephrine and norepinephrine observed during endotoxicosis may 
result from endogenous TNF activity. Although the mechanism responsible 
for the TNF-induced elevation in plasma catecholamine concentrations is 
unknown, there are three possible explanations for this finding. First, 
TNF may increase sympathetic activity by acting directly on the hypo-
thalamus to increase sympathetic outflow. Second, TNF may increase 
circulating levels of plasma catecholamines by interfering with 
peripheral sympathetic activity. TNF may directly increase nor-
epinephrine release at the nerve terminals and/or interfere with nor-
epinephrine reuptake and degradation. Third, the elevation in plasma 
epinephrine, primarily, may result from TNF-stimulated release from the 
adrenal medulla. Even though TNF's mechanism of action was not examined 
in th'~ study, the findings suggest that the elevated catecholamine 
concentrations observed during endotoxicosis may result from two stimuli: 
l) an initial baroreceptor reflex response to the ETX induced hypotension 
resulting in the immediate elevation in plasma catecholamine concentra-
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tion; and 2) endogenous TNF induced increase in plasma epinephrine and 
norepinephrine by, as yet, an unknown mechanism. 
Finally, elevation in the stress hormone corticosterone during 
endotoxicosis may result from endogenous TNF activity. Although it was 
not determined in this study, plasma corticosterone concentrations are 
generally increased during endotoxicosis (107,123): plasma levels 
in~Lease approximately 45% two hours after a bolus injection of ETX. As 
shown in this study and in other studies (253,276), TNF induced a 
significant increase in plasma corticosterone concentrations within 30 
minutes. This may have resulted directly from a stimulatory effect of 
TNF on the adrenal glands or indirectly by TNF increasing plasma 
adrenocorticotrophic hormone levels (174,175). The time course for the 
elevation in plasma corticosterone concentrations observed after ETX 
administration compared to the response elicited with exogenous TNF 
suggests that endogenous TNF produced in ~esponse to an ETX challenge may 
mediate the increase in plasma corticosterone reported during endo-
toxicosis. 
These observations indicate that TNF may be a primary mediator of 
the following neuro-endocrine alterations observed during endotoxic 
shock: 1) hypoinsulinemia; 2) persistant elevation of plasma epinephrine 
and norepinephrine; and 3) elevated corticosterone concentrations. 
5. Additional pathophysiological effects 
In addition to the lethal, hemodynamic, metabolic, and neuro-
endocrine effects examined in this study, TNF may mediate some additional 
pathophysiological changes observed during endotoxicosis, such as: fever 
(31,66,126,154,156,276); stimulation of acute phase protein synthesis 
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(59,151,178,181,199,236,276); muscle protein degradation (276); depressed 
plasma iron concentrations (175); complement activation (181); increased 
procoagulant activity (29,186); decreased lipogenesis (194,196,248); and 
PMN infiltration (58,176,229). Exogenous TNF also induced histological 
changes in the lungs, liver, kidneys, and gastrointestinal tract which 
were similar to those observed during endotoxicosis, such as PMN 
infiltration, fv~al areas of necrosis, and vascular congestion (personal 
observations) (88,195,210,249,253,254). All these changes induced by TNF 
administration alone further support the belief that endogenous TNF 
activity is a primary mediator of pathophysiological changes observed 
during septic shock. 
6. Other mediators and interactions 
Significant concentrations of TNF are measurable not only after 
ETX challenge, but also during bacterial meningitis (147), visceral 
leishma~iasis (227), malaria (227), meningococcal meningitis, septicemia, 
or both meningitis and septicemia (269). As discussed previously, there 
appears to be a positive correlation between the severity of the insult 
and the amount of TNF detected (103 1 224). However, detection of plasma 
TNF alone is not enough to determine the severity of the insult 
(127,179), therefore suggesting that additional inflammatory mediators 
may be just as important in the progression of lethal infections (103). 
One such mediator, interleukin 1, might have an important role in the 
pathophysiology observed after TNF and ETX administration. TNF 
stimulates IL-1 production and release both in y:iyQ (66) and in vitro 
(12,62,150,185,202) as does ETX (57,65). As reviewed by Dinarello (65), 
IL-1 mediates many of the responses prevalent during inflammation such 
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as fever, neutrophilia, alterations in plasma divalent cations, synthesis 
of acute phase proteins, stimulation of muscle proteolysis, and stimu-
lation of B and T cell function. IL-1 also induces hypoglycemia (63,104) 
and enhances the rate of glucose clearance after a glucose challenge 
(219). Endocrine alterations resulting from IL-1 administration include 
hyperinsulinemia (63,219), hyperglucagonemia (63) and elevated serum 
corticosterone levels (213). These findings suggest that endogenous IL-1 
may be an important mediator in both ETX- and TNF-induced shock, since 
many of the pathophysiological changes observed after ETX and TNF 
administration can also be produced by IL-1. 
More importantly, perhaps, may be the interaction between TNF and 
IL-1. IL-1 increases the lethal effects of TNF (268): the LD50 dose for 
TNF is reduced 3 fold when administered in conjunction with a non-lethal 
dose of IL-1. The shock-like (190) and lethal effects (268) observed 
after co-treatment with TNF and IL-1 were more than additive. Further-
more, TNF and IL-1 synergize in stimulating PMN infiltration (274), islet 
cell destruction (206), and tumor cell cytostasis (192). 
Other mediators, such as arachidonic acid metabolites, oxygen 
derived free radicals, and platelet activating factor, also may 
contribute to the pathogenesis of TNF and ETX. Prostaglandin E2 and 
prostacyclin production and release are stimulated by TNF (12,61,120, 
125,182) and ETX (84,124,144) and may mediate the fever, glucose al-
terations, gastrointestinal dam ~a, and mortality observed after either 
agent (66,84,124,125,144,182,235,247). Oxygen derived free radicals 
released from infiltrating PMNs in response to TNF (11,140,166,260,277) 
and ETX (84) challenge contribute to the tissue damage elicited by each 
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agent. Platelet-activating factor, likewise, is released in response to 
TNF (38,245) and ETX (44,99,138,271) and may contribute to the hemo-
dynamic changes as well as the tissue injury demonstrated after their 
administration. Furthermore, macrophage released mediators such as 
macrophage insulin-like activity (74,284) and macrophage insulin re-
leasing activity (79) may be important in mediating the glucose and 
endocrine alterations observed during endotoxicosis. 
IFN-~ is also involved in the pathogenesis of endotoxicosis. It 
is released after ETX stimulation (264) and subsequently increases TNF 
production (27,36,52,91,92) and TNF binding sites (5,217,257,259). 
Moreover, IFN-~ synergizes with TNF in causing mortality (247), cyto-
toxicity (45,244), and tissue damage to organs such as liver, lung, 
gastrointestinal tract, spleen, and uterus (247). The sequential 
production of TNF, IL-1, and IFN-~ in response to an ETX or bacterial 
challenge may be crucial in the development of irreversible shock (103): 
all three mediators are produced sequentially after a lethal bacterial 
challenge, whereas only TNF and IL-1 are sequentially produced after a 
non-lethal endotoxin challenge. 
C. IN VIVO EFFECTS OF TNF PLUS ETX CO-TREATMENT 
1. Mortality and morbidity 
A further assessment of TNF as a mediator of endotoxic shock was 
performed using a co-treatment model to determine whether low doses of 
each agent given within seconds of each other \'ould produce a highly 
lethal shock-like effect similar to that observed after challenge with 
highly lethal doses of either agent given alone. In this study, the 
effects of TNF plus ETX co-treatment on mortality, hemodynamic, 
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metabolic, and endocrine parameters were evaluated. As reported in this 
study and by Rothstein and Schreiber (214), exogenous TNF plus exogenous 
ETX co-treatment produces a highly lethal response within a matter of 
hours. TNF not only synergizes with exogenous ETX (214), but also 
enhances the lethal effects of endogenous bacteria released subsequent to 
cecal ligation and puncture (263). 
The enhanced lethality observed after TNF plus ETX co-treatment 
may be mediated by the dual elevations in plasma TNF concentrations 
produced in response to both agents. As demonstrated by Mathison, et al. 
(161), infusion of exogenous TNF followed by a bolus injection of ETX 
produced 2 peaks in blood TNF concentrations: the initial peak cor-
responded to the infused exogenous TNF and the second peak corresponded 
to endogenous TNF production and release in response to the ETX 
challenge. This response is unique to stimulation with TNF and ETX, for 
repeated stimulation with a single agent, such as ETX or TNF, did not 
produce such a response. Stimulation with repeated doses of ETX (90,161) 
or repeated doses of TNF (272) failed to elicit repeated elevations in 
plasma TNF concentration. Macrophages produce a limited quantity of TNF 
in response to ETX challenge, therefore repeated stimulation with ETX 
does not increase the amount of TNF produced (25,81,90,91). The 
inability to repeatedly elevate plasma TNF concentrations may be the 
basis for the desensitization which occurs relative to the respective 
stimulus. 
The synergism observed between TNF and ETX may be a major 
component in the pathophysiology of TNF- and ETX-induced shock. Sig-
nificant gastrointestinal damage is induced by both agents, which may 
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result in the release of gut-derived bacteria and endotoxin. This, in 
turn, may exacerbate the condition in two ways. First, the gut-derived 
bacteria and ETX can synergize with circulating TNF, thus augmenting the 
mortality and pathophysiological changes elicited by each agent. Se-
condly, the gut-derived bacteria and ETX may stimulate the macrophages to 
release TNF, thereby maintaining or further increasing circulating levels 
of TNF. Moreover, ETX interacts with the macrophages, perhaps through 
the myristoylation of macrophage receptors (2,3), and increases intra-
cellular protein kinase C levels (218,279). Elevation of intracellular 
protein kinase C stimulates TNF mRNA production (102) as well as reduces 
TNF receptor binding (4,109,115,262), thereby further increasing cir-
culating levels of TNF. Low concentrations of circulating TNF appear to 
have beneficial effects which destroy invasive agents and protect the 
host. However, it appears that extremely high concentrations of TNF 
and/or prolonged elevation of TNF may mediate the eventual demise of the 
host. 
2. Hemodynamic, metabolic, and endocrine effects 
The hemodynamic, metabolic, and endocrine changes induced by TNF 
plus ETX co-treatment were evaluated with the expectation that they might 
provide some insight in how these agents combine to produce a highly 
lethal shock-like effect. TNF plus ETX co-treatment may compromise 
cardiac function, as evidenced by the failure to elicit a significant 
tachycardia in response to the significant hypotension observed 30 
minutes afer TNF plus ETX co-treatment. Highly lethal doses of either 
TNF or ETX induced significant elevations in heart rate even though high 
dose TNF did not induce an initial hypotension. However, co-treatment 
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prevented such a response, suggesting that ETX plus TNF together may be 
directly toxic to the heart or that the reflex stimulation of cate-
cholamine release was somehow compromised. However, since plasma 
epinephrine and norepinephrine levels were not determined for the TNF 
plus ETX co-treated animals, these suggestions are all speculative. 
The possibility that TNF plus ETX co-treatment compromises cardiac 
function is supported by the greater degree of hyperlactacidemia produced 
after co-treatment than produced after treatment with high doses of 
either agent alone. Elevated lactate concentrations are indicative of 
anaerobic u.etabolism due to inadequate oxygen supply. Insufficient 
oxygen delivery to the vital organs may result from inadequate cardiac 
function and/or inadequate blood flow due to enhanced procoagulant 
activity. 
The delayed increase in insulin secretion relative to the hyper-
glycemia observed after TNF plus ETX co-treatment indicates that the 
responsiveness of the islets to a glucose stimulus was compromised or 
that the blood supply to the pancreas was altered. Normally, insulin 
levels increase in less than 10 minutes after a glucose stimulus (96), 
whereas after TNF plus ETX co-treatment, 60 minutes passed before a 
significant hyperinsulinemia was elicited in response to the hyper-
glycemic stimulus. 
The lethal hypoglycemia observed after treatment with high doses 
of TNF or ETX alone was also induced in the TNF plus ETX co-treated rat~. 
The hypoglycemia accompanying the death of the rats occurred earlier, as 
evidenced by the 100% mortality rate in 4 hours. These extremely low 
plasma glucose concentrations suggest that the fuel delivery to the vital 
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organs was probably inadequate to meet metabolic demands and therefore 
contributed to the demise of the animals. 
The enhanced lethality and pathophysiological changes induced by 
TNF plus ETX co-treatment may be caused not only by the dual elevation in 
plasma TNF levels butt also by additional mediators known to be released 
in response to TNF and ETX. Perhaps it is the combination of mediators 
at various concenL~ations which induce irreversible shock since TNF 
synergizes with ETX, IL-1 and IFN-~. Experiments with "mediator 
cocktails" analogous to Coley's cocktails may provide some important 
insights. By controlliitg the levels of a particular mediator in question 
with specific antibodies, the mediator cocktails can be given in the 
hopes of ascertaini~g which mediators at what concentrations are required 
to induce a shock like state. 
C. IN VITRO EFFECTS OF TNF ON HEPATIC GLUCOREGULATION 
The in vivo changes induced by exogenous TNF suggested that it may 
actively mediate some of the pathophysiological changes in plasma glucose 
and lactate concentrations observed during endotoxic shock. Because the 
liver functions as the major produc~r of plasma glucose, TNF was tested 
in vitro for direct hepatic glucoregulatory activity using two in vitro 
models: isolated perfused rat livers and isolated liver cells. The 
perfused rat liver model was used to examine the direct effects of TNF on 
whole organ function vis-a-vis alterations in net glucose and lactate 
production, oxygen consumption, and organ perfusion. This in vitro model 
of hepatic function would demonstrate: 1) if TNF altered plasma glucose 
and lactate production by interfering with organ blood flow via changes 
in vascular resistance; and 2) if TNF influenced hepatic glucose and 
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lactate production by stimulating mediator release, such as prosta-
glandins, from the lining endothelial and Kupffer cells (48,93). The 
isolated hepatocytes demonstrated only the direct effects of TNF on 
parenchymal cAll glucose and lactate production, since the preparations 
were virtually devoid of contaminating non-parenchymal cells. Together, 
these two in vitro models would ascertain whether or not TNF influences 
hepatic glucoregulation and if the response was a direct TNF-induced 
alteration in hepatocyte glucogenesis or a secondary response due to TNF-
induced mediator release and/or vascular tone alteration. 
The direct hepatic glucoregulatory effect of TNF was initially 
examined using the isolated perfused rat liver model. Initial exogenous 
TNF concentrations in the perfusate were comparable to plasma TNF 
concentrations found circulating in vivo after a lethal ETX challenge. 
Exogenous TNF failed to modulate net glucose production by isolated 
perfused livers, suggesting that the slight hyperglycemia observed after 
TNF administration was not due to TNF-stimulated hepatic glucose 
production. If TNF either directly stimulated liver glucose production 
or indirectly stimulated glucose production through the production of 
prostaglandins, changes in net glucose production by the isolated 
perfused rat livers would have occurred within the time frame of the 
perfusions (148). Furthermore, the slight hyperglycemia observed after 
TNF administration was not stimulated by TNF-induced hepatic hypo-
perfusion or inadequate oxygen cons-1.1.rnption since such alterations in flow 
rate and oxygen consumption were not demonstrated with the isolated 
perfused livers. 
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When applied to the ETX model of septic shock, these in vitro 
observations suggest that endogenous TNF probably is not directly 
responsible for the hyperglycemia observed shortly after ETX 
administration. However, our in&bility to directly stimulate glucose 
production in vitro with ETX using isolated perfused livers suggested 
that a mediator was responsible for the hyperglycemic effect of ETX (data 
not shown). Only one study conducted by Casteleijn, et al. (42) de-
monstrated a direct glycogenolytic effect of ETX using perfused livers. 
The perfusion flow rate, however, was insufficient for adequate oxygen 
delivery to the perfused livers, thus implying that the perfused livers 
in their study were hypoxic. The data in this study proposes that the 
hyperglycemia observed during ETX- and TNF-induced shock is m~diated at 
least in part by the elevated catecholamine levels produced indirectly by 
the reflex response to ETX-induced hypotension and directly by the 
administration of exogenous TNF. The elevated corticosterone levels 
observed at 2 hours and 30 minutes after ETX and TNF challenge, 
respectively, also contributed to the plasma glucose concentration by 
stimulating glucose production by the liver. 
The hypothesis that a hepatic action of TNF may be responsible for 
mediating the hypoglycemia observed late in the course of ETX- and TNF-
induced shock is not supported by the perfused liver data. TNF failed to 
significantly reduce net glucose production rate under both basal and 
glucagon-stimulated conditions. If TNF directl; prevented the mobil-
ization of glucose or interfered with glucose mobilization in response to 
hormone stimulation, then the perfused liver model would have demon-
strated such a response. Perhaps, longer treatment with TNF is required 
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to elicit such an effect, since treatment with TNF for more than 12 hours 
was required to demonstrate a direct in vitro effect of TNF on hepatic 
protein synthesis (59,151,181,199). Additionally, other mediators re-
leased by TNF and ETX administration may be involved in the hypoglycemia. 
For instance, a significant hypoglycemic response was demonstrated after 
IL-1 administration (63,104), but preliminary studies from this 
laboratory failed to demonstrate a direct glucoregulatory effect of IL-1 
on perfused rat livers. 
The hyperlactacidemia observed after ETX and TNF administration 
suggested that TNF may be responsible for the hyperlactacidemia of septic 
shock. When examined using perfused rat livers, TNF did not induce any 
changes in hepatic lactate production under basal or hormone stimulated 
conditions, thus suggesting that the elevated lactate concentrations 
observed after TNF and ETX treatment were not produced as a result of 
altered hepatic function. This hypothesis is supported by the following 
observations. First, TNF did not directly stimulate lactate production 
by the perfused rat livers, indicating that the hyperlactacidemic effect 
of TNF was not the result of enhanced basal lactate production by the 
liver. Second, TNF did not interfere with glucagon-stimulated hepatic 
uptake of lactate, suggesting that the gluconeogenic ability of the liver 
was not compromised by treatment with TNF. Third, TNF did not stimulate 
lactate production by altering hepatic perfusion flow or oxygen con-
sumption, thus suggesting that liver function is not compromised by TNF 
treatment in a blood-free media. However, since the livers were perfused 
with a KRB media and not with whole blood, this system was devoid of the 
procoagulant activity induced by TNF (29,186). Since TNF strongly 
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stimulates blood coagulation, our data suggests that the hyperlact-
acidemia observed during TNF- and ETX-induced shock probably resulted 
from tissue hypoxia due to inadequate oxygen delivery rather than a 
direct TNF-induced alteration in liver function. 
In order to assure that the results obtained using the perfused 
liver model were a true indication of the short term effects of TNF on 
hepatic function, isolated liver parenchymal cells were challenged with 
TNF directly. In this manner, the initial concentration of TNF directly 
stimulating the hepatic parenchymal cells was dependent on the con-
centration of TNF in the incubation medium. Unlike the perfused liver 
model, these isolated cell preparations were virtually devoid of con-
taminating non-parenchymal cells such as endothelial and Kupffer cells 
which may interfere with the concentration of TNF directly in contact 
with the parenchymal cells. Since the concentration of TNF directly in 
contact with hepatocytes after ETX stimulation in vivo has not been 
determined, this model allowed for a range of TNF concentrations to be 
tested directly. Isolated hepatocytes were incubated directly with TNF, 
at concentrations ranging from 0.01 to 5.0 µg/ml. In agreement with the 
isolated perfused liver data reported in this study and the isolated 
hepatocyte data of Rofe, et al. (212), TNF did not enhance the basal 
glucose production by isolated hepatocytes. Thus, the hyperglycemia 
induced with TNF does not result from a direct hepatic action of TNF. 
Instead, th 0 hyperglycemia observed during TNF- and ETX-induced shock is 
most likely mediated by the elevated catcholamine as well as cortico-
sterone levels, as discussed previously. 
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TNF also did not interfere with hormone-stimulated glucose 
production using two glucogenic hormones; glucagon and vasopressin. 
Glucagon and vasopressin stimulate glucose production via two different 
intracellular mechanisms: glucagon stimulates hepatic glucose production 
by a cAMP-dependent mechanism whereas ~asopressin stimulates glucose 
production by a ca++-dependent mechanism. TNF did not interfere with the 
ability of either hormone to stimulate hepatic glucose production, sup-
porting the hypothesis that TNF-treatment does not alter the intra-
cellular second messengers involved in hepatic glucose production. 
TNF not only failed to influence basal and hormone-stimulated 
glucose production, but also failed to alter the gluconeogenic capability 
of the liver as assessed by net glucose production (212). Although not 
shown in this dissertation, TNF at concentrations of 0.01-5 µg/ml did not 
alter the gluconeogenic capability of isolated hepatocytes. A similar 
finding was demonstrated by the depressed lactate production observed 
with glucagon-stimulated hepatocytes. TNF did not inhibit the uptake of 
the gluconeogenic substrate lactate by the isolated hepatocytes 
stimulated with the gluconeogenic-stimulatory hormone, glucagon. Thus, 
this data supports the hypothesis that the hypoglycemia observed during 
the agonal stages of TNF- and ETX-induced shock was not mediated by a 
direct TNF-induced inhibition of hepatic gluconeogenesis. Furthermore, 
increased hepatic glucose utilization by the parenchymal cells of the 
liver does not seem to be involved in the hypoglycemia induced by TNF and 
ETX since TNF failed to directly enhance glucose utilization by isolated 
hepatocytes in vitro. Perhaps, as proposed by Meszaros, et al. (173), 
enhanced glucose utilization by the macrophage-rich organs may contribute 
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to the hypoglycemia of TNF- and ETX-induced shock. Since glucose 
utilization by the isolated perfused liver was not assessed in this 
study, that may be a direct hepatic effect of TNF. Additional studies 
evaluating the role of TNF on hepatic glucoregulation may require longer 
treatment with TNF or more sensitive indices of altered hepatic function 
such as changes in key glucoregulatory enzyme levels and activity. 
The in vitro data obtained using isolated perfused rat livers and 
isolated liver parenchymal cells suggests that TNF does not mediate the 
hyper- and hypoglycemia observed during TNF- and ETX-induced shock by 
directly altering hepatic glucoregulation. However, previous studies 
from this laboratory (76) demonstrated that the glucoregulatory changes 
observed during end9toxic shock could not be reproduced in vitro using 
isolated hepatocytes stimulated with ETX. Therefore, mediators released 
from the sinusoidal Kupffer cells were proposed to be responsible for the 
glucoregulatory changes observed after ETX administration (41,171). In 
light of the results reported in this study and by Rofe et al. (212), the 
search for a direct hepatic glucoregulatory mediator is not over. Ad-
ditional in vitro studies using a n1,l1Ilber of important inflammatory 
mediators such as IL-1, IFN-~. and TNF, as well as the development of 
techniques to measure the concentrations of inflammatory mediators in 
contact with hepatic parenchymal cells in vivo, may provide further data 
concerning the role of inflarnmtory mediators in hepatic glucoregulation. 
CHAPTER VI 
SUMMARY AND CONCLUSIONS 
Thts study examined the role of TNF in the pathophysioJogy of septic 
shock. In specific, the role of TNF as an important mediator of the 
endotoxic syndrome was evaluated in three ways. First, the hemodynamic, 
metabolic, and endocrine alterations induced by bolus injections of E~X 
were compared to the hemodynamic, metabolic, and neuro-endocrine al-
terations induced by comparably lethal injections of TNF using conscious, 
unrestrained, cannulated, adult rats. Second, the lethal, hemodynamic, 
metabolic, and endocrine alterations induced by the co-administration of 
low doses of TNF plus ETX were examined. Third, the direct gluco-
regulatory effects of TNF on liver glucose and lactate production were 
examined using two different in vitro models -- isolated perfused rat 
livers and isolated liver parenchymal cells. The following conclusions 
were derived from the data in this study. 
1) TNF induced a dose-dependent, lethal, shock-like stat~ in 
conscious, unrestrained, cannulated rats similar to that induced by ETX. 
2) The morbidity induced after TNF administration was identical to 
that induced after ETX administration: rats exhibited such signs as 
piloerection, hunched-over posture, labored breathing, and progressive 
cyanosis. 
3) The initial hypotension induced after ETX ac: .. 1inistration was not 
mediated by endogenous TNF activity, for exogenous TNF did not induce any 
significant changes in mean blood pressure. 
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4) Endogenous TNF may mediate the prolonged elevation in heart rate 
observed after the mean blood pressure returned to control values 
following the hypotensive response to ETX administration: high dose 
exogenous TNF induced a progressive i~crease in pulse rate. 
5) The elevated pulse rates observed after TNF administration may be 
a secondary response due to the elevation in plasma epinephrine and 
norepinephrine concentrations induced by TNF. 
6) Both TNF and ETX induced a hyperglycemic response. However, the 
hyperglycemia observed after ETX and TNF administration did not result 
from a direct hepatic effect of TNF, as evidenced from the inability to 
demonstrate an increase in the net glucose production rates by isolated 
perfused livers and isolated hepatocytes treated with TNF in vitr..Q. 
7) The hyperglycemia induced after ETX and TNF administration was 
probably mediated by the elevated catecholamine and corticosterone 
concentrations observed following ETX and TNF administration. 
8) Both TNF and ETX elicited a profound hypoglycemia coincident with 
the death of the rats. The hypoglycemia observed during the agonal 
stages of TNF- and ETX-induced shock was probably not mediated by a 
direct effect of TNF on hepatic function: TNF did not interfere with the 
net glucose production rates of isolated perfused livers or isolated 
liver cells. 
9) Endogenous TNF activity may contribute to the hyperlactacidemia 
that developed after ETX administration, for a prc.;::'essive hyper 
lactacidemia developed subsequent to exogenous TNF administration. 
10) Tissue hypoxia and organ damage which develop as a result of TNF-
induced procoagulant activity and vascular disruption may be responsible 
for the hyperlactacidemia observed after TNF and ETX administration. 
11) TNF may mediate the hyperinsulinemia reported during endo-
toxicosis. 
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12) The hypoinsulinemia observed after TNF administration suggested 
that TNF may be responsible for the hypoinsulinemia observed during the 
latter stages of endotoxicosis by reducing insulin release in response to 
a glucose stimulus. 
13) Endogenous TNF-induced elevation in plasma epinephrine and nor-
epinephrine concentrations may contribute to the persistant elevation in 
plasma catecholamines observed during endotoxicosis after the mean blood 
pressure returned to control values. Exogenous TNF induced a progressive 
increase in plasma epinephrine and norepiniephrine concentrations by 
acting centrally, peripherally, or on the adrenal medulla to increase the 
circulating concentrations of catecholamines. 
14) Endogenous TNF may mediate the elevation in plasma corticosterone 
concentrations observed after ETX administration: exogenous TNF induced 
a significant elevation in plasma corticosterone. 
15) Co-treatment with low doses of TNF plus ETX augmented the lethal 
effects of both agents. 
16) The mechanism responsible for the enhanced lethality observed 
after co-treatment with low doses of TNF plus ETX remains to be deter-
mined, however, compromised cardiac function may be a possibility. 
17) TNF does not directly influence short-term hepatic glyogenolysis, 
gluconeogenesis, or glucose utilization under both basal and hormone-
stimulated conditions vitro. 
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18) TNF does not directly interfere with in vitro liver perfusion 
flow or oxygen consumption. 
Figure 19 is a schematic representation of TNF's role in the 
pathogenesis of septic shock, as caused by invading gram negative bac-
teria and its constituent ETX. TNF is surely an important mediator of 
the hemodynamic, metabolic, and neuro-endocrine alterations associated 
with septic shock. However, to conclude that TNF is the major mediator 
of the lethal effects of septic shock would be naive in light of the 
other inflammatory mediators known to be released and to interact with 
TNF, such as IL-1 and IFN-7. Moreover, the interaction between TNF and 
ETX suggests that the organ pathology induced in vivo, in particular the 
hemorrhagic necrosis of the gastrointestinal tract, may be a crucial 
factor contributing to the lethal demise of the host. 
Further studies examining the role of inflammatory mediators in the 
pathophysiology accompanying gram negative bacterial infection may pro-
vide helpful insights into the sequence of events which are responsible 
for causing a gram negative infection to progress to a lethal state of 
septic shock. In this way, therapeutic intervention can be better 
directed toward the lethal agent(s) and thus decrease the mortality 
associated with this modern day health problem. 
FIGURE 19: TUMOR NECROSIS FACTOR AND THE PATHOPHYSIOLOGV .OF SEPTIC SHOCK 
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